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SUMMARY
The aim of this research was to investigate the effects of oral soy-derived 
phosphatidylserine (S-PtdSer) supplementation on the physiological responses to 
exercise, exercise performance/capacity and recovery following exercise.
The purpose of the first study was to investigate the effects of 750 mg S-PtdSer or a 
glucose polymer placebo, administered daily for 10 d, on markers of oxidative 
stress, perceived soreness, and muscle damage initiated by intermittent exercise 
(designed to simulate soccer match play) immediately followed by an exhaustive 
run. After familiarisation, 16 male soccer players completed an exhaustive 
intermittent exercise protocol on two further occasions (T1 and T2) separated by 
approximately 14 d. Ten days prior to T2 the subjects were assigned, in a double­
blind manner, to receive either S-PtdSer (PS) or a placebo (P). Exercise time to 
exhaustion, sprint performance, ratings of perceived exertion and heart rate were 
recorded throughout both main exercise trials. Venous blood samples were obtained 
at rest (Pre-exercise), 15-min following exercise (Post-exercise), 24 hours after 
exercise (Post-24 h) and 48 hours after exercise (Post-48 h). Pre-exercise and Post­
exercise concentrations of plasma 7-tocopherol were increased following 
supplementation in PS, although supplementation had no effect on plasma 
concentrations of other non-enzymatic antioxidants (vitamin C, a-tocopherol, retinol 
and /3-carotene). Serum cortisol concentrations, perceived soreness, markers of 
muscle damage (creatine kinase and myoglobin) and lipid peroxidation 
(hydroperoxides and conjugated diene lag times) were elevated to an equal extent in 
PS and P following exhaustive exercise prior to and following supplementation. The
changes in running times to exhaustion from T1 to T2 in PS and P were 4.2 ± 0.7 
and -3.7 ± 4.2%, respectively (P=0.084). Supplementation with S-PtdSer was not 
effective in attenuating the cortisol response, perceived soreness, and markers of 
muscle damage and lipid peroxidation following exhaustive running; however, PS 
tended to improve running and sprint performance following supplementation while 
no differences were observed following supplementation in P.
As S-PtdSer supplementation tended to affect performance in study one, the original 
hypotheses were difficult to evaluate. Therefore, the purpose of study two was to 
investigate the effects of 750 mg S-PtdSer, administered daily for 7 days prior to a 
bout of eccentric exercise and for 2 days following exercise, on delayed onset of 
muscle soreness and markers of muscle damage, inflammation and oxidative stress 
that follow prolonged downhill running. Following preliminary testing and a 
familiarisation session, eight recreationally active males repeated an individualised 
downhill run at -16.5% for 51.0 ± 1.5 min at 8.7 ± 0.3 km-h'1 on four occasions 
(trials 1-4). Trials 1 and 3 were pre-supplementation control trials. After trials 1 and 
3 the subjects received, in a double-blind and crossover fashion, either S-PtdSer or a 
glucose polymer placebo. Trials 2 and 3 were separated by a 4-week ‘washout’ 
period. Venous blood, joint ranges of motion, ratings of perceived soreness and 
feeling states were assessed prior to exercise, after exercise and at 24 and 48 h 
following exercise during each trial. Downhill running led to elevations in perceived 
soreness (P<0.05), plasma creatine kinase activities (PO.OOl), myoglobin 
concentrations (PO.OOl), serum interleukin-6 concentrations (PO.OOl) and lipid 
hydroperoxide concentrations (P<0.01). However, supplementation did not 
significantly attenuate these responses. These results suggested that the current
regime of S-PtdSer supplementation did not afford additional protection against 
delayed onset of muscle soreness and markers of muscle damage, inflammation and 
oxidative stress that follow prolonged downhill running.
Based on the potential ergogenic properties of S-PtdSer identified in study one, the 
purpose of study three was to investigate the effects of 750 mg S-PtdSer, 
administered daily for 10 days, on exercise capacity, oxygen uptake kinetic 
response, neuroendocrine function and feeling states during exhaustive intermittent 
cycling. Following preliminary testing and a familiarisation trial, fourteen active 
males completed a staged intermittent exercise protocol on two further occasions 
(T1 and T2) separated by 16 ± 1 d. The protocol consisted of three 10-min stages of 
cycling at 45, 55 and 65% V o2max followed by a final bout at 85% V o2max that was 
continued until exhaustion. Approximately 5 days after T1 the subjects were 
assigned, in a double-blind manner, to either S-PtdSer (PS) or placebo (P). Breath- 
by-breath respiratory data and heart rate were continually recorded throughout the 
exercise protocol, and blood samples were obtained at rest (Pre-exercise), during the 
rest periods within the protocol (Post-55, Post-65), at the end of exercise (Post-85), 
20 min after the completion of exercise (Post-exercise) and the day following 
exercise (Post-24 h). The main finding of this study was that supplementation had a 
significant effect on exercise time to exhaustion at 85% V02max (P=0.005). The 
exercise time to exhaustion in PS increased following supplementation (7:51 ± 1:36 
min:s to 9:51 ± 1:42 min:s, /M).001), while P remained unchanged (8:09 ± 0:54 
min:s to 8:02 ± 0:54 min:s, P=0.670). Supplementation did not significantly affect 
oxygen kinetic mean response times (MRTon and MRT0ff), serum cortisol 
concentrations, substrate oxidation and feeling states during the trial. This is the first
study to report an improvement in exercise capacity following S-PtdSer
supplementation.
Together, the results from this research provide evidence that short-term 
supplementation with 750 mg-d'1 S-PtdSer:
1. does not influence concentrations of cortisol or adrenocorticosteroid
hormone in the circulation in young active male subjects. These data suggest 
that the current supplementation regime does not affect exercise-induced 
changes in the hypothalamo-pituitary-adrenal (HPA) axis.
2. is ineffective in attenuating the deleterious effects of exercise on perceived 
soreness, muscle damage, inflammation and oxidative stress in young active 
male subjects following eccentric exercise with a relatively low metabolic 
demand.
3. improved exercise capacity following intermittent cycling and tended to
improve performance during prolonged intermittent running. These findings 
suggest that S-PtdSer might possess potential ergogenic properties. However, 
the mechanism(s) responsible for these findings remain to be determined.
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CHAPTER ONE
GENERAL INTRODUCTION
l
1.1 INTRODUCTION
Phosphatidylserine (PtdSer) was initially identified as a constituent of the cephalin 
fraction of bovine brain (Folch and Schneider, 1941). All phospholipids, which 
include the PtdSer species, are comprised of a glycerol molecule, two fatty acids, 
and a phosphate group. Although the head group is similar in all PtdSer species, the 
associated fatty acids can vary in composition (Blokland et a l, 1999). Molecular 
PtdSer species derived from soybean (S-PtdSer) are rich in linoleic and palmitic 
acids whereas stearic and oleic acids are abundant in those derived from bovine 
cortex (BC-PtdSer) (Sakai et a l , 1996). It has been suggested that this variation in 
chemical structure might alter the functionality of this acidic phospholipid within 
cell membranes. Nevertheless, similar pharmacological responses (Sakai et al., 
1996) and behaviour effects (Sakai et al., 1996; Blokland et a l , 1999) have been 
reported in rodents following PtdSer supplements derived from soybean and bovine 
cortex.
It is now evident that PtdSer is a universal component of the plasma membranes in 
eukaryotic cells (Vance and Steenbergen, 2005) and is integral in the maintenance of 
a wide range of normal cellular functions. Rich dietary sources of PtdSer include 
offal and fish (Souci et a l, 2000). In addition, mammalian cells are capable of de 
novo PtdSer synthesis from phosphatidylcholine catalysed by the enzyme 
phosphatidylserine synthase 1 (Voelker and Frazier, 1986) and from 
phosphatidylethanolamine using the enzyme phosphatidylserine synthase 2 (Suzuki 
and Kanfer, 1985); consequently, PtdSer might not qualify as an ‘essential’ nutrient.
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The quantity of research that has been, and continues to be, undertaken on the 
biochemistry of PtdSer is a testament to the array of functions performed by this 
group of phospholipids. For the purpose of this thesis, these biochemical functions 
have been broadly defined as: (1) enzyme cofactors; (2) neuroendocrine actions; (3) 
actions on the immune system; and (4) potential antioxidant actions. A review of 
these functions can be found in Section 1.3.
It has been hypothesised that PtdSer influences cognitive function by maintaining 
the excitability of neuronal membrane (through the activation of various ATPases; 
Section 1.3), maintaining dendritic density (as a cofactor for protein kinase C and 
Raf-1 protein kinase; Section 1.3), and maintaining cell-to-cell communication (by 
moderating the release of various neurotransmitters, such as dopamine and 
acetylcholine; Section 1.3). Indeed, the administration of PtdSer to rodents enhances 
cognitive function (Blokland et a l , 1999), improves learning/memory (Sakai et al., 
1996; Furushiro et a l, 1997; Alves et a l, 2000; Suzuki et a l, 2001) and attenuates 
the effects of stress (Drago et a l, 1991). Additionally, the pharmacological actions 
of PtdSer on cognitive functions have been reported in other animals (Koutoku et 
a l, 2005). Furthermore, exogenous PtdSer has been demonstrated to exert 
therapeutic actions on higher brain functions in human patients with cognitive 
decline (Amaducci and SMID group, 1988; Crook et a l, 1992; Cenacchi et a l, 
1993), although the efficacy of PtdSer supplementation in the treatment of cognitive 
decline has been a matter of debate (Soares and Gershon, 1994).
The majority of investigations that have evaluated the effects . of PtdSer 
supplementation have appraised this potential therapeutic agent in humans and
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animals with cognitive dysfunction (Section 1.2). In addition, PtdSer has been 
demonstrated to exert a range of pharmacological actions in healthy individuals 
(Section 1.2). The purpose of this chapter was to evaluate the potential application 
of PtdSer as a supplement for use by humans, with a particular focus on the 
pharmacological effects of PtdSer supplementation on the responses to exercise.
4
1.2 PHOSPHATIDYLSERINE SUPPLEMENTATION
Many of the proposed pharmacological effects following PtdSer administration rely 
on exogenous PtdSer reaching the inner membrane and exerting the various 
biochemical actions that have been ascribed to endogenous PtdSer (Pepeu et al., 
1996). In addition, it is plausible that unbound PtdSer (i.e., PtdSer that is not 
incorporated in cell membranes) might be effective also as an antioxidant and, 
subsequently, contribute to the cellular defence against oxidative stress.
Fate of Exogenous Phosphatidylserine
In-vitro studies have established that exogenous PtdSer is effectively internalised 
and incorporated in cultured mammalian cells (Kuge et al., 1986; Nishijima et a l, 
1986; Voelker and Frazier, 1986). Consequently, PtdSer supplementation regimes 
that are successful in elevating extracellular PtdSer will probably enhance 
intracellular PtdSer. In support of this hypothesis, Palatini et al. (1991) demonstrated 
that radioactively labelled PtdSer was present in organ tissues as well as in the 
plasma of rats 60 min following the bolus intravenous (i.v.) injection of 
radioactively labelled PtdSer liposomes. These authors rationalised that the rapid 
initial decline in plasma concentrations (half-life of 0.85 min) was caused by uptake 
in the mononuclear phagocyte system, as demonstrated by the accumulation of 
PtdSer in liver and spleen tissues. The slow component (half-life of 40 min) was 
hypothesised to reflect PtdSer that is incorporated in high density plasma 
lipoproteins. In addition, the analysis of biotransformation products suggested that
5
decarboxylation to phosphatidylethanolamine and extensive hydrolytic degradation 
probably reflected the mechanisms of PtdSer uptake, incorporation into the plasma 
membrane and internalisation by endocytosis, respectively (Palatini et al., 1991). 
Although not specifically addressed in this study, it is likely that the majority of the 
PtdSer that interacts with the phospholipid pool of the plasma membrane will be 
maintained in the inner leaflet of the plasma membrane while a small proportion will 
be translocated to the mitochondria and golgi apparatus (Heikinheimo and 
Somerhaiju, 2002).
Bruni et a l (1992) investigated the fate of PtdSer following orally administered 
PtdSer using duodenal infusion with radioactively labelled PtdSer in rats. Following 
the determination of radioactivity in the lymph over 5 h, these authors concluded 
that the majority of the PtdSer supplement was hydrolysed or converted to other 
phospholipids (mainly phosphatidylethanolamine and phosphatidylcholine); 
importantly, small quantities of PtdSer reached the systemic circulation. 
Consequently, oral supplementation potentially increases the systemic PtdSer pool 
and probably increases tissue PtdSer.
In summary, the fate and pharmacokinetics of PtdSer in humans, following oral or 
i.v. PtdSer supplementation, have yet to be characterised. However, the data from in- 
vitro mammalian cell cultures and in-vivo rat experiments provide indirect evidence 
that i.v. and oral administration of PtdSer are effective in increasing extracellular 
PtdSer and lead to quantifiable, albeit small, increases in PtdSer within the plasma 
membrane of tissues.
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Safety of Phosphatidylserine Supplementation
The biochemical tolerability of orally administered bovine cortex derived PtdSer 
(BC-PtdSer; 300 mg-d’1 for 30 d) was determined in 130 human patients (Cenacchi 
et a l, 1987). Using laboratory data from 6 different laboratories these authors 
calculated changes (pre to post supplementation) in a range of haematological 
variables. PtdSer caused no detrimental changes in blood biochemistry; indeed, 
favourable non-significant reductions in uric acid and serum glutamate pyruvate 
transaminase were identified following supplementation. However, BC-PtdSer is 
currently considered unsuitable for use in human supplementation due to the 
potential transfer of infectious disease, such as bovine spongiform encephalopathy 
(mad cow disease), through the consumption of prion contaminated brain.
S-PtdSer has been proposed as an alternative supplement. Jorissen et a l (2002) 
reported the effects of placebo, 300 or 600 mg-d'1 of S-PtdSer, administered orally to 
120 elderly patients, on biochemical and haematological safety parameters, blood 
pressure, heart rate and adverse effects at baseline and after 12 weeks of treatment in 
a randomised placebo-controlled clinical trial. These authors reported no differences 
between treatment groups in all the outcomes measured and, therefore, concluded 
that S-PtdSer was a safe nutritional supplement when administered under these 
conditions. Additionally, no side effects have been reported when young healthy 
adults consume up to 800 mg-d"1 of BC-PtdSer (Monteleone et al., 1992) or S- 
PtdSer (Fahey and Pearl, 1998) for 10 and 12 d, respectively. Moreover, according 
to Pepeu et a l (1996), no side effects had been reported in the very large number of 
patients that have been treated with PtdSer prior to the publication of their review
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and this statement appears to remain current. Indeed all fatty acids, including PtdSer, 
are considered non-toxic to individuals without specific allergies, at least in the 
quantities likely to be obtained from diet and other supplements.
In summary, PtdSer was initially obtained from bovine cortex; however* due to the 
potential transfer of infectious disease, this supplement is now considered unsuitable 
for human consumption. More recently, soy-derived PtdSer (S-PtdSer) has become 
accepted as a safe alternative with no known side effects.
Supplementation Strategies
Monteleone et al. (1990) demonstrated that the acute i.v. administration of 50 and 75 
mg BC-PtdSer blunted plasma adrenocorticotropic hormone (ACTH) and cortisol 
responses to cycling in 8 healthy untrained males. Although there was a tendency for 
lower concentrations of these hormones during exercise following 75 mg BC-PtdSer 
when compared with 50 mg BC-PtdSer, these responses were not significantly 
different. Consequently, there was no evidence to substantiate a dose-response to 
this attenuation in the neuroendocrine response to cycling.
More recently, oral supplementation has been the method of choice for supplying 
exogenous PtdSer to humans. The oral administration of 800 mg-d'1 BC-PtdSer for 
10 d was demonstrated to significantly attenuate plasma cortisol concentrations in 
healthy inactive males (Monteleone et al., 1992). However, 400 mg-d'1 BC-PtdSer 
did not significantly affect cortisol concentrations (Monteleone et al., 1992);
8
thereby, suggesting that, over a 10-d supplementation period, higher doses might be 
necessary to counteract the stress-induced activation of the hypothalamo-pituitary- 
adrenal (HPA) axis in humans. However, the optimal dose of S-PtdSer might vary 
between participants.
Most studies that have reported enhanced higher brain functioning following PtdSer 
supplementation have employed lower daily doses (<500 mg-d'1) for longer 
durations. For example, Cenacchi et a l (1993) reported improvements in 
behavioural and cognitive functions in a group of geriatric patients with cognitive 
impairment after 300 mg-d'1 BC-PtdSer for 6 months. Furthermore, 300 mg-d’1 S- 
PtdSer for 1 month has been shown to be associated with feeling less stressed and 
having better mood in a sub-group of healthy young males (Benton et a l , 2001). 
Alternatively, Fahey and Pearl (1998) confirmed the potential efficacy of 800 mg-d1 
S-PtdSer over 2 weeks using a counter-balanced, placebo-controlled, cross-over 
study design in 11 healthy resistance trained males. These authors reported that this 
supplementation regime was effective in reducing perceived muscle soreness and 
increasing subjective feelings of well-being. Although, at present, too few data 
exists to determine the optimal S-PtdSer supplementation regime (to include: dose, 
length of supplementation duration and timing of supplementation), oral doses of up 
to 800 mg-d"1 S-PtdSer for durations of up to 2 weeks have been demonstrated to 
modify physiological and higher brain functions while no detrimental side effects 
have been reported. Furthermore, it remains unclear whether the optimal 
supplementation regime will vary depending upon individual characteristics such as 
age, gender or training status.
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The pharmacokinetics of PtdSer following supplementation in humans has not been 
elucidated and the turnover of PtdSer in the cell membrane is unknown; 
consequently, no information is currently available on the washout duration of 
exogenous PtdSer. In addition, evidence has been presented to demonstrate that the 
actions of PtdSer continue after supplementation has ceased (Amaducci and SMID 
group, 1988), suggesting that the incorporated PtdSer might accumulate in body 
tissues. Therefore, the interpretation of studies that have employed a simple cross­
over experimental design might be problematic.
In summary, investigators have administered PtdSer through i.v. and oral routes; 
nevertheless, oral supplementation has greater appeal. Although the optimal oral 
dose of PtdSer is not clear at present, doses of 800 mg-d' 1 for up to 2 weeks have 
been demonstrated to attenuate the exercise-induced activation of the HPA axis, 
reduce perceived muscle soreness and improve well-being.
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1.3 MECHANISMS OF PHOSPHATIDYLSERINE ACTION
In addition to the structural role of PtdSer, this phospholipid species is required for a 
range of specific cellular functions. For the purpose of this chapter these functions 
have been broadly defined as: (1) enzyme cofactors; (2) neuroendocrine actions; (3) 
actions on the immune system; and (4) potential antioxidant actions.
Enzyme Cofactor
A myriad of proteins have been identified that require PtdSer for optimal activity 
(for a review consult Toffano and Bruni (1980)); of which, a number might have 
specific relevance to physiological function during exercise. Phosphatidylserine is 
the most effective phospholipid in activating the conventional isoforms of protein 
kinase C (Takai et al., 1979), which undertake crucial functions in diverse signal 
transduction pathways (Nishijima et a l, 1986). Similarly, PtdSer interacts with Raf- 
1 protein kinase to promote a cascade of reactions that are believed to be crucial 
during cell growth (Ghosh et al., 1994), through the translocation of protein to the 
plasma membrane (Nagai et al., 1999). Importantly, enrichment of rat neuronal cells 
with PtdSer has been demonstrated to reduce Raf-1 translocation and ultimately 
reduce apoptosis induced by serum starvation (Kim et al., 2000). These data suggest 
that increasing the cell membrane concentration of PtdSer might afford protection 
against cell death, at least in neuronal cells.
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In-vitro studies have demonstrated that low concentrations of PtdSer are effective in 
activating (Na+ -K+)-dependent ATPase in mammalian kidney (Specht and Robinson, 
1973) and brain (Tsakiris and Deliconstantinos, 1984) preparations. Similarly, Ca2+-
9+ATPase, an enzyme primarily responsible for Ca re-uptake from the muscle 
cytosol into the sarcoplasmic reticulum (SR), is known to require PtdSer (Morrot et 
al., 1990; Sepulveda and Mata, 2004). Furthermore, PtdSer is preferentially 
associated with the Ca -ATPase of cardiac and skeletal muscle SR, at least in 
isolated canine tissues (Bick et a l , 1998).
The aetiology of fatigue, defined as the decline in muscle performance during 
exercise, has not been fully elucidated and might include central and peripheral 
components (Kent-Braun, 1999). As the exercise (mode, intensity and duration) and 
participant characteristics (such as muscle characteristics and training status) 
probably influence the site of fatigue, many theories currently exist to explain 
fatigue. Nevertheless, failure in the excitation-contraction coupling process is 
currently considered to be a major mechanism responsible for peripheral fatigue 
(Allen, 2004). This process includes action potential propagation along the 
sarcolemma, Ca2+ release from the SR leading to activation of myofilament 
contraction, and Ca2+ reuptake into the SR (Giannesini et al., 2003). Therefore, it is 
plausible that exogenous PtdSer might maintain ionic balance for longer during 
exercise by enhancing enzyme activities and consequently delay the onset of fatigue.
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Neuroendocrinological Regulation
Seminal work by Bruni et al. (1976) confirmed that PtdSer was able to modify 
endocrine function. These authors showed that injecting mice with PtdSer liposomes 
promoted increases in brain glucose and blood glucose that were probably 
associated with the release of catecholamines (Toffano et al., 1976) and histamine 
from peripheral tissues (Bigon et a l, 1979). Since this time PtdSer has been 
demonstrated to influence cortical acetylcholine release (Casamenti et al., 1979; 
Pepeu et al., 1986; Casamenti et a l, 1991; Yamatoya et al., 2000), dopamine and 
noradrenaline release (Toffano et a l, 1976), at least following i.v. administration in 
rodents.
Monteleone and colleagues were among the first to identify the effectiveness of BC- 
PtdSer to influence neuroendocrine functions in humans. Both i.v. (Monteleone et 
al, 1990) and oral (Monteleone et a l, 1992) supplementation methods have been 
shown to attenuate the cortisol and ACTH responses to acute cycling exercise.
It has been proposed that changes in neuroendocrine function might affect cognitive 
functions and feelings. Benton et al. (2001) confirmed that S-PtdSer 
supplementation (300 mg'd'1 continued for 30 d) led to improvements in the feeling 
states of a sub-group of young healthy participants when they were asked to perform 
demanding mental tasks. However, prior to the current research, no data existed to 
assess the effects of PtdSer supplementation on feeling states during exercise.
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Effects on Immune Function
The acute inflammatory response is the body’s generic reply to a variety of stimuli 
that initiate the damage of tissues. This non-specific response mobilises the defences 
that lead to the destruction and removal of injured tissues and is characterised by 
local dilation of blood vessels, heat, swelling, pain and disturbances of function. 
Following injury, including exercise induced tissue damage, mediators of 
inflammation such as plasma kinins and histamine derived from mast cells and 
basophils are activated in order to increase the permeability of blood vessels. In 
addition, circulatory increases in proinflammatory and inflammation-responsive 
cytokines, such as tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1) beta 
and interleukin-6 (IL-6), are observed. Neutrophils and macrophages migrate from 
blood to the site of tissue damage and phagocytose damaged cells.
The ability of PtdSer to regulate immune function in mammalian tissues was 
recognised in the early 1970’s (Goth et al., 1971; Mongar and Svec, 1972). Mongar 
and Svec (1972) demonstrated, using in-vitro methods, that low concentrations of 
PtdSer augmented the release of histamine by antigen from sensitized rat tissues. 
Subsequently, PtdSer has been demonstrated to enhance the calcium dependent 
anaphylactic histamine release initiated by IgE antibodies (Shores and Mongar, 
1980) and IgG antibodies (Moodley and Mongar, 1981). Furthermore, i.v. injection 
with lysophosphatidylserine (lyso-PtdSer), the deacylated product of PtdSer 
hydrolysis that is produced at the site of tissue injury, has been shown to increase 
blood histamine concentrations in mice by specifically activating connective tissue 
mast cells (Monastra et al., 1991). However, it remains plausible that the in-vitro
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activation of mast cells might be peculiar to the administration of PtdSer via 
injections, where transient increases in plasma PtdSer and lyso-PtdSer (especially at 
the site of injection) have been reported (Palatini et a l, 1991).
As PtdSer is usually maintained in the inner bilayer of the plasma membrane 
(Devaux, 1991), contact with the extracellular environment is normally prevented; 
however, when cells become damaged PtdSer becomes externalised to the outer 
bilayer of the plasma membrane. Extemalisation of PtdSer is believed to signal 
apoptosis and initiate cell phagocytosis (Tanaka and Schroit, 1983; Tyurina et al., 
2000). Phagocytes rapidly identify, engulf and remove apoptotic cells; thus, 
preventing the release of potentially toxic intracellular contents from damaged cells.
Additionally, PtdSer exposure inhibits the production of pro-inflammatory cytokines 
(Gilbreath et al., 1986; Aramaki et al., 1997) and induces anti-inflammatory 
responses (Huynh et al., 2002) in in-vitro preparations. Based on in-vitro tests 
demonstrating that PtdSer does not affect antigen processing and presentation by 
macrophages, these authors suggested that these immunological actions reflect a 
direct action of PtdSer with the lymphocytes. In addition, the modulation of immune 
response was evident when PtdSer was administered 4 h prior to immunisation; 
however, PtdSer had no effect when administered 24 h prior to or indeed following 
immunisation. These findings suggest that the influence of PtdSer on lymphocyte 
activity is transient (Ponzin et a l, 1989). Consequently, the actions of PtdSer 
moderate the acute inflammatory response, thereby reducing non-specific damage to 
normal cells in the local environment.
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Furthermore, in-vivo experiments have demonstrated anti-inflammatory properties 
of PtdSer in a variety of animal models. The i.v. administration of BC-PtdSer has 
been demonstrated to reduce T-dependent and T-independent antibody production to 
immunisation in mice (Ponzin et a l, 1989). Also, the injection of mice 
(intraperitoneal injection 30 mg'd’1 for 3 d) and rabbits (i.v. injection 30 mg d'1 for 5 
d) with phospholipid mixtures rich in BC-PtdSer effectively reduced the endotoxin- 
induced production of TNF-a (Monastra and Bruni, 1992). In addition, the 
introduction of a synthetic analogue of PtdSer (cholesterylphosphorylserine) (Bruni 
et al., 1994) via intraperitoneal injection has been shown to inhibit the rise in plasma 
TNF-a that followed monocyte activation in rodents (Facci et al., 2000). Acute 
inflammation in rats, initiated by subcutaneous toxin injection, has been 
demonstrated to increase endogenous PtdSer synthesis in the endoplasmic reticulum 
of liver tissue (Vincent et al., 2001). At present the significance of this increase in 
PtdSer is unclear; however, it might reflect an increased requirement for PtdSer 
during the acute inflammation response.
Although the mechanism(s) by which PtdSer inhibits the immune response remains 
unclear, recent data suggest that PtdSer inhibits immune responses by acting on cell 
types (e.g., macrophages, fibroblasts, neutrophils, endothelial cells, epithelial cells) 
at the site of inflammation (Hoffmann et al., 2005). However, the efficacy of PtdSer 
as an immunoactive agent in humans remains, in the main, unscrutinised. 
Consequently, investigations are warranted to assess the effects of S-PtdSer 
supplementation on markers of inflammation following exercise.
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Potential Antioxidant
PtdSer has been demonstrated, using in-vitro experiments, to possess an iron- 
binding ability that is similar to other acid phospholipids (such as phosphatidic acid, 
phosphatidylglycerol) (Dacaranhe and Terao, 2001). In addition to this function, 
Dacaranhe and Terao (2001) demonstrated that PtdSer was unique in its ability to 
suppress the iron-induced lipid peroxidation of egg yolk phosphatidylcholine. BC- 
PtdSer has been shown to reduce human low density lipoprotein (LDL) oxidation 
mediated by cupric sulphate (Lou et a l, 1994), as measured by the formation of 
liperoxides and conjugated dienes. However, these authors also reported that BC- 
PtdSer did not inhibit the oxidation of human LDL mediated by macrophages in the 
presence of a complex cell medium (Ham’s F-10). Even so, the incubation of human 
skin cells with BC-PtdSer has been previously shown to attenuate lactate 
dehydrogenase production in response to generated oxygen free radicals using in- 
vitro preparations (Latorraca et a l, 1993). The processes responsible for tissue 
oxidation have not been fully defined and as such the specific mechanism(s) 
responsible for the reported antioxidant properties of PtdSer, additional to the 
binding of free metal ions, are not clear and might explain these equivocal findings. 
Nevertheless, these studies suggest that under a variety of circumstances, PtdSer 
might be an effective antioxidant against cell and tissue oxidation.
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1.4 EFFECTS OF PHOSPHATIDYLSERINE SUPPLEMENTATION ON 
EXERCISING HUMANS
PubMed and Science Direct were used as the primary databases for searching the 
topic of PtdSer supplementation and exercise. Prior to the current research, three 
peer-reviewed full articles were identified from this search that involved human 
subjects. A summary of these studies is presented in Table 1.1. One study was 
identified that used PtdSer derived from bovine cortex while the remaining studies 
used PtdSer derived from soy beans (Table 1.1). As described previously, in the 
introduction section of this chapter, the structure of PtdSer is dependent upon the 
source used to obtain the supplement; consequently, the source used to obtain 
concentrated PtdSer for oral supplements might be important when comparing the 
outcomes from these studies.
Effects on Neuroendocrinological Function
As previously mentioned, orally administered BC-PtdSer has been reported to blunt 
the cortisol response to acute exercise stress in untrained males (Monteleone et al., 
1992). These authors interpreted this change to represent an attenuation in the stress- 
induced activation of the HPA axis (Monteleone et a l , 1990). However, training 
status of the participants might affect this outcome, especially considering that 
trained subjects experience attenuated HPA alterations during exercise (Luger et a l , 
1987). Prior to the current research, no data existed that investigates the effects of 
PtdSer supplementation on neuroendocrine responses to exercise in active 
participants.
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Effects on Subjective Feelings
Short-term S-PtdSer supplementation has been reported to improve subjective well­
being when compared to supplementation with placebo during two weeks of heavy 
resistance training that was designed to cause overtraining (Fahey and Pearl, 1998). 
Furthermore, subjective feelings of soreness were purportedly lower following 
supplementation with S-PtdSer when compared to supplementation with the 
placebo. Although the potential mechanism(s) responsible for these findings were 
speculative, these authors suggested that alterations in the HPA axis during exercise 
and during the ensuing recovery periods might have led to reductions in circulatory 
ACTH and cortisol concentrations which might have attenuated the perceptions of 
well-being and muscle soreness.
Effects on Exercise-Induced Muscle Damage and Delayed Onset of Muscle 
Soreness
As a ubiquitous component of the cell membrane, PtdSer is thought to play an 
important function in maintaining the structural integrity of cell membranes (Singer 
and Nicolson, 1972). Consequently, the effective incorporation of exogenous PtdSer 
within the cell membrane might alter cell membrane fluidity and reduce the physical 
damage that is associated with unaccustomed muscle activity. In addition, following 
exercise, secondary sources of muscle damage include: (1) invading phagocytes 
during the acute inflammatory response that follows initial muscle damage (Tidball, 
2005); (2) loss of Ca2+ homeostasis (Armstrong et a l , 1991); and (3) elevated
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oxidative stress from increases in oxygen flux through the mitochondria (Dekkers et 
a l, 1996). Therefore, it is plausible that the antioxidant and immunosuppressive 
properties of PtdSer might afford additional protection against secondary muscle 
damage.
Structural damage to muscle cells is associated with leakage of proteins, which are 
usually maintained in the intracellular compartment, such as creatine kinase (CK) 
and myoglobin into the circulation (Feasson et a l, 2002). Consequently, increases in 
CK activity and myoglobin concentration within the blood are often used as indirect 
markers of muscle damage in exercise studies (e.g., Thompson et a l, 2001a; Peake 
et a l, 2005). Additionally, subjective ratings of muscle soreness have been 
extensively used to monitor the development and progression of delayed onset of 
muscle soreness that often follows exercise associated with muscle damage (e.g., 
Thompson et a l, 2001a; Miller et a l, 2004; Peake et a l, 2005).
Employing a double-blind cross over study design, Fahey and Pearl (1998) reported 
that oral administration of S-PtdSer (800 mg’d"1) during two weeks of intense weight 
training did not significantly attenuate serum CK activity when compared with the 
placebo; nevertheless, these authors did report that S-PtdSer reduced subjective 
ratings of muscle soreness during training. It has been suggested that mechanical 
damage leads to the removal of the most susceptible muscle fibres (Friden et a l, 
1983), through phagocytosis and repair. Therefore, it remains plausible, as suggested 
by these authors, that S-PtdSer supplementation might have influenced the structural 
integrity of the muscle cell in the vulnerable muscle fibres.
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1.5 EFFECTS OF EXERCISE ON PHOSPHATIDYLSERINE CONTENT 
WITHIN CELL MEMBRANES
Tibbits et a l (1981) reported that extended exercise training increased the levels of 
phospholipids, especially PtdSer content, in rat cardiac sarcolemma. This adaptation 
to training suggests that additional PtdSer within the heart muscle has functional 
benefits during exercise. An increase in membrane bound PtdSer might have the 
potential to enhance myocardial excitation-contraction coupling, possibly through 
the activation of different protein kinase C isoforms (Sugden and Bogoyevitch, 
1995) and/or enhanced calcium uptake (Pepeu et a l, 1996).
To the contrary, Liang et a l (1993) demonstrated that exercise training (10 weeks of 
intense aerobic training) led to significant reductions in the PtdSer content of 
predominantly oxidative skeletal muscles (soleus), while no changes were observed 
in predominantly anaerobic skeletal muscles (plantaris) in rats. Additionally, short 
term endurance exercise training has been reported to reduce the rate of PtdSer re­
modelling in rat skeletal muscle when compared with the control animals (Gorski et 
a l, 1999). These findings suggest that additional PtdSer is required during exercise 
training to maintain the normal PtdSer content within the inner membrane of skeletal 
muscle, at least in rats.
Sumidikawa et a l (1993) showed that trained students (rowers that participated in 
regular training 3 h or more a day (6 d week'1) for at least 2 years) had significantly 
lower erythrocyte PtdSer when compared with control students of similar age, 
stature and body mass. Interestingly, these authors also found that a maximal 
exercise test led to selective reductions in the PtdSer content of erythrocyte
22
membranes in the untrained group only. These data demonstrate that undertaking 
acute and chronic exercise lessens the PtdSer content of erythrocyte membranes. 
However, as blood samples were only taken before and after maximal exercise, the 
time course for the reduction and subsequent recovery of erythrocyte PtdSer 
membrane content following acute exercise was not available. Furthermore, as 
chronic endurance training was shown to reduce the PtdSer content in erythrocytes, 
it would appear that de novo synthesis was not able to restore ‘normal’ resting 
concentrations. Accordingly, it is plausible that exogenous S-PtdSer might allow the 
maintenance of PtdSer concentrations in cell membranes under the stress of acute 
and chronic exercise.
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1.6 RESEARCH AIMS
Phosphatidylserine is a ubiquitous component of the plasma membrane in eukaryotic 
cells, which has been demonstrated to influence cellular functions (as described 
earlier in this chapter), such as: cell excitability and communication; neuroendocrine 
responses; responses to inflammation; and antioxidant actions. The ability of PtdSer 
to moderate this array of cellular functions has been suggested to explain the 
findings that PtdSer supplementation enhances cognitive function in humans and 
other mammals. S-PtdSer supplements are considered a safe method of enhancing 
circulatory and tissue concentrations of PtdSer. Indeed, S-PtdSer is commercially 
available as an oral supplement that is intended to improve cognitive function.
Exercise poses wide-ranging challenges to cellular function; consequently, it is 
plausible that enhancing the availability of PtdSer might enhance cellular function 
during exercise. Few studies have investigated the effects of exogenous PtdSer on 
physiological function during exercise. Nevertheless, the available data suggest that 
supplementation with S-PtdSer modifies neuroendocrine function by attenuating the 
exercise induced activation of the HPA axis. In addition, oral supplementation with 
S-PtdSer has been reported to reduce perceived soreness and improve well-being 
after exercise (Fahey and Pearl, 1998); however, the mechanisms responsible for 
these results were unclear. Although not evaluated in this study, it is possible that 
antioxidant and/or anti-inflammatory actions of the supplement could explain these 
findings. Furthermore, at the commencement of this research, no studies had 
evaluated the in-vivo effects of S-PtdSer supplementation on oxidative stress or 
exercise performance/capacity during exercise.
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The series of experiments contained within this thesis were designed to investigate
the following aims:
i In light of in-vitro research that suggests antioxidant functions of PtdSer, the 
purpose of the first experimental study was to investigate the effects of short­
term oral S-PtdSer on antioxidant status, tissue oxidation, muscle damage, 
and muscle soreness following exhaustive prolonged intermittent exercise in 
familiarised active participants. Hypotheses are located in section 3.1.
ii As supplementation tended to improve exercise performance in the first 
experimental study, it was difficult to evaluate the effects of supplementation 
on exercise induced oxidative stress. Consequently, the exercise protocol in 
the second experimental study was designed to cause repeatable amounts of 
muscle damage and oxidative stress. The purpose of this study was to 
investigate the proposed antioxidant and anti-inflammatory effects of short­
term S-PtdSer supplementation on markers of muscle damage, inflammation 
and lipid peroxidation following prolonged downhill running. Hypotheses 
are located in section 4.1.
iii The third experimental chapter was designed to investigate the potential 
ergogenic effects of supplementation that were identified in experimental 
study one. Therefore, this study was designed to investigate the efficacy of 
short-term S-PtdSer supplementation on exercise capacity, neuroendocrine
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function, oxygen uptake kinetic response and perceived feeling states during 
and following intermittent cycling. Hypotheses are located in section 5.1.
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CHAPTER TWO
GENERAL METHODS
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2 GENERAL METHODS
This chapter describes the general methods and procedures that were used 
throughout the experimental studies (Chapters 3 to 5) contained within this thesis. 
Specific methods and procedures that are not presented within this section are 
described in the methods sections within the relevant experimental chapters.
2.1 SUBJECTS AND STUDY APPROVAL
All of the experimental studies described within this thesis (Chapters 3 to 5) 
involved human volunteers. The subject groups that participated in this thesis were: 
university standard male soccer players (Chapter 3) and active young males (Chapter 
4 and Chapter 5). The inclusion and exclusion criteria for each study are presented in 
the relevant experimental chapters.
Prior to undertaking each experimental study, approval was sought and gained from 
an ethical committee of the University of Wales Swansea (Appendix A). All 
participants received verbal and written information (Appendix B) that explained the 
purpose and requirements of the study that they volunteered to undertake. After 
completing health questionnaires (Appendix C), all subjects provided written 
informed consent (Appendix D) before taking part in any investigation. In addition, 
the subjects were made aware of their right to withdraw from the experiment at any 
stage without explanation.
28
2.2 EXPERIMENTAL DESIGN
Experimental studies one and three followed a double-blind placebo controlled 
design. The subjects within each supplementation group were matched by measured 
(study three) or predicted (study one) maximum oxygen uptake ( V o 2 max)- The main 
limitation to this design is the use of subjects as their own control. However, the 
washout kinetics of PtdSer from human tissues are yet to be defined; consequently, 
it might be difficult to interpret the results from crossover studies, where some 
subjects will receive the placebo during the second trial and PtdSer concentrations 
within various tissues might remain elevated from the previous supplementation 
period.
A double-blind placebo controlled crossover design was used in study two. 
However, due to the aforementioned problem associated with this study design, 
control trials were included prior to both supplementation trials (PS and placebo). 
Consequently, a lack of difference between data from these pre-supplementation 
trials was interpreted to confirm that pre-supplementation data were similar; hence, 
the washout period provided was deemed to be sufficient for these data.
Familiarisation trials were included in all experiments in order to reduce the effect of 
trial order. The details of these trials are included in the methods section within each 
experimental chapter (Chapters 3 to 5).
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2.3 SUPPLEMENTATION
All of the experimental studies (Chapters 3 to 5) describe placebo controlled oral 
PtdSer supplementation studies. The composition of the PtdSer supplement and 
placebo were consistent throughout these chapters.
The method used to manufacture PtdSer (Lucas Meyer, Germany) makes use of the 
enzymatic transesterification of soybean lecithin. During this process, the headgroup 
of the starting phospholipids, obtained from the soybean lecithin (mainly 
phosphatidylcholine and phosphatidylethanolamine), are converted to PtdSer. 
Although the total amount of phospholipids remains unchanged, the concentration of 
PtdSer in this product is in the range of 45-54%. The variation in concentration is 
mainly due to differences in the composition of the starting soybean lecithin. 
Subsequently, this product is blended with soybean lecithin to provide a final 
supplement, as used throughout the experimental sections of this thesis, which 
contains approximately 20% PtdSer. Table 2.1 shows the typical composition of the 
concentrated PtdSer product. The remaining content reflects the composition of the 
source soybean lecithin. Lecithin is usually used as a synonym for 
phosphatidylcholine; although, the composition of lecithin is variable depending 
upon the source soybean. Soybean lecithin also contains, to a lesser extent, a mixture 
of phospholipids, tocopherols, triglycerides, and free fatty acids. The approximate 
content of the final product is presented in Table 2.2.
Weight matched placebo capsules (containing a glucose polymer) were provided in 
generic packaging to ensure that the supplements were delivered to all participants
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Table 2.1: Typical composition of concentrated phosphatidylserine product.
Phospholipids Composition
Phosphatidylserine 45-54%
Phosphatidylcholine 5-7%
Phosphatidylethanolamine 6-10%
Phosphatidylinositol 1-3%
Phosphatidic acid 4-7%
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Table 2.2: Approximate composition of final phosphatidylserine product.
Phospholipids Composition
Phosphatidylserine 20%
Phosphatidylcholine 9%
Phosphatidylethanolamine 2%
Phosphatidylinositol 2%
Linoleic Acid 23%
Linolenic Acid 2%
Oleic Acid 2%
Stearic Acid <1%
Palmitic Acid 5%
Capric Acid 10%
Caprylic Acid 26%
Phosphorus 2%
Potassium <1%
Others (including tocopherol) Not listed
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in a double blind manner. During the supplementation period the subjects were 
instructed to consume a total of 10 capsules per day with food (3 in morning, 3 at 
midday and 4 in evening). None of the subjects reported any side effects.
2.4 DIETARY ANALYSIS
All subjects were requested to weigh and record their dietary intake on three 
consecutive days during each main trial (beginning on the day prior to each exercise 
test). Subsequently, energy intake and dietary composition were determined for each 
subject using a commercially available computerised programme (CompEat version 
5.8.0; Nutrition Systems, UK). These results were used to ensure that any changes in 
performance and/or antioxidant vitamins were not the result of changes in dietary 
intake.
2.5 ANTHROPOMETRY
Body mass and height were recorded in accordance with the International Standards 
for Anthropometric Assessment (ISAK, 2001) published by the International Society 
for the Advancement of Kinanthropometry. Body mass (BM) was determined using 
beam balance scales (model 710; Seca, UK). The subjects were dressed in minimal 
clothing and stood on the centre of the platform with their body weight evenly 
distributed on both feet (recorded to the nearest 0.05 kg). Free standing height was 
determined using a stadiometer (Harpenden Portable Stadiometer; Holtain, UK) to
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the nearest 0.001 m. The subjects stood with feet together and heels touching the 
scale as the head board of the stadiometer was lowered to the vertex of the head, 
which was placed in the Frankfort plane.
2.6 EXPERIMENTAL CONTROLS
The subjects were asked to refrain from undertaking strenuous activities before and 
after each exercise trial. The time period for this request during each experimental 
study are described within the specific methods section contained within each 
experimental chapter (Chapters 3 to 5). This experimental control was included in 
order to reduce the influence of additional activities on performance and markers of 
muscle damage, inflammation, oxidative stress and soreness. All of the subjects 
gave their verbal assurance that they had complied with these instructions.
2.7 BLOOD ANALYSES
Venous blood was obtained using venepuncture (Vacutainer system; Becton- 
Dickinson Ltd, UK) from an antecubital vein during all of the experimental studies 
described in this thesis (Chapters 3 to 5). The explicit procedures of blood 
preparation and blood analyses used in each experiment are described in the specific 
methods sections contained within Chapters 3 to 5. This section provides a 
description of the principle and precision of each assay employed during the 
experimental chapters of this thesis.
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Determination o f Blood Lactate and Glucose Concentrations
Small aliquots of whole blood were removed for the triplicate determination of 
blood lactate concentration and glucose concentration using an automated 
electrochemical analyser (YSI 2300, Yellow Springs Instruments, USA). Both 
assays are based on the principle that the substrate is rapidly oxidased to form 
hydrogen peroxide (H2O2) when it comes in contact with the specific immobilised 
oxidase enzyme (Reaction 1). The H2O2 produced, is in turn, oxidised by the 
platinum anode which produces electrons (Reaction 2); consequently, the electron 
flow is linearly proportional to the substrate, as follows:
Reaction 1: /5-D-glucose + O2 => Glucoono-5-lactone + H2O2
(Glucose) Immobilised oxidase enzyme
Reaction 2: H2O2 => 2H+ + O2 + 2e'
Platinum electrode
The precision of measurement across the measurement ranges for blood lactate and 
glucose concentrations had coefficients of variation (CV) of 1.4 and 1.0%, 
respectively.
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Calculation o f Plasma Volume Changes
Estimated changes in plasma volume (%) were calculated from measured 
haemoglobin and haematocrit values, using the method described by Dill and Costill 
(1974).
(a) Haemoglobin
Haemoglobin concentrations were determined (in triplicate) from whole blood using 
an automated 2-wavelength (570 and 880 nm) spectrophotomer (B-Hemoglobin 
Analyser; Hemocue Ltd, UK) as described by the manufacturers instructions. The 
precision of measurement across the range of values had a CV of 1.0%.
(b) Haematocrit
Haematocrit was determined in triplicate using standard microhaematocrit tubes. 
Each tube was filled with blood and centrifuged for 5 min at 12000 x g (Micro 
Haematocrit MK IV, Hawksley, UK). A Hawksley reader was used to quantify the 
packed cell volume (haematocrit %). The precision of measurement across the range 
of values had a CV of 0.9%.
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Determination o f Creatine Kinase Activities
Creatine kinase (CK) activities were determined using an automated 
spectrophotometer (MIRA S; ABX Diagnostics, UK) with commercially available 
kits (kit A11A00008; ABX Diagnostics, UK). The CK is activated by N- 
acetylcysteine and determined by the following reaction sequence:
Reaction 1: Creatine phosphate + ADP => creatine + ATP
CK
Reaction 2: ATP + D-glucose => ADP + D-glucose-6-P
HK
Reaction 3: D-glucose-6-P + NADP+ => D-gluconate-6-P + NADPH + H+
G6P-dehydrogenase
Where the rate of NADPH was measured photometrically at 340 nm, and is directly 
related to the CK activity. The intra and inter assay CVs, across the measurement 
range, were 0.7 and 0.9%, respectively.
Determination o f Myoglobin Concentrations
Myoglobin concentrations were determined using an automated spectrophotometer 
(MIRA S; ABX Diagnostics, UK) with commercially available kits (kit 
A11A00165; ABX Diagnostics, UK). The assay is based on the principle that a clear 
agglutination is formed when myoglobin contained within the sample is mixed with 
the Myoglobin Lated reagent. This product was measured by turbidimetric
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immunoassay. The intra and inter assay CVs, across the measurement range, were 
3.8 and 4.8%, respectively.
Determination o f Cortisol Concentrations
Experimental studies 1 and 3 (Chapters 3 and 5) used an automated time-resolved 
flouroimmunoassay (AutoDELFIA™ Cortisol kit, Perkin Elmer, Life Sciences, UK) 
to determine serum total cortisol concentrations. Plasma total cortisol concentrations 
were determined using enzyme-linked immunosorbent assays (ELISA) during 
experiment 2 (Chapter 4).
(a) Flouroimmunoassay
The assay is a solid phase time resolved flouroimmunoassay and is based on the 
principle that europium chelate (Eu) labelled cortisol competes for a fixed time with 
sample cortisol for a limited number of cortisol specific, biotinylated monoclonal 
antibodies. Washing off the supernatant terminates the competition and leaves the 
antibody-bound cortisol fraction immobilised to the wall of the polypropylene tube. 
After an enhancement solution has been added a new flourescent chelate is formed 
and measured on the automated flourometer. Using a calibration curve, the 
radioactivity in the tube can be converted to quantify the cortisol present within the 
sample. The intra and inter assay precisions had CVs of <10% across the range of 
values undertaken.
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(b) ELISA
This solid-phase ELISA was performed in duplicate using commercially available 
kits (kit EIA-1887; DRG Instruments, Germany) on a spectrophotometric microplate 
reader (BP800; Biohit, UK). The assay is based on the principle that horseradish 
peroxidase-labelled cortisol (HRP-cortisol) competes with cortisol present in the 
sample for a fixed and limited number of antibody sites that are immobilised on the 
wells of the pre-prepared microstrips. Once the competitive immunoreaction had 
occurred, the wells were rinsed using an automated plate washer (BW50; Biohit, 
UK), and the HRP-cortisol fraction bound to the antibody in the solid phase was 
measured by adding a chromogen/substrate solution that produced a blue coloured 
compound. After 15 min of incubation, the enzymatic reaction was stopped with 
hydrochloride acid, which changed the solution to a yellow colour.
The absorbance of each solution was photometrically measured at 450 nm. Total 
cortisol concentrations were calculated with reference to calibration curves that were 
developed for each 96 well microplate. The intra assay precision across the 
measurement range had a CV of 4.5%.
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Determination o f Plasma Adrenocorticotropic Hormone Concentrations
Plasma adrenocorticotropic hormone (ACTH) concentrations were determined in 
duplicate using solid-phase enzyme-linked immunosorbent assays (ELISA) with 
commercially available kits (kit 7023; Biomerica, US). This two-site ELISA uses a 
goat polyclonal antibody to human ACTH and a mouse monoclonal antibody to 
human ACTH, which are specific for well defined regions on the ACTH molecule. 
One antibody is prepared to bind only the C-terminal ACTH 34-39 and this antibody 
is biotinylated. The other antibody is prepared to bind only to the mid-region and N- 
terminal ACTH 1-24 and this antibody is labelled with horseradish peroxidase for 
detection. The samples were simultaneously incubated with the enzyme labelled 
antibody and a biotin coupled antibody in the pre-prepared streptavidin-coated 
microplate wells. At the end of the assay incubation, the microwells were washed 
(BW50; Biohit, UK) to remove unbound components and the enzyme bound to the 
solid phase were incubated with the substrate, tetramethylbenzidine. Sulphuric acid 
was then added to stop the reaction and convert the colour to yellow.
The intensity of the yellow colour in each microwell was read at 450 nm (BP800; 
Biohit, UK) and ACTH concentrations were determined using calibraton curves that 
were developed for each 96 well plate. The intra assay precision across the 
measurement range had a CV of 8.1%.
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Determination o f Serum Interleukin-6 Concentrations
Interleukin-6 (IL-6) concentrations in serum were assayed in duplicate using 
commercially available high sensitivity ELISA kits (Diaclone Research, France). 
The samples were added to wells within each microplate that were pre-coated with a 
monoclonal antibody specific for IL-6. The IL-6 antigen and a biotinylated 
monoclonal antibody specific for IL-6 were incubated for 3 h. After washing 
(BW50; Biohit, UK), the enzyme (streptavidin-peroxydase) was added. After a 
second incubation (30 min) and washing (BW50; Biohit, UK), a substrate solution 
(tetramethylbenzidine), which acts on the bound enzyme, was added to induce a 
coloured reaction product. Sulphuric acid was then added to stop the reaction and 
convert the colour to yellow.
The intensity of this yellow coloured product was read at 450 nm (BP800; Biohit, 
UK) and IL-6 concentrations were determined using calibraton curves that were 
developed for each 96 well plate. The intra assay precision across the measurement 
range had a CV of 12.1%.
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Determination o f Lipid Peroxidation
Serum hydroperoxide concentrations were measured using the method of Wolff 
(1992) as described in McEneny et a l (1998). Serum (90 /xL) was incubated with 10 
juL of triphenylphosphine (10 mmol'L'1) for 30 min. Subsequently, 900 /xL of FOX- 
II reagent (250 /xM ammonium ferrous sulphate, 100 /xM xylenol orange, 25 mM 
H 2 S O 4  and 4 mM butylated hydroxytoluene in 90% methanol) was added to the test 
sample. Samples and standards were incubated for 30 min at room temperature and 
centrifugation in a Beckman microfuge for 5 min. The absorbance of the supernatant 
was read at 560 nm.
Hydroperoxides oxidise ferrous ions to ferric ions in dilute acids and the resultant 
ferric ions can be determined using ferric-sensitive dyes as an indirect measure of 
hydroperoxide concentration, using the following principle:
Reaction 1: Fe2+ + ROOH => Fe3+ + OH‘ + RO'
(peroxides) (oxyl radicals)
Reaction 2: RO' + Sorbitol => Ketone + HO2'
Reaction 3: HO2' + Fe2+ => Fe3+ + H2O2
The inter and intra assay precision, across the measurement range, had CVs less than 
5%.
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Susceptibility and Resistance to LDL Oxidation
Low density lipoprotein was isolated from plasma and oxidised according to the 
method of McDowell et al. (1995). Low density lipoprotein (LDL) was isolated 
using a density gradient method with a Beckman TL100 ultracentrifuge (Beckman 
Instruments, UK). Plasma (0.9 mL) was added to a centrifuge tube' containing 
potassium bromide (0.4451 g; Sigma, UK) and gently mixed until the salt dissolved. 
Subsequently, 2.1 mL of 0.15 mol-L"1 NaCl was added and centrifuged at 100 000 
rpm for 60 min at 4°C. The density gradient forms a layer of LDL that was carefully 
removed with a 21 gauge hypodermic needle. The preparation containing LDL was 
then desalted using gel filtration at 4°C using columns containing Sephadex G25 
(PD-10; Pharmacia Ltd, UK). Additionally, albumin and salt were removed by gel 
filtration at 4°C using column packed with Sephacryl 300 HR (C l0-20; Pharmacia 
Ltd, UK). Fractions were collected at 1 min intervals.
The production of conjugated dienes was followed in duplicate at 234 nm 
(SpectraMax 190; Molecular Devices Corp, US) using the computer software 
SoftMax Pro Version 3.0 (Molecular Devices Corp, US); the change in absorbance 
(from baseline to the end of reaction) was used to quantify the change in conjugated 
diene concentration.
The lag times were used as a measure of the resistance of the particle to oxidation in 
experimental study 1. Lag times are taken as the intercept between absorbance at 
time zero and the point on the curve when maximum LDL oxidation occurred 
(Figure 2.1).
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The time taken to reach half of the maximum oxidation (t>/2max LDL oxidation) was 
taken as a measure of resistance of the particle to oxidation in experimental study 2. 
The t>/2 max is the time taken to reach half of the maximum change in conjugated diene 
production (Figure 2.1).
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Figure 2.1 Low density lipoprotein (LDL) oxidation, displaying the identification 
of conjugated diene lag time and time to half maximum LDL oxidation (ti/2max)-
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Determination o f Plasma Vitamin C concentrations
Fresh aliquots of plasma (100 /xL) were added to 900 fiL of freshly prepared 10% 
metaphosphoric acid, mixed and frozen at -70°C for subsequent vitamin C analysis. 
Vitamin C concentrations were determined by means of a fluorimetric assay using a 
centrifugal analyser (Cobas Fara) with fluorescence attachment according to the 
method of Vuilleumier (1993).
This procedure is based on the enzymatic oxidation of ascorbic acid and subsequent 
quinoxaline formation to generate a fluorescent derivative measured on the 
centrifugal analyser. Aliquots of standards and samples (200 pL) were placed in 
Cobas cups. Oxidising reagent (9.9 ml of 2 mol'L'1 acetate buffer and stock 
ascorbate oxidase) and coupling reagent (20 mg of 1,2-phenylenediamine dissolved 
in 20 ml deionised water) were added to appropriate reagent wells. The automated 
assays were then started. The intra assay CVs at mean vitamin C concentrations of 
4.2, 50.6 and 151.0 pm olL '1 were 6.8, 0.72% and 1.50%, respectively.
Determination o f Plasma Vitamin A and D concentrations
Plasma concentrations of a-tocopherol, 7-tocopherol, retinol, a-carotene, /3-carotene 
and lycopene were measured by high-performance lipid chromatography (HPLC) 
with electrochemical detection according to the methods of Catignani and Bieri 
(1983) and Thumham et al. (1988).
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Plasma samples and standards (300 pL) were pipetted into glass tubes (4 mL). 
Ethanol (250 pL) containing the internal standards (e.g., a-tocopherol acetate) and 
0.25 g'L'1 butylated hydroxy toluene was added. Subsequently, 500 pi heptane was 
added and the tubes were vortexed vigorously for 1 min to extract the lipid soluble 
vitamins into the heptane. The sample tubes were then centrifuged for 5 min at 1200 
x g and 350 pL of the supernatant were transferred into clean glass tubes. The 
original tube was re-extracted and a further 350 pL of supernatant was removed and 
added to the first extraction giving a final volume of 700 pL. Theses tubes were 
evaporated to dryness in a rotary evaporator under vacuum for 1.2-2 h. These 
samples were frozen at -70°C until they were analysed by HPLC. Samples and 
standards were reconstituted in 150 pL methanol, vortexed and assayed by HPLC 
using a diode array detector (Thermo Separation Products). Samples and standards 
were injected onto a Hypersil ODS 5 pm column. The mobile phase contained 97% 
methanol: 3% tetrahydrofurin. The intra assay CVs for these assays ranged from 
1.4% for a-tocopherol to 12% for lycopene.
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CHAPTER THREE
EXPERIMENTAL STUDY ONE
Effects o f phosphatidylserine supplementation on performance 
and oxidative stress following intermittent running
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3.1 INTRODUCTION
Soccer is a multiple-sprint sport that requires high-intensity, intermittent activity to 
be undertaken over an extended period of time (approximately 90 min). The rapid 
decelerations and changes in direction undertaken during soccer match play generate 
large eccentric forces that have frequently been associated with muscle damage 
(Friden et a l, 1983), leakage of unbound iron from the cytosolic region (Jenkins et 
a l, 1993) and delayed onset of muscle soreness (DOMS) (Clarkson et al., 1992). 
Free radical production has been associated with muscle damaging exercise (Aoi et 
al., 2004) and the ensuing inflammatory response (Macintyre et a l , 1995). In 
addition, the elevation in oxygen consumption and the rapid changes in 
mitochondrial oxygen flux that are associated with prolonged intermittent exercise 
have the potential to greatly increase the production of free radicals (Dekkers et a l, 
1996). These radicals have the potential to cause oxidative damage to a wide range 
of molecular structures including lipids, proteins and DNA, where the antioxidant 
defences are overwhelmed (Kanter et a l, 1988).
Consequently, the mechanisms responsible for muscle damage include primary 
damage caused by direct mechanical stress and/or elevated oxygen uptake and 
secondary damage caused by autogenic processes that lead to inflammation and 
phagocytosis. Although it is evident that activities involving substantial amounts of 
eccentric muscular activity accompanied with elevated oxygen uptake have potential 
to cause muscle damage, it is not possible to separate the potential mechanisms that 
lead to this phenomenon.
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The symptoms of exercise-induced muscle damage often include: soreness, decrease 
in the range of motion of joints in affected limbs, decreased muscular strength, 
decreased power output, leakage of myofibre proteins, inflammation and oedema 
(Kendall and Eston, 2002). Furthermore, prolonged intermittent shuttle-running 
designed to simulate multiple-sprint sports has been previously demonstrated to 
cause muscle soreness, and elevate blood markers of muscle damage and lipid 
peroxidation in accustomed individuals (Thompson et a l , 2001a).
Phosphatidylserine (PtdSer) is an essential phospholipid, mainly located within the 
cytosolic monolayer (Devaux, 1991), that has been shown to have important 
regulatory functions within mammalian cells (Blokland et a l , 1999). Exogenous 
PtdSer supplementation has shown benefits in diverse measures of cognitive 
functions. Furthermore, intravenously and orally administered bovine cortex-derived 
PtdSer have been shown to blunt the cortisol response to acute exercise stress 
(Monteleone et a l, 1990; Monteleone et a l, 1992) and, therefore, might attenuate 
the stress-induced activation of the hypothalamo-pituitary-adrenal axis in man. 
Moreover, Fahey and Pearl (1998) reported that short-term oral supplementation 
with 800 mg-d"1 soybean derived PtdSer (S-PtdSer) was effective in reducing serum 
cortisol concentrations and muscle soreness following intensive resistance training. 
In addition to a myriad of membrane related functions, in-vitro studies have 
demonstrated that PtsSer has the potential to act as an antioxidant (Latorraca et a l, 
1993; Dacaranhe and Terao, 2001). Therefore, it is plausible that exogenous 
supplementation with PtdSer might provide additional defence against the oxidative 
stress caused by soccer match play. In light of the above, the aim of the present 
study was to determine whether antioxidant status, tissue oxidation, muscle damage,
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and muscle soreness following exhaustive prolonged intermittent exercise would be 
affected by short-term oral S-PtdSer supplementation in accustomed active 
university soccer players.
Null Hypotheses
HOi: Exhaustive intermittent running will not influence markers of antioxidant 
status, tissue oxidation, muscle damage, and muscle soreness.
HO2: Supplementation with S-PtdSer will not influence markers of'antioxidant
status, tissue oxidation, muscle damage, and muscle soreness after 
exhaustive intermittent running.
H O 3 : Supplementation with S-PtdSer will not influence neuroendocrine responses
to exhaustive intermittent running.
H O 4 : Supplementation with S-PtdSer will not influence exercise performance 
during exhaustive intermittent running.
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3.2 METHODS
Subjects
Sixteen young males who participated regularly in soccer match play and practice 
volunteered to participate in this study, which was approved by a university ethics 
committee. All subjects were informed in writing about the potential risks of the 
study and gave written informed consent for their participation in the study. No 
subject had prior history of cardiovascular or respiratory disease and all subjects 
were non-smokers. Potential subjects attended an interview prior to undertaking the 
study and were subsequently excluded if they were smokers or had taken nutritional 
supplements in the last 8 weeks. The subjects’ physical characteristics are presented 
in Table 3.1.
Experimental Design
All subjects completed two preliminary visits to the laboratory prior to undertaking 
the main exercise trials. Maximum oxygen uptake ( V 0 2 max) was estimated using a 
multistage fitness test (MSFT) (Ramsbottom et al., 1998) during the initial visit. 
These V 0 2max values were used in conjunction with the linear regression developed 
by Ramsbottom et al. (1988), to calculate appropriate running speeds for the 
exercise protocol as described previously by Nicholas et al. (2000).
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Table 3.1 Subject characteristics for phosphatidylserine supplementation group (PS) 
and placebo group (P).
Characteristic PS (N=8) P (N=8) P-value
Age (dec. years) 21.7 ±0.3 22.6 ± 0.7 0.320
Mass (kg) 81.7 ±2.4 74.0 ±2.4 0.042
Height (m) 1.82 ±0.03 1.80 ±0.04 0.714
Estimated maximal oxygen uptake (ml kg'1 min'1) 52.8 ±2.1 54.7 ± 1.7 0.493
Values are mean ± SEM. P-value calculated using independent sample f-test.
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During their second preliminary visit the subjects underwent a familiarisation 
exercise trial in order to minimise anticipated trial order effects. Subjects then 
performed two main exercise trials (T1 and T2), separated by 14 ± 1 d. The subjects 
were assigned, in a randomised double-blind fashion, to receive either 750 mg-d'1 S- 
PtdSer (PS) or a weight matched glucose polymer (P) for exactly 10 days prior to 
the T2. The S-PtdSer supplements were manufactured using the method of specific 
transesterification of soybean lecithin and then blended with additional soybean 
lecithin to provide a concentration of 20% PtdSer (Lucas Meyer; Hamburg, 
Germany). Both supplements were administered in capsules and placed in generic 
packaging. Subjects were instructed to maintain their normal diet and activity 
patterns throughout the study. Food was weighed and recorded by the subjects for 
the two days before and after each main exercise trial. These food records were 
subsequently analysed using commercial software (CompEat version 5.8.0; 
Nutrition Systems, UK). In addition, the subjects were instructed to abstain from 
strenuous exercise for three days prior to and two days following each trial. At the 
completion of the study, all subjects gave their verbal assurance that they had 
complied with all instructions.
Main Trial Procedures
On the day of both main exercise trials the subjects reported to the laboratory in 
pairs (matched by estimated V o2max and paired in different supplementation groups) 
at approximately the same time of day (± 1 h) and following an overnight fast. 
Subjects were asked to void, then mass (model 712; Seca, Germany) and height
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(Portable Stadiometer; Holtain, UK) were recorded. Subsequently, the intensity of 
muscle soreness for the whole body general soreness (GS), hamstrings (HS) and 
quadriceps (QS) were rated on an eleven-point scale ranging from 0 (not sore) to 10 
(very, very sore) (Appendix E).
Following a Pre-exercise venepuncture (Vacutainer system; Becton-Dickinson Ltd, 
UK), taken from an antecubital vein in the right arm (after maintaining a seated 
position for approximately 10 min), the subjects completed an exercise protocol that 
consisted of two sections (Part A and Part B) in an indoor wooden floored 
gymnasium. Part A was based on the Loughborough Intermittent Shuttle Test 
(Nicholas et al., 2000), but included additional components designed to further 
replicate the physiological demands of soccer match play. Briefly, the protocol 
consisted of variable intensity shuttle running over a 20-m distance that included 
walking, jogging (55% V 02max), cruising (85% V o2max), backward cruising 
(85% V o2 max)? zigzag sprinting, rest periods and timed sprinting (Brower; Utah, 
USA) undertaken in a repeated sequence dictated by pre-recorded audio compact 
discs. This sequence was undertaken for 45 min, followed by a 10-min recovery 
period (half-time), and then continued for a subsequent 30-min exercise period. 
Immediately after the intermittent exercise, the MSFT was completed until 
volitional fatigue (Part B), thus the total exercise time was approximately 90 min 
(Figure 3.1).
Heart rates were continuously recorded each 5-s interval using short-range telemetry 
(Polar S610; Polar Electro, Finland). Subjective ratings of perceived exertion (RPE) 
and capillary blood samples were obtained at the beginning of the half-time recovery
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period (Half-time) and immediately following volitional fatigue (Post-MSFT). 
Ambient temperature and humidity were recorded at the beginning and end of 
exercise (ETHG-912; Oregan Scientific, USA). Ad Libitum water consumption was 
encouraged throughout T l; this volume was measured and each individual was 
required to match his fluid intake during T2. Fifteen min following the termination 
of exercise venous blood samples were taken, in a seated position, by venepuncture 
from an antecubital vein in the left arm as previously described.
On the day following (Post-24 h) and the second day following (Post-48 h) each 
main exercise trial the subjects returned to the laboratory at approximately the same 
time (± 1 h) after overnight fasts. Blood samples were drawn by venepuncture and 
the subjects rated the intensity of soreness as previously described.
Blood Sampling and Analysis
Venous blood was collected in a 5-mL container (Becton-Dickinson Ltd, UK) 
containing the anticoagulant ethylenediamine tetra-acetic acid (EDTA). Several 
small aliquots were removed for the triplicate determination of blood lactate and 
glucose concentrations (YSI 2300 Stat, Yellow Springs Instruments, USA), blood 
haemoglobin concentration (Hemocue limited, UK), haematocrit (Micro 
Haematocrit MK IV, Hawsley, England) and changes in plasma volume as 
previously described (Dill and Costill, 1974). The remaining blood was centrifuged 
at 3000 x g for 15 min to obtain plasma. An aliquot of plasma (100 /xL) was added to 
900 /xL of freshly prepared 10% metaphosphoric acid, mixed and frozen at -70°C for
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subsequent vitamin C analysis. The remaining plasma was frozen and stored at 
-70°C prior to subsequent analysis. Two additional 7-mL blood samples were 
collected in serum separation tubes (Becton-Dickinson Ltd, UK), left to stand for 15 
min and then centrifuged at 3000 x g for 15 min to obtain serum. The serum was 
transferred to appropriate containers and subsequently stored at -70°C before 
subsequent analysis.
Serum myoglobin (Mb) concentrations and creatine kinase (CK) activities were 
measured with commercial available kits (A11A00165 and A11A00008, 
respectively; ABX Diagnostics, UK) using an automated spectrometer (MiraS; ABX 
Diagnostics, UK). Serum cortisol concentrations were determined using an 
automated time-resolved fluoroimmunoassay (AutoDELFLA™ Cortisol kit, Perkin 
Elmer, Life Sciences, UK). Serum hydroperoxide (HPO) concentrations were 
measured using the method of Wolff (1992) as described in McEneny et al. (1998). 
Low density lipoprotein was isolated from plasma and oxidised according to the 
method of McDowell et al. (1995). Subsequently, the production o f’ conjugated 
dienes was followed at 234 nm and the lag time taken as a measure of the resistance 
of the particle to oxidation. Vitamin C concentrations were determined using a 
fluorimetric assay using a centrifugal analyser with fluorescence attachment 
according to the method of Vuilleumier (1993). Plasma concentrations of 
a-tocopherol, 7-tocopherol, retinol and /3-carotene were measured by high- 
performance lipid chromatography with electrochemical detection according to the 
methods of Thumham et al. (1988).
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Statistical Analysis
Statistical analysis was carried out using SPSS software (version 12.0;- SPSS Inc., 
IL). Group data were expressed as mean ± SEM and statistical significance was set 
at the P < 0.05 level. Subject characteristics were compared under supplementation 
groups using independent samples /-tests (Table 3.1). Environmental conditions 
were compared using paired samples /-tests. The percentage change in exercise 
times to exhaustion during part B (individual delta values) was compared under PS 
and P conditions using an independent samples /-test. The remaining data, which 
contained multiple time points during each trial, were analysed using mixed-model 
repeated measures ANOVA (within subject factors: trial x time of sample; between 
subject factor: supplementation groups). Mauchly’s test was consulted and 
Greenhouse-Geisser correction was applied if the assumption of sphericity was 
violated. If a significant P  value was identified for the interaction effect 
(supplementation group x trial x time of sample), supplementation was deemed to 
have a significant effect. If a significant P  value was identified for the main effect of 
time (time of sample), multiple pairwise comparisons were made using Bonferonni 
confidence interval adjustment, with statistical significance set at P < 0.01.
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3 .3  R E SU L TS
The environmental conditions were not significantly different during all trials, 
ambient temperature being 19.6 ± 0.7 and 21.3 ± 0.5°C, and humidity 51.5 ± 2.6 and 
54.0 ± 2.8%, respectively for T1 and T2. Mean and peak exercising heart rates were 
not significantly different for PS and P during T1 (PS, P: 151 ± 6, 153 ± 6; 196 ± 4, 
196 ± 4 beats-min'1, respectively) and during T2 (PS, P: 149 ± 5, 149 ± 7; 196 ± 4, 
195 ± 3 beats min'1, respectively). Blood lactate concentrations were similarly 
elevated from Pre-exercise (1.3 ±0.1 mmol-L'1) at Half-time (2.4 ± 0.2 mmol-L'1), 
Post-MSFT (6.1 ± 0.2 mmol-L'1) during all trials (PO.01). Blood glucose 
concentrations were not significantly different for Pre-exercise, Half-time, Post- 
MSFT and Post-exercise, being 4.2 ± 0.1, 4.5 ± 0.1, 5.3 ± 0.1, 4.0 ± 0.1 mmol-L'1, 
respectively for all trials. Ratings of perceived exertion were not different between 
trials at Half-time or at exhaustion, being 14 ± 1 and 18 ± 1 units, respectively for all 
trials. Estimated changes in plasma volume were not different between trials or at 
any point during the course of the data collection (Table 3.2). No differences were 
observed in the calculated amount or composition of the food consumed during any 
trial (Table 3.3).
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Table 3.2 Estimated percentage changes in plasma volume throughout both trials for
phosphatidylserine supplementation group and placebo group.
Tl Tl T l Tl T2 T2 T2 T2
Pre-ex Post-ex Post-24 h Post-48 h Pre-ex Post-ex Post-24 h Post-48 h
PS
-
2.0 ± 2.5 6 .3  ± 3 .6 4.0 ± 2.1 -3.6 ±2.1 -2 .8  ± 1.5 0.5 ± 1.7 4.1 ± 3.1
p - 3.6 ± 1.5 6 .3  ± 1 .9 5.3 ± 1.5 -1.4 ± 1.7 0 .5  ± 1 .4 1.9 ± 1.4 5.1 ± 1.6
Values are mean ± SEM (N=8). PS: phosphatidylserine group; P: placebo group. Tl: trial 1; T2: trial 
2; Pre-ex: pre-exercise; Post-ex: post-exercise; Post-24 h: 24 hours post-exercise; Post-48 h: 48 hours 
post-exercise.
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Table 3.3 Energy intake and dietary composition during both exercise trials for
phosphatidylserine supplementation group and placebo group.
Energy
(M Jd'1)
CHO 
(% energy)
Fat 
(% energy)
Protein 
(% energy)
VitC
(m g d 1)
VitE
(m g d 1)
PS Trial 1 11.4 ±0.9 44 ±3 30 ±3 24 ±2 57 ± 13 8 ± 2
PS Trial 2 10.8 ±0.8 42 ± 2 30 ± 2 23 ± 1 65 ± 14 8 ± 1
P Trial 1 9.5 ±0.9 43 ± 1 30 ±2 25 ± 2 68 ± 17 8 ± 2
P Trial 2 9.7 ±0.6 45 ± 1 30 ±2 24 ± 1 55 ±15 8 ± 2
Values are mean ± SEM (N=8). PS: phosphatidylserine group; P: placebo group. Analysis does not 
include S-PtdSer supplementation.
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Exercise Performance
Exercise times to exhaustion during Part B of the exercise protocol were similar 
between the groups prior to supplementation (P: 11.3 ± 0.6; PS: 11.2 ± 0.7 min; 
P=0.894). There was a non-statistical tendency for the change (i.e. T2 - Tl, 
expressed as a percentage of T2) in the exercise times to exhaustion to be longer in 
PS when compared with P, being 4.2 ± 0.7 and -3.7 ± 4.2%, respectively (^=1.86; 
P=0.084; Cohen’s d= 0.92) (Figure 3.2). Supplementation had no significant effect 
on sprint speeds during Part A of the exercise protocol (supplementation group x 
trial x time of sample, P=0.143). The changes (i.e. T2 - T l, expressed as a 
percentage of T2) in sprint speeds during sprints 1-6, 7-11 and 12-17 were 3.7 ± 1.3, 
4.1 ± 1.4, 7.3 ± 2.6% and 3.7 ± 2.8, 4.4 ± 2.8, 0.4 ± 2.8% for PS and P, respectively 
(Figure 3.3).
Serum Cortisol Concentrations
Pre-exercise, Post-exercise, Post-24 h and Post-48 h serum cortisol concentrations 
for all trials were 392 ± 15, 526 ± 24, 295 ±17  and 306 ± 17  nmol-L"1, respectively 
(time of sample effect, F=43.80; P 0 .001 ; partial eta2=0.16) (Figure 3.4). 
Supplementation had no affect on cortisol values (supplementation group x trial x 
time of sample, P=0.437).
63
16 n
o  15 
E
~  14 
o
'% 133cs
JZ 
X 
0
0
E'<P
0</>
O
0
X
LJJ
CO
t:0
CL
12
11
10
9
8
7
6
D- •a
i i—
Trial 1 Trial 2
P la c e b o  G roup
o — —
C r
O
5- • -
o -
0-
o -
■o
o
■o
■e
o
■o
_  — — — — °
Trial 1 Trial 2
P S  G roup
Figure 3.2 Performance during the multistage fitness test (MSFT) undertaken 
during Part B of each exercise trial. Individual data is presented as open shapes and 
filled shapes present mean group values. Trial 1: pre-supplementation; Trial 2: post­
supplementation.
64
6.6 PS Trial 1
6.4
^6.2TJ
©a>a</>
.E 6 
a.W
0)
2  5.8 
0)
5.6
—• — P S  Trial 2 
- -D --P  Trial 1 
P Trial 2
5.4
Sprints 1-5 Sprin ts 6-11 
Sprints
Sprints 12-17
Figure 3.3 Sprinting speeds during Part A of the exercise protocol. Values 
represent mean ± SEM (supplementation group x trial x time of sample, P=0.143; 
time of sample, P=0.055). PS: phosphatidylserine group; P: placebo group.
65
500 -
700 n
tJ 600 H 
o 
E
c o
2~  400 ^
0) o c o o
oto
t  o o
E3
300 -
200 -
!s 100-
PS Trial 1
-PS Trial 2
P Trial 
P Trial
P re-exercise  Post-exercise  Post-24 hr
Time of sample
Post-48 hr
Figure 3.4 Serum cortisol concentrations. Values represent mean ± SEM (N=8; 
supplementation group x trial x time of sample, P=0.437; time of sample, P0.001). 
PS: phosphatidylserine group; P: placebo group.
66
Markers o f Muscle Damage and Perceived Soreness
Serum Mb concentrations and CK activities are shown in Figure 3.5. Post-exercise 
Mb and CK were above Pre-exercise values in all trials, being elevated by 296 ± 48 
and 76 ± 7%, respectively (time of sample effects being: F=42.65; PO.OOl; partial 
eta2=0.75 and F=16.59; PO.OOl; partial eta2=0.54, respectively). The activity of 
CK peaked at Post-24 h in all trials, while Mb values had returned to Pre-exercise 
values at Post-24 h. No significant interaction effects were determined for Mb and 
CK (supplementation group x trial x time of sample being P=0.190 and P=0.596, 
respectively). General soreness was elevated the day following exercise (Post-24 h) 
above Pre-exercise values and then returned to baseline values at Post-48 h (Table 
3.4). The pattern of soreness was not significantly influenced by supplementation.
Serum Hydroperoxide Concentrations and Conjugated Diene Lag Times
Serum HPO concentrations were significantly elevated at Post-exercise by 
approximately 24 ± 5% (time of sample effect, F=9.31; F=0.001; partial eta2=0.40) 
in all trials (Figure 3.6). Supplementation had no significant effect on HPO 
(supplementation group x trial x time of sample, P=0.500). Exercise caused a 
significant elevation in conjugated diene lag times at Post-exercise (time of sample 
effect, F=4.20; P=0.011; partial eta2=0.23), being 67.5 ± 1.4, 69.8 ± 1.1, 68.4 ± 1.0 
and 66.5 ± 1.2 min at Pre-exercise, Post-exercise, Post-24 h and Post-48 h, 
respectively (Figure 3.7). Supplementation did not affect conjugated diene lag times 
(supplementation group x trial x time of sample, P=0.489).
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Figure 3.5 (a) Serum myoglobin concentrations and (b) creatine kinase activities. 
Values represent mean ± SEM (N=8; supplementation group x trial x time of 
sample, P=0.190 and P=0.596, respectively; time of sample, PO.OOl and PO.OOl, 
respectively). PS: phosphatidylserine group; P: placebo group.
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Plasma Antioxidant Vitamin Concentrations
Post-exercise plasma vitamin C concentrations were significantly elevated when 
compared with Pre-exercise values in all trials (time of sample effect, iM).001), 
although these values were similar before and after supplementation in PS and P 
(Table 3.5). Plasma concentrations of Q'-tocopherol, retinol and /3-carotene were 
similar throughout the duration of each trial and were not significantly different 
between trials (Table 3.5). Supplementation significantly affected plasma 
7-tocopherol concentrations (supplementation group x trial x time of sample, 
F= 4.52; P=0.008; partial eta2=0.24). Following supplementation the change in Pre­
exercise and Post-exercise values were 75 ± 21 and 94 ± 22% higher than Tl values, 
respectively in PS (Table 3.5).
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3.4 DISCUSSION
The study primarily aimed to investigate whether short-term S-PtdSer 
supplementation would influence muscle soreness and markers of muscle damage 
and oxidative stress following an exhaustive running protocol consisting of 
intermittent running designed to simulate the physiological demands of soccer that 
was immediately followed by a progressive run in well-accustomed university 
soccer players. The supplementation regime significantly increased plasma y- 
tocopherol concentrations throughout the day of exercise; but did not cause increases 
in the concentrations of any other antioxidant vitamin measured. Moreover, 
supplementation with S-PtdSer had no effect on perceived muscle soreness or 
markers of muscle damage and lipid peroxidation. An unexpected and potentially 
useful outcome from this investigation was that oral supplementation with 750 mg-d' 
1 S-PtdSer for 10 d tended to improve running performance.
The uptake and biokinetics of PtdSer following oral administration in humans are 
largely unknown. However, oral administration with PtdSer in rats suggests that 
although the majority of the exogenous phospholipid content is hydrolysed and 
degraded, small fractions of PtdSer remain available (Pepeu et al., 1996). 
Furthermore, the addition of exogenous PtdSer to mammalian cell cultures results in 
efficient incorporation within a variety of cell membranes (Nishijima et al., 1986). 
Therefore, it is likely that the short-term supplementation regime used in the current 
study will have caused transient increases in the PtdSer content within systemic 
circulation and incorporation of PtdSer within cell membranes in the PS group.
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In the present study, exercise caused rises in serum cortisol concentrations that were 
similar to those previously reported following comparable activities (Thompson et 
a l, 2001a), suggesting that the protocol activated the hypothalamo-pituitary-adrenal 
(HPA) axis (Monteleone et al., 1990). However, supplementation had no effect on 
serum cortisol concentration at any time during the investigation. This finding does 
not support those of Monteleone et a l (1990; 1992) who reported that PtdSer 
supplementation resulted in significant reductions in plasma adrenocorticotrophic 
hormone (ACTH) and cortisol concentrations during submaximal exercise in 
untrained subjects.
The dose of S-PtdSer used in the current study was similar to the regime employed 
by Monteleone et a l (1992) that used 800 mg-d'1, but the possibility exists that this 
dose might not have been high enough to attenuate the cortisol response in these 
active individuals. Alternatively, increased blood cortisol concentration is a generic 
response to stress from both psychological and physical origin; consequently, as the 
current experimental design was completed until volitional exhaustion during both 
trials, the overall stress might have been similar during all trials. It remains 
plausible, although speculative, that exogenous S-PtdSer might have influenced 
membrane-mediated factors that might have attenuated the stimulation of ACTH and 
subsequent cortisol release (Monteleone et al., 1992) at some time point during 
exercise (although serial blood samples were not available during the exercise 
protocol to evaluate this). Thus, a blunted activation of the HPA axis might have led 
to a reduced perception of stress and partially contributed to the finding that S- 
PtdSer supplementation tended to enhance running performance in PS when 
compared with P. Also, increases in membrane-bound PtdSer might have the
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potential to enhance muscle excitation-contraction coupling, potentially through the 
activation of different protein kinase C isoforms (Kajikawa et al., 1983) and/or 
enhanced calcium uptake (Pepeu et al., 1996), which might have contributed to the 
finding that supplementation tended to improve exercise performance.
The exercise induced increases in perceived soreness and serum concentration of Mb 
and the activity of CK were comparable to those previously reported for accustomed 
individuals that completed similar activity patterns (Thompson et al., 2001). 
Nevertheless, supplementation had no effect on markers of muscle damage (CK and 
Mb) or the extent of perceived soreness in PS or P. These findings are in spite of a 
tendency for the PS group to increase exercise performance during Part B of the 
protocol. Exercise elevated serum hydroperoxide concentrations and conjugated 
diene lag times to a similar extent before and following supplementation, 
demonstrating that exercise caused radical production that overwhelmed antioxidant 
defence and led to comparable lipid peroxidation during all trials. Therefore, it is 
possible that S-PtdSer might have had some protective effect in reducing muscle 
damage and inflammation that was masked by the unexpected tendency for 
performance to be improved in the PS group. Further protection might have been 
afforded against the delayed onset of muscle damage that has been recently 
associated with inflammatory processes caused by ffee-radicals (Aoi et al., 2004), 
had supplementation been continued on the days following exercise.
Supplementation in PS led to approximately 2-fold increases in plasma 7-tocopherol 
concentrations before and following exercise; although, concentrations returned to 
basal levels Post-24 h. Oral supplementation with foods containing high
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concentrations o f 7 -tocopherol have been demonstrated to elevate blood 
7 -tocopherol concentrations; however, the mechanism for the increases in plasma 
7 -tocopherol concentrations following S-PtdSer supplementation are unclear, since 
soy oil consumption has previously been shown to have no effect on blood 
7 -tocopherol concentrations in humans (Cooney et al., 2001). Nonetheless, increases 
in plasma and tissue 7 -tocopherol in rats have been demonstrated to attenuate protein 
and ascorbate oxidation following inflammation-mediated damage without affecting 
a-tocopherol concentrations (Jiang et al., 2002). Thus, the transient increases in 
plasma 7 -tocopherol concentrations and probable increases in tissue 7-tocopherol 
concentrations might have augmented the antioxidant defence in PS during T2, 
although supplementation had no effect on concentrations o f the other plasma 
antioxidant vitamins (vitamin C, a-tocopherol, retinol and ^-carotene) or lipid 
peroxidation. In addition, evidence has been presented suggesting anti-inflammatory 
effects o f 7-tocopherol that are different from its free radical scavenging actions 
(Jiang and Ames, 2003) possibly mediated through specific protein binding 
interactions (Hensley et al., 2003).
In conclusion, S-PtdSer supplementation had no effect on perceived soreness and 
markers o f muscle damage and oxidative stress caused by exhaustive exercise 
designed to simulate the movement patterns o f soccer. There are several plausible 
reasons for the lack of effect o f S-PtdSer supplementation in the current study. The 
supplementation regime used in the current study might not have been optimal in 
attenuating the activation o f the HPA axis, oxidative stress and inflammation 
responses to exhaustive exercise. In addition, as the exercise was continued to 
exhaustion, any effect o f supplementation might have been shrouded by differing
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amounts of external work. The tendency for PS to improve running performance 
when compared with P suggested that there might be a true effect of PtdSer 
supplementation; therefore, the potential ergogenic effects of S-PtdSer warrant 
future investigation.
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CHAPTER FOUR
EXPERIMENTAL STUDY TWO
Phosphatidylserine supplementation and recovery 
following downhill running
19
4.1 INTRODUCTION
Phosphatidylserine (PtdSer) is a phospholipid species that is incorporated in the 
membrane of eukaryotic cells and exhibits a range of important regulator functions 
within mammalian cells (Blokland et a l, 1999). The addition of PtdSer to 
mammalian tissues inhibits the production of pro-inflammatory cytokines (Gilbreath 
et a l, 1986; Aramaki et a l, 1997) and induces anti-inflammatory responses (Huynh 
et a l, 2002) in in-vitro preparations. In addition, intravenously injected PtdSer has 
been demonstrated to have an inhibitory effect on the immune response to 
endotoxin-induced inflammation in rodents (Monastra and Bruni, 1992). Although 
the mechanism(s) by which PtdSer inhibits the immune response remain unclear, 
recent data suggest that PtdSer inhibits immune responses by acting on cell types 
(e.g., macrophages, fibroblasts, neutrophils, endothelial cells, epithelial cells) at the 
site of inflammation (Hoffmann et a l, 2005). Furthermore, in-vitro studies have 
demonstrated that PtdSer has the potential to act as an antioxidant with the ability to 
protect cells against oxygen-derived free radicals (Latorraca et a l, 1993) and 
suppress iron-dependent lipid peroxidation (Dacaranhe and Terao, 2001).
Soybean-derived PtdSer (S-PtdSer) has been established as a safe oral supplement 
for human consumption, using established biochemical and haematological 
parameters (Jorissen et a l, 2002); additionally, no side effects following various 
supplementation regimes have been reported (Pepeu et a l, 1996). Fahey and Pearl 
(1998) reported that short-term oral S-PtdSer attenuated the perception of muscle 
soreness that followed intense weight training. Although the mechanism(s) 
responsible for this action were unclear, these authors suggested that reductions in
80
circulatory cortisol concentrations following exercise might have been associated 
with decreased protein degradation. The aforementioned anti-inflammatory and 
antioxidant properties of PtdSer led to experimental study 1, where the effect of 
S-PtdSer supplementation on the magnitude of lipid peroxidation following 
exhaustive intermittent running was investigated. Changes in serum HPO 
concentrations suggested that this exercise elevated lipid peroxidation to an equal 
extent before and following 750 mg'd"1 S-PtdSer for 10 d. However, exercise 
performance tended to be improved following S-PtdSer supplementation and since 
the blood samples were taken following the completion of maximal exercise, free 
radical production was probably higher following S-PtdSer supplementation. 
Consequently, it was plausible that the potential antioxidant properties of PtdSer 
might have been concealed in this study. In addition, supplementation was ceased on 
the day of exercise and it is possible that continuing S-PtdSer supplementation 
during the early stages of an ensuing acute inflammatory response, might afford 
greater protection.
Eccentric muscle activity causes muscle injury and leads to an acute inflammatory 
response (Childs et a l , 2001). During this response, neutrophils and macrophages 
migrate to the location of muscle damage, penetrate the damaged tissue, elevate free 
radical production and activate cytokines (Macintyre et al., 1995). Additionally, 
exercise produces increases in mitochondrial oxygen flux that have been implicated 
as a source of free radicals during the reduction of molecular oxygen in the electron 
transport chain (Dekkers et al., 1996). Free radicals can lead to oxidative damage in 
a wide range of molecular structures including lipids, proteins and DNA, where the 
antioxidant defences are overwhelmed (Kanter et a l, 1988). Therefore, downhill
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treadmill running has the potential to initiate inflammation and increase oxidative 
stress. These processes have the potential to cause muscle damage, the symptoms of 
which include: soreness, decrease in the range of motion of joints in affected limbs, 
decreased muscular strength, decreased power output, leakage of myofibre proteins, 
inflammation and oedema (Kendall and Eston, 2002).
The purpose of the current study was to investigate the antioxidant and anti­
inflammatory effects of short-term S-PtdSer supplementation on markers of muscle 
damage, inflammation and oxidative stress following prolonged downhill running.
Null Hypotheses
HOi: Downhill running will not influence markers of antioxidant status, tissue 
oxidation, muscle damage, inflammation, perceived feeling states, and 
muscle soreness.
HO2: Supplementation with S-PtdSer will not influence markers of inflammation,
antioxidant status, lipid peroxidation, muscle damage, and muscle soreness 
after downhill running.
H O 3: Supplementation with S-PtdSer will not influence neuroendocrine responses
to downhill running.
H O 4: Supplementation with S-PtdSer will not alter perceived feeling states during
downhill running.
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4.2 METHODS
Subjects
Ten healthy males volunteered to undertake this study; however, eight subjects (age: 
21.0 ± 0.3 years; height: 1.79 ± 0.02 m; body mass: 81.2 ± 3.2 kg) completed all of 
the study requirements and were included in the subsequent analyses. All subjects 
were informed about the potential risks of the study and gave written informed 
consent for their participation in the study, which was approved by a university 
ethics committee and completed in accordance with the policy statement of the 
American College of Sports Medicine. No subject had prior history of 
cardiovascular or respiratory disease and all subjects were non-smokers. Potential 
subjects attended an interview prior to undertaking the study and were subsequently 
excluded if they had taken nutritional supplements in the last 8 weeks.
Experimental Design
Over a period of approximately eleven weeks, each subject completed five downhill 
runs on a motorised treadmill. Approximately 14 d after an initial familiarisation 
trial the subjects completed four main trials (trials 1-4). Trials 1 and 3 provided pre­
supplementation control trials as the washout kinetics of PtdSer are currently 
unknown. Following trials 1 and 3 the subjects were assigned, in a double-blind and 
balanced order crossover fashion, to receive either 750 mg-d'1 S-PtdSer (PS) or a 
weight matched glucose polymer placebo (P). Supplementation was taken for a 10-d
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period that began 7 d prior to Trials 2 and 4. The duration between trials 1 and 2 and 
trials 3 and 4 was exactly 14 d. Trials 2 and 3 were separated by a 4-week ‘washout’ 
period. Venous blood, measurements of joint range of motion, and ratings of 
perceived soreness and feelings were assessed prior to exercise (Pre-exercise), after 
exercise (Post-exercise) the day following exercise (Post-24 h) and the second day 
after exercise (Post-48 h) during each Trial. The experimental design is illustrated in 
Figure 4.1.
The S-PtdSer supplements were manufactured using the method of specific 
transesterification of soybean lecithin and then blended with additional soybean 
lecithin to provide a concentration of 20% PtdSer (Lucas Meyer; Hamburg, 
Germany). Both supplements were administered in capsules and placed in generic 
packaging. Subjects were instructed to maintain their normal diet and activity 
patterns throughout the study. Subjects weighed and recorded the food that they 
consumed for two days prior to and for three days after exercise. Weighed food 
records were analysed using commercial software (CompEat v5.8.0; Nutrition 
Systems, UK). In addition, the subjects were instructed to abstain from strenuous 
exercise for three days prior to and two days following exercise. At the completion 
of the study all subjects gave their verbal assurance that they had complied with all 
instructions.
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Preliminary Procedures
The familiarisation exercise trial served to reduce the anticipated trial order effects 
that are apparent following eccentric exercise protocols and to define individualised 
exercise intensities for trials 1 to 4. Exercise started with a 3-min stage of horizontal 
running at 5 km-h'1. Subsequent 3-min stages were undertaken at -17.5% at a speed 
that began at 5 km-h'1 and increased at a rate of 1 km-h'1 until the subject reached a 
heart rate of 70% of age-predicted maximal heart rate. After a 3-min passive rest 
period each subject completed a -17.5% treadmill run for 30 min at the terminal 
speed reached during the progressive section of the protocol. This individualised 
exercise protocol was recorded and repeated during each subsequent trial (trials 1 to 
4).
Main Trial Procedures
On the day of each main exercise trial the subjects reported to the laboratory at 
approximately the same time of day (± 1 h) and following an overnight fast. Subject 
mass (model 712; Seca, Germany) and height (Portable Stadiometer; Holtain, UK) 
were recorded. The intensity of muscle soreness for the whole body general soreness 
(GenS), hamstrings soreness (HS), quadriceps soreness (QS) and gluteal soreness 
(GS) were rated on an eleven-point scale ranging from 0 (not sore) to 10. (very, very 
sore) (Appendix E). The subjects completed exercise-induced feeling inventories 
(EFI) as described in detail by Gauvin and Rejeski (1993). Briefly, the subjects rated 
their feelings using the 12-item adjective scale on an analogue scale from 0 (do not
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feel) to 5 (feel very strongly) (Appendix F). The appropriate adjectives were 
averaged to obtain four perceived feeling states (Positive Engagement, 
Revitalisation, Tranquillity and Physical Exhaustion). Active range of motion 
(ROM) during knee flexion and hip flexion were assessed on the dominant leg with 
a Leighton Flexometer (Spokane, USA) using standard protocols described by 
Hubley-Kozey (1991). During hip flexion the subject started in a supine position on 
a bench with the instrument attached to the lateral side of the upper segment of the 
dominant leg; the dial was aligned with the greater trochanter of the femur. The 
dominant knee was extended and the dial was zeroed and locked while in a 
horizontal position on the bench. The subject was asked to move the leg in an arc 
upwards as far as possible with the average of 3 trials at each time point being 
recorded. Care was taken to confirm that the back remained in contact with the 
bench and that the pelvis was stabilised throughout the movement. During knee 
flexion the subject started in a prone position with the knees positioned at the end of 
the bench. The instrument was attached to the lateral side of the lower segment of 
the dominant leg; the dial was aligned with the lateral epicondyle and the lateral 
malleolus. The dominant knee was held in a neutral position and the dial* was zeroed 
and locked while in a horizontal position on the bench. The subject was asked to 
move the leg in an arc upwards as far as possible with the average of 3 trials at each 
time point being recorded. Care was taken to confirm that the ankle position was 
kept constant and that the pelvis was stabilised throughout the movement.
Following a venepuncture (Vacutainer system; Becton-Dickinson Ltd, UK), taken 
from an antecubital vein in the right arm, the subjects completed the eccentric 
exercise protocol (mean exercise time, gradient and speed were: 51.0 ± 1.5 min,
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-16.5 ± 0.0%, 8.7 ± 0.3 km-h'1, respectively). Heart rates (Polar S610; Polar Electro, 
Finland) and subjective ratings of perceived exertion (Borg, 1998) were monitored 
throughout the eccentric exercise protocol. Ambient temperature and humidity were 
recorded at the beginning and end of exercise (ETHG-912; Oregan Scientific, USA). 
Post-exercise EFI were obtained and venous blood samples were taken from an 
antecubital vein in the left arm as previously described.
Subjects returned to the laboratory on the day following (Post-24 h) and the second 
day following (Post-48 h) each main exercise trial at approximately the same time (± 
1 h) after overnight fasts. During these visits blood samples were drawn, joint ROM 
were measured and ratings of soreness were completed, as previously described.
Blood Sampling and Analysis
Venous blood was collected in a 5-mL container (Becton-Dickinson Ltd, UK) 
containing the anticoagulant ethylenediamine tetra-acetic acid (EDTA). Several 
small aliquots were removed for the triplicate determination of blood lactate 
concentration, glucose concentration (YSI 2300, Yellow Springs Instruments, US), 
haemoglobin concentration (Hemocue Ltd, UK), haematocrit (Micro haematocrit 
MK IV, Hawksley, UK) and changes in plasma volume were estimated as 
previously described (Dill and Costill, 1974). The remaining blood was centrifuged 
at 3000 x g for 15 min to obtain plasma. An aliquot of plasma (100 pL) was added to 
900 pL of freshly prepared 10% metaphosphoric acid, mixed and frozen at -70°C for 
subsequent vitamin C analysis. The remaining plasma was frozen and stored at
-70°C prior to subsequent analysis. Two additional 7-mL blood samples were 
collected in serum separation tubes (Becton-Dickinson Ltd, UK), left to stand for 15 
min then centrifuged at 3000 x g for 15 min to obtain serum. The serum was 
transferred to appropriate containers and subsequently stored at -70°C prior to 
analysis.
Plasma cortisol (kit EIA-1887; DRG Instuments, Germany) and adrenocorticotropic 
hormone (ACTH) (kit 7023; Biomerica, US) concentrations were determined in 
duplicate using solid-phase enzyme-linked immunosorbent assays (ELISA). 
Interleukin-6 (IL-6) concentrations in serum were assayed in duplicate using 
commercially available high sensitivity ELISA kits (Diaclone Research, France). An 
automated spectrophotometer (MiraS; ABX Diagnostics, UK) was used to measure 
plasma myoglobin (Mb) concentrations and creatine kinase (CK) activity in 
duplicate with commercially available kits (A11A00165 and A11A00008, 
respectively; ABX Diagnostics, UK). Serum hydroperoxide (HPO) concentrations 
were measured using the method of Wolff (1992) as described in McEneny et al 
(1998). Low density lipoprotein was isolated from plasma and oxidised according to 
the method of McDowell et a l (1995). Subsequently, the production of conjugated 
dienes was followed in duplicate at 234 nm (SpectraMax 190; Molecular Devices 
Corp, US) using the computer software SoftMax Pro Version 3.0 (Molecular 
Devices Corp, US); the change in absorbance (from baseline to the end of reaction) 
was used to quantify change in conjugated diene concentration and the time taken to 
reach half of the maximum oxidation (t>y2Tmx LDL oxidation) was taken as a measure 
of the resistance of the particle to oxidation. Vitamin C concentrations were 
determined using a fluorimetric assay using a centrifugal analyser with fluorescence
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attachment according to the method of Vuilleumier (1993). Plasma concentrations of 
a-tocopherol, 7-tocopherol, retinol, a-carotene, /3-carotene and lycopene were 
measured by high-performance lipid chromatography with electrochemical detection 
according to the methods of Catignani and Bieri (1983) and Thumham et al. (1988).
Statistical Analysis
Statistical analysis was carried out using SPSS software (version 13.0; SPSS Inc., 
IL, US). Group data were expressed as mean ± SEM and statistical significance was 
set at the P  < 0.05 level. All data were assessed for normality (Shapiro-Wilk’s test) 
and data that were not normally distributed (Mb and CK) were log transformed prior 
to analyses. Data from trials 1 and 3 (pre-supplementation control trials) were 
analysed using mixed-model repeated measures ANOVA (within subject factors: 
trial x time of sample; between subject factor: group). If the P  value for the 3-way 
interaction (group x trial x time of sample) reached significance, the subject groups 
reacted differently and supplementation order was deemed to have had an effect. 
The data from all trials were analysed using repeated measures ANOVA (within 
subject factors: trials x time of sample). Mauchly’s test was consulted and 
Greenhouse-Geisser correction was applied if the assumption of sphericity was 
violated. Where a significant P  value was identified for the main effect of trial or 
time (time of sample), multiple pairwise comparisons were made using Bonferonni 
confidence interval adjustment. Pearson product moment analysis was used to 
determine the strength of correlation between plasma ACTH and cortisol 
concentrations.
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4 .3  R E SU L TS
Ambient temperature and relative humidity were similar during all trials, with mean 
values during all trials being 20.1 ± 0.3°C and 71 ± 3%, respectively. All 3-way 
interactions from trial 1 and 3 were non-significant (P >0.172). The mean exercising 
heart rates ranged from 136 ± 4 to 137 ± 3 beats-min'1 and were similar during all 
trials (P=0.951). Blood lactate concentrations were not different between trials 
(P=0.548), with Post-exercise values ranging from 0.9 ± 0.1 to 1.1 ± 2  mmol-L'1 
(Table 4.1). Blood glucose concentrations did not differ between trials (P=0.057) or 
timing of sample (P=0.113), with Post-exercise values ranging from 4.2 ± 0.1 to 4.4 
± 0.2 mmol-L'1 (Table 4.1). Estimated changes in plasma volume were significantly 
lower at Post-exercise when compared with all other time points in the study 
(P <0.039); however, no differences were observed between trials (P=0.972) (Table
4.1). No differences were observed in the calculated amount or composition of the 
food consumed during any trial. The average daily diet comprised of 10.3 ± 0.3 
MJ-d'1, of which 44 ± 1, 30 ± 1, 24 ± 1 and 2 ± 1% of energy intake was obtained 
from carbohydrates, fats, proteins and alcohol, respectively.
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Plasma Adrenocorticotropic Hormone and Cortisol Concentrations
Post-exercise plasma ACTH and cortisol concentrations were 20 ± 6 and 27 ± 3% 
below Pre-exercise values, respectively (time of sample effect, F=4.40; P=0.015; 
partial eta2=0.80 and F=20.29; P=0.001; partial eta2=0.1 A, respectively) (Figure
4.2). These values did not differ between trials (trial effect, P=0.150 and P=0.166, 
respectively). Plasma ACTH concentrations and plasma cortisol concentrations were 
significantly correlated (r=0.412; PO.OOl).
Plasma Myoglobin Concentrations and Creatine Kinase Activities
Plasma Mb concentrations were elevated by 78 ± 12% above Pre-exercise at Post- 
exercise in all trials (time of sample effect, F=15.50; PO.OOl; partial eta =0.69; 
Figure 4.3). Plasma CK activities peaked at Post-24 h in all trials (time of sample 
effect, F=23.25; PO.OOl; partial eta2=0.11\ Figure 4.3), being 200 ± 39% above 
Pre-exercise. There were no significant differences between trials for either Mb or 
CK (trial effect, P=0.865 and P=0.911, respectively).
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Figure 4.2 (a) Plasma adrenocorticotropic hormone (ACTH) concentrations and 
(b) plasma cortisol concentrations throughout each trial. Values represent mean ± 
SEM (N=8). Pre-P: trial prior to supplementation with placebo; P: trial 
supplemented with placebo; Pre-PS: trial prior to supplementation with 
phosphatidylserine; PS: trial supplemented with phosphatidylserine.
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Figure 4.3 (a) Plasma myoglobin concentrations and (b) plasma creatine kinase 
activities throughout each trial. Values represent mean ± SEM (N=8). Pre-P: trial 
prior to supplementation with placebo; P: trial supplemented with placebo; Pre-PS: 
trial prior to supplementation with phosphatidylserine; PS: trial supplemented with 
phosphatidylserine.
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Perceived Soreness and Joint Ranges o f  Motion
Exercise caused increases in perceived soreness at Post-24 h in general soreness 
ratings (GenS) and in all of the reported lower body locations (QS, HS and GS); 
however, no differences were identified between trials (Table 4.2). Table 4.3 
displays mean knee ROM and hip ROM at all time points by trials. Although these 
values were significantly reduced at Post-24 h, there were no differences between 
trials.
Serum interleukin-6 Concentrations
Serum IL-6 concentrations were elevated at Post-exercise by approximately 123 ± 
39% above Pre-exercise values (time of sample effect, F=22.67; PO.OOl; partial 
eta2=0.16) in all trials (Figure 4.4). No differences were identified between the trials 
(trial effect, P=0.871).
Serum Hydroperoxide Concentrations
Serum HPO concentrations were significantly elevated at Post-exercise by 
approximately 27 ± 8% (time of sample effect, F=6.44; P=0.003; partial eta2=0.48) 
in all trials (Figure 4.5). There were no differences between trials (trial effect, 
P=0.789).
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Table 4.2 Perceived ratings of general soreness (GenS) quadriceps soreness (QS), 
hamstring soreness (HS), and gluteal soreness (GS) during all trials.
Pre-supp
Pre-exercise
Pre-supp 
Post-24 h
Pre-supp 
Post-48 h
Post-supp
Pre-exercise
Post-supp 
Post-24 h
Post-supp 
Post-48 h
Effect: P  
trial, 
timing
GenS P 0.4 ± 0.2 2.4 ±0.6 2.4 ± 0.7 0.4 ±0.2 3.1 ± 1.1 1.5 ±0.6 0.766
(0-10) PS 0.5 ±0.6 3.1 ± 1.1 2.6 ±0.7 0.5 ±0.6 2.3 ±0.6 1.1 ±0.8 0.002
QS p 0.3 ±0.2 1.5 ±0.6 0.9 ±0.3 0.3 ±0.2 0.9 ±0.6 0.3 ±0.3 0.092
(0-10) PS 0.3 ±0.2 1.4 ±0.7 1.1 ±0.4 0.3 ±0.2 1.4 ±0.7 1.1 ±0.4 0.043
HS p 0.3 ±0.2 1.1 ±0.4 1.5 ± 0.8 0.3 ± 0.2 2.4 ± 1.1 0.8 ±0.4 0.819
(0-10) PS 0.4 ± 0.2 0.8 ±0.5 0.9 ±0.5 0.3 ± 0.2 1.3 ±0.5 0.4 ± 0.4 0.024
GS p 0.3 ± 0.2 2.9 ±0.8 2.8 ± 0.9 0.4 ±0.2 3.1 ± 1.0 0.9 ±0.4 0.781
(0-10) PS 0.4 ± 0.2 3.3 ± 1.1 3.1 ± 1.2 0.4 ±0.2 2.3 ±0.5 1.3 ±0.8 0.001
Values represent mean ± SEM (N=8). Pre-supp: pre-supplementation trials (trial 1 and trial 3); Post- 
supp: post-supplementation trial (trial 2 and trial 4); P: trial supplemented with placebo; PS: trial 
supplemented with phosphatidylserine. Effects present P-values for the main effect o f trial and the 
main effect o f time o f sample.
97
Table 4.3 Active range of motion during knee flexion (knee ROM) and hip flexion 
(hip ROM) during all trials.
Pre-supp
Pre-exercise
Pre-supp 
Post-24 h
Pre-supp 
Post-48 h
Post-supp
Pre-exercise
Post-supp 
Post-24 h
Post-supp 
Post-48 h
Effect: P 
trial, 
timing
Knee ROM P 118±2 115 ± 3 113 ± 3 120 ± 3 113 ± 2 115 ± 1 0.783
O PS 116 ± 2 113 ± 2 112 ± 3 117 ± 2 111 ± 4 116 ± 3 0.001
Hip ROM P 84 ± 5 73 ± 6 78 ± 7 85 ± 3 84 ± 2 88 ± 6 0.877
O PS 86 ± 4 84 ± 2 88 ± 6 86 ± 4 77 ± 4 76 ± 2 0.011
Values represent mean ± SEM (N=8). Pre-supp: pre-supplementation trials (trial 1 and trial 3); Post- 
supp: post-supplementation trial (trial 2 and trial 4); P: trial supplemented with placebo; PS: trial 
supplemented with phosphatidylserine. Effects present P-values for the main effect o f trial and the 
main effect o f time o f sample.
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Figure 4.4 Serum interleukin (IL-6) concentrations throughout each trial. Values 
represent mean ± SEM (N=8). Pre-P: trial prior to supplementation with placebo; P: 
trial supplemented with placebo; Pre-PS: trial prior to supplementation with 
phosphatidylserine; PS: trial supplemented with phosphatidylserine.
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represent mean ± SEM (N=8). Pre-P: trial prior to supplementation with placebo; P: 
trial supplemented with placebo; Pre-PS: trial prior to supplementation with 
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Susceptibility and Resistance to LDL Oxidation
Average changes in conjugated diene concentrations at Pre-exercise, Post-exercise, 
Post-24 h and Post-48 h were 14.2 ± 0.6, 15.6 ± 0.8, 14.8 ± 1.0, 14.2 ± 0.8 pmol-L'1, 
respectively (time of sample effect, P=0.077; trial effect, P=0.338) (Figure 4.6). 
Post-exercise tyimax LDL oxidation were elevated from Pre-exercise (time of sample 
effect, P=0.001), with average Pre-exercise, Post-exercise, Post-24 h and Post-48 h 
values being 79.2 ± 2.2, 87.2 ± 2.5, 86.1 ± 2.6, 82.5 ± 2.7 min, respectively (Figure 
4.7). No differences existed between trials (trial effect, P=0.192).
Plasma Antioxidant Vitamin Concentrations
Plasma concentrations of vitamin C, a-tocopherol, a-carotene, /3-carotene, lycopene 
were similar throughout the duration of each trial and were not significantly 
different between trials (Table 4.4). Plasma 7-tocopherol concentrations were 
significantly higher in PS when compared with all other trials (trial effect, F=5.32; 
P=0.008; partial eta2=0Al) (Table 4.4).
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Figure 4.6 Change in conjugated diene concentrations throughout each trial. Values 
represent mean ± SEM (N=8). Pre-P: trial prior to supplementation with placebo; P: 
trial supplemented with placebo; Pre-PS: trial prior to supplementation with 
phosphatidylserine; PS: trial supplemented with phosphatidylserine.
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Feeling States
No significant temporal changes were observed in revitalisation (time of sample 
effect, P=0.295), positive engagement (time of sample effect, P=0.357), tranquillity 
(time of sample effect, P=0.671) or physical exhaustion (time of sample effect, 
P=0.081) (Table 4.5). Additionally, no differences were identified between trials in 
any of the EFI subscales (trial effect, P  >0.121) (Table 4.5).
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4.4  DISCUSSION
The main findings of this study were that the supplementation regime (750 mg d'1 S- 
PtdSer administered for 7 d prior to and continued for 2 d following exercise) was 
not effective in attenuating markers of muscle damage, inflammation and oxidative 
stress that followed prolonged downhill treadmill running in previously familiarised 
individuals.
In light of the finding that supplementation with 750 mg-d'1 S-PtdSer for 10 d tended 
to improve performance during exhaustive intermittent running (study 1), the current 
exercise protocol was chosen in order to provide each subject with a repeatable dose 
of exercise that was intended to cause muscle damage, oxidative stress, acute 
inflammation and DOMS. Indeed, this exercise protocol led to increases in markers 
of muscle damage (plasma Mb concentrations and CK activities), lipid peroxidation 
(serum HPO concentrations), inflammation (serum IL-6 concentrations) and DOMS 
(perceived soreness).
The 3-way interactions for the analysis of trial 1 and 3 (pre-supplementation control 
trials) were all non-significant. These data confirmed that the subject groups reacted 
similarly during these trials. Although the washout kinetics of PtdSer are currently 
unknown, there is no evidence to suggest that an effect of supplementation lasted 
longer than the washout period provided.
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As anticipated, plasma cortisol concentrations were positively correlated with 
plasma ACTH concentrations. Plasma concentrations of cortisol and ACTH 
decreased after eccentric exercise. This finding probably reflects the low metabolic 
demand that is associated with downhill running at the current relative intensity and 
is concurrent with previous data (Smith et a l, 1989). Alterations in the 
concentrations of these hormones within the circulation have been interpreted to 
reflect changes in the hypothalamo-pituitary-adrenal (HPA) axis (Monteleone et a l , 
1990). Consequently, it is likely that this bout of exercise did not cause a stress 
induced increase in hypothalamic corticotrophin-releasing factor that has concurrent 
stimulatory effects on a range of regulatory hormones from the anterior pituitary 
(including growth hormone) and sympathoadrenal system (such as adrenaline and 
noradrenaline). Therefore, it is unlikely that the intensity of exercise was sufficient 
to augment the mobilisation of neutrophils into the peripheral circulation as 
mediated by exercise induced increases in catecholamines, cortisol and growth 
hormone (Suzuki et a l , 1999). Interestingly, S-PtdSer supplementation did not alter 
the pattern of ACTH and cortisol release. Fahey and Pearl (1998) reported that 
similar doses of S-PtdSer reduced serum cortisol concentrations following resistance 
training, leading these investigators to support the efficacy of PtdSer to modulate the 
neuroendocrine response to overtraining. The disparity in these findings might be 
partly explained by the different mode of exercise used in these respective studies; 
downhill running, unlike resistance training, did not stimulate the stress-induced 
activation of the HPA axis.
The elevations in plasma Mb concentrations and CK activities were comparable in 
magnitude and followed similar temporal patterns to those that have been previously
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reported following downhill running protocols (Peake et al., 2005). This protocol 
also led to increased soreness (GenS, QS, HS and GS) and decreased the ranges of 
motion recorded during active knee and hip flexion on the day following exercise. 
Furthermore, the time course of the changes in the ratings of soreness, joint 
flexibility, plasma Mb concentrations and plasma CK activities following eccentric 
exercise were similar across all trials; consequently, it was concluded that 
supplementation with S-PtdSer did not affect muscle damage and other important 
corollaries induced by an acute bout of eccentric exercise. In contrast, a similar S- 
PtdSer supplementation regime has been demonstrated to reduce muscle soreness 
during intense weight training (Fahey and Pearl, 1998). These authors postulated 
that exogenous PtdSer might have improved cell membrane stability and/or reduced 
protein degradation by attenuating the stress-induced activation of the HPA axis. 
Although markers of protein catabolism were not measured in the present study, 
there was no evidence to suggest that S-PtdSer affected protein degradation 
following eccentric exercise.
Downhill running led to significant increases in Post-exercise serum IL-6 
concentrations that were comparable to those previously reported to follow similar 
exercise protocols (Peake et al., 2005). The magnitude of the IL-6 increases 
following downhill running were relatively small when compared with the changes 
that have been reported to occur following prolonged endurance exercise (Suzuki et 
al., 2000). This finding probably reflects both the type and duration of activity 
undertaken. Although the stimulus for eccentric exercise induced IL-6 remains 
largely unknown, it is likely that mechanical damage to muscle tissue led to the 
rapid invasion of neutrophils (Tidball, 2005) which produce free radicals that
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stimulate cytokine production. However, supplementation did not affect circulatory 
concentrations of IL-6 in the current study.
Serum HPO concentrations were elevated to a similar extent following exercise in 
all trials; consequently, exercise caused an increase in free radical production that 
overwhelmed the antioxidant defences and, independent of supplementation, 
contributed to comparable amounts of lipid peroxidation.
Exercise did not significantly affect the susceptibility of LDL to copper-induced 
oxidation as measured by changes in conjugated diene concentrations. However, 
t'/imax LDL oxidation times were elevated at post-exercise. As t./2max LDL oxidation is 
a measure of resistance to copper-induced oxidation, the increase following exercise 
might reflect an increase in the mobilization of antioxidant defences following 
downhill running. Supplementation did not influence susceptibility or resistance of 
LDL to in-vitro peroxidation.
Supplementation led to significant increases in plasma 7-tocopherol concentrations 
throughout the PS trial. This increase is in agreement with the findings from 
experimental study 1; however, the mechanism for increasing plasma 7-tocopherol 
following supplementation are unclear. Nevertheless, there is insufficient evidence 
to suggest that the elevations in plasma 7-tocopherol concentrations and probable 
increases in tissue 7-tocopherol affected oxidative stress or inflammation caused by 
eccentric exercise. In addition, supplementation had no effect on concentrations of
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the other plasma antioxidant vitamins (vitamin C, a-tocopherol, 7-tocopherol, 
retinol, a-carotene, /3-carotene and lycopene).
Downhill running did not affect any of the EFI subscales. The EFI was developed to 
assess distinct feeling states that occur during exercise (Gauvin and Rejeski, 1993) 
and these scales have been demonstrated to be sensitive to change during exercise in 
recreationally active males. This difference probably reflects the low metabolic 
demand associated with this downhill running protocol and suggests that DOMS 
does not change the feeling states that are measured by these subscales. The lack of 
change in these feeling states might have contributed to the lack of an identifiable 
difference between trials; nevertheless, the current data does not suggest that 
S-PtdSer modifies feeling states before or following downhill running.
In summary, short-term S-PtdSer supplementation before and following exercise did 
not attenuate perceived soreness and markers of muscle damage, inflammation and 
oxidative stress caused by moderate intensity downhill running. These findings 
indicate that the current supplementation regime is not effective in reducing the 
deleterious effects of eccentric muscle activity.
Il l
CHAPTER FIVE
EXPERIMENTAL STUDY THREE
Effects o f phosphatidylserine supplementation on 
exercise capacity during staged intermittent cycling
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5.1 INTRODUCTION
Phosphatidylserine (PtdSer) is a naturally occurring phospholipid nutrient that 
appears to be essential to the functioning of all mammalian cells (Blokland et a l , 
1999). In humans, PtdSer is most concentrated in organs with high metabolic 
activity, such as brain, heart, skeletal muscle and liver (Diagne et al., 1984). The 
biochemical actions of PtdSer include: [1] regulation of calcium ion uptake, [2] 
regulation of substrate binding (e.g., opiate and glutamate), and [3] the stimulation 
of specific enzymes activities (e.g., ATPase and acetylcholinesterase) (Pepeu et al., 
1996). The discovery of these actions has led investigators to examine the 
pharmacological effects of PtdSer supplementation in humans. Traditionally, PtdSer 
supplements were derived from bovine cortex (BC-PtdSer); however, this source is 
now considered unsuitable due to the risk of transferring infectious diseases and soy- 
derived PtdSer (S-PtdSer) has emerged as a safe alternative. Although Blokland et 
al. (1999) found no differences between the bioactivity of S-PtdSer and BC-PtdSer 
in rats, it remains unclear whether the source of the supplement is an important 
factor in determining the pharmacological actions of PtdSer in humans.
The majority of PtdSer supplementation studies have evaluated higher brain 
functions; indeed, BC-PtdSer has been shown to improve a variety of cognitive 
functions that include memory and verbal response in aging patients (Amaducci and 
SMID group, 1988; Cenacchi et a l , 1993), and more recently S-PtdSer has been 
demonstrated to enhance mood in a subsection of young individuals during mental 
stress (Benton et a l , 2001). Few studies have investigated the effects of PtdSer 
supplementation prior to exercise (Monteleone et a l , 1990; Monteleone et a l, 1992;
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Fahey and Pearl, 1998) and the available data suffer from the methodological 
limitation of using cross-over supplementation designs while the washout kinetics of 
PtdSer remains unclear (Pepeu et al., 1996). Orally administered BC-PtdSer (800 
m gd'1) has been reported to attenuate the serum cortisol response to acute exercise 
stress (Monteleone et al., 1992). Additionally, Fahey and Pearl (1998) reported that 
oral supplementation with 800 mgd'1 S-PtdSer was effective in reducing serum 
cortisol concentration following intensive resistance training. These findings suggest 
that both BC-PtdSer and S-PtdSer act to partly counteract the stress-induced 
activation of the hypothalamo-pituitary-adrenal (HPA) axis, although the 
significance of altering this neuroendocrine response on metabolic function (such as 
substrate utilisation) during exercise has not been evaluated.
Assuming that exogenous PtdSer is effectively incorporated into cardiac and skeletal 
muscles, the aforementioned biochemical actions of PtdSer have the potential to 
influence mitochondrial enzymatic activity. Therefore, PtdSer supplementation 
might affect ‘metabolic inertia’, a proposed determinant of the primary oxygen 
uptake (V o 2) kinetic response to exercise (Grassi, 2000). Consequently, it was 
hypothesised that PtdSer supplementation could reduce accumulated oxygen deficit 
and improve exercise tolerance.
Therefore the purpose of the current study was to investigate the efficacy of short­
term S-PtdSer supplementation on exercise capacity, neuroendocrine function, 
oxygen uptake kinetic response, and perceived feeling states during and immediately 
following intermittent cycling.
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Null Hypotheses
HOi: Intermittent cycling will not influence markers of neuroendocrine function, 
oxygen uptake kinetic responses, and perceived feeling states.
HO2: Supplementation with S-PtdSer will not influence exercise time to 
exhaustion at 85%Vo2max during the final stage of an intermittent cycling 
protocol.
H O 3: Supplementation with S-PtdSer will not influence markers of neuroendocrine 
function, and oxygen uptake kinetics during and following staged 
intermittent cycling.
H O 4: Supplementation with S-PtdSer will not alter perceived feeling states during
and following staged intermittent cycling.
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5.2 METHODS
Subjects
Sixteen healthy males volunteered to participate in this study; fourteen subjects 
(Table 5.1) completed all the study requirements and were included in the analyses. 
All subjects were informed about the potential risks of the study and gave written 
informed consent for their participation in the study, which was approved by a 
university ethics committee. In addition, all subjects were informed that they might 
be asked to consume a supplement rich in S-PtdSer; however, there are currently no 
reported, or inferred, side effects associated with S-PtdSer supplementation (Pepeu 
et al., 1996; Jorissen et a l , 2002). The experimental procedures were in accordance 
with the policy statement of the American College of Sports Medicine. No subject 
had prior history of cardiovascular or respiratory disease and all subjects were non- 
smokers. Potential subjects attended an interview prior to undertaking the study and 
were subsequently excluded if they had taken nutritional supplements in the last 8 
weeks.
Experimental Design
Before the main exercise trials, all subjects visited the laboratory on two occasions 
in order to complete an incremental exercise test and a familiarisation trial. Subjects 
then performed two main exercise trials, which consisted of staged intermittent 
cycling, separated by 16.0 ± 1.3 d. Approximately 5 d after completion of the first 
main exercise trial the subjects were assigned, in a randomised double-blind fashion,
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Table 5.1 Subject characteristics for phosphatidylserine supplementation group 
(PS) and Placebo group (P).
Characteristic PS (N=7) P (N=7) P-value
Age (dec. years) 23.4 ± 1.9 22.2 ± 1.1 0.638
Mass (kg) 84.9 ±3.8 87.7 ±3.2 0.630
Height (m) 1.79 ±0.01 1.81 ± 0.02 0.528
Maximal oxygen uptake (ml-kg'^min'1) 43.8 ±2.0 42.4 ± 1.7 0.645
Values are mean ± SEM. P -  value calculated using independent sample /-test.
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to either a PS group or a placebo (P) group and instructed to take supplements for 
the 10 days prior to trial two. The experimental design is illustrated in Figure 5.1.
The PS group ingested 750 mg d'1 S-PtdSer and the P group ingested a weight 
matched glucose polymer. The S-PtdSer supplements were manufactured using the 
method of specific transesterification of soybean lecithin and then blended with 
additional soybean lecithin to provide a concentration of 20% PtdSer (Lucas Meyer; 
Hamburg, Germany). Both supplements were administered in capsules and placed in 
generic packaging. Subjects were instructed to maintain their normal diet and 
activity patterns throughout the study. Food was weighed and recorded by the 
subjects for two days prior to each exercise trial and for the day afterwards. Analysis 
using commercial software (CompEat v5.8.0; Nutrition Systems, UK) revealed that 
there were no differences in energy intake or dietary composition between 
supplementation groups or trials. The daily diet comprised of 11.2 ± 0.6 MJ d'1, of 
which 52 ± 3%, 30 ± 1%, 16 ± 1% and 2 ± 1% of energy intake was obtained from 
carbohydrates, fat, protein and alcohol, respectively. In addition, the subjects were 
instructed to abstain from strenuous exercise for three days prior to and two days 
following each trial. At the completion of the study all subjects gave their verbal 
assurance that they had complied with all instructions.
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Procedures
During their initial visit to the laboratory the subjects completed an incremental 
exercise test on an electromagnetically braked cycle ergometer (Lode Excalibur 
Sport; Lode, Holland). The work rate began at 60 W and thereafter increased in 30- 
W increments every 3 min until volitional exhaustion. Subjects were instructed to 
pedal at a constant cadence between 75 and 85 revmin"1. Heart rate (Polar S810; 
Polar Electro Oy, Finland) and breath-by-breath respiratory parameters (Oxycon 
Pro; Jaeger, Germany) were simultaneously recorded. The test was used to identify 
maximal oxygen uptake (V o 2max) and also to calculate, using linear regression, the 
work rates required for the staged intermittent exercise protocol.
The subjects then completed a staged intermittent exercise protocol on three separate 
occasions. The intermittent protocol required subjects to complete three 10-min 
stages of cycling at work rates calculated to elicit 45, 55 and 65% V o2max, followed 
by a final exercise bout at 85% V o2max that was continued until exhaustion (an 
inability to maintain a cadence of 60 rev-min'1 despite verbal encouragement). All 
exercise stages were interspaced with 5-min passive rest periods. The first exercise 
trial served to familiarise the subjects with the intermittent exercise protocol, and the 
subjects remained blind to their exercise times to exhaustion throughout the study in 
order to prevent an anticipated trial-order effect. The subsequent main exercise trials 
(T1 and T2) were completed 14-21 d apart. Breath-by-breath respiratory data 
(Oxycon Pro; Jaeger, Germany) and heart rate (Polar S810; Polar Electro Oy, 
Finland) were monitored throughout T1 and T2. Exercise-induced feeling inventory 
(EFI) (Gauvin and Rejeski, 1993) was completed at Pre-exercise and following each
exercise stage. Blood samples were taken by venepuncture (Vacutainer system; 
Becton-Dickinson Ltd, UK) from an antecubital vein at Pre-exercise, on completion 
of the 55% V o2max (Post-55%) and 65% V o2max (Post-65%) exercise stages, 20 
min after the completion of the trial (Post-exercise) and 24 hours after the trial (Post- 
24 h). An additional capillary blood sample was taken immediately after exhaustion 
(Post-85%) for the analysis of blood lactate and glucose concentrations.
Analysis o f Oxygen Uptake and Heart Rate
Breath-by-breath oxygen uptake, carbon dioxide production and 5-s heart rate data 
were averaged for the last minute of exercise for all exercise intensities. 
Subsequently non-protein respiratory exchange ratios were used to calculate the 
rates of carbohydrate and fat oxidation for Pre-exercise and during each exercise 
stage up to and include 65% V02max as previously described (Van Loon et a l, 
2001), using equations derived by Peronnet and Massicotte (1991). Linear 
regression was applied to the final 3 min of oxygen uptake data for each of these 
stages and the 95% confidence interval for the slope was inspected; steady state was 
assumed if the 95% confidence interval included zero.
In addition, breath-by-breath oxygen uptake data were initially edited to remove 
occasional errant breaths (from coughs, sighs or swallows) when values were greater 
than four standard deviations from the local mean (Rossiter et a l,  2000). The data 
for all exercise stages and rest periods were interpolated, using a cubic spline, in 1-s
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intervals. The data for moderate intensity exercise (45-65% V o2max) and subsequent 
rest periods during each trial were normalised (normalised to the respective last 
minute V o2 values), time-aligned and averaged. The data for the final bout (85% 
Vo 2 max) were modelled separately, as the oxygen uptake response to different 
intensity domains (below and above lactate threshold) have been suggested to differ 
(Ozyener et al., 2001). The traditionally defined phase II oxygen uptake on-kinetic 
response (Whipp et al., 1982) was determined for 45-65% V o2max and 85% V o2max- 
The end of phase I was set to 20 s after the onset of constant-load exercise and a 
mono-exponential function (Equation 1) was fitted between the end of phase I and 3 
min of exercise (Schneider et a l , 2002) using iterative non-linear regression 
techniques (SPSS version 12.0; SPSS Inc., IL). Similarly, the off-kinetic response to 
each exercise stage was determined using a mono-exponential function (Equation 2) 
after omission of the first 20 s of post-exercise data (Figure 5.2)
(Equation 1) VO2(0  = V o 2(B) + G - ( l - e ^ - ^ )
(Equation 2) V0 2 (t) = V0 2 ( EE)  -  G' ■ (1 -  )
where V o2(0 is oxygen uptake at time t, V o2(B) is baseline oxygen uptake 
(average V o2 during the minute prior to the onset of exercise), V o2{EE) is end of 
exercise oxygen uptake (average V o2 during the last minute of exercise), G is the 
primary gain (i.e., the calculated change in oxygen uptake), TD is the on-kinetic 
time delay and r  is the time constant (prime mark designates off-kinetics 
parameters). Mean response times for the on-kinetic responses (MRTot1) and off- 
kinetic responses (MRT0ff) were calculated as TD + t  and TD' + x', respectively.
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Blood Sampling and Analysis
Venous blood was collected in a 5-mL container (Becton-Dickinson Ltd, UK) 
containing the anticoagulant ethylenediamine tetra-acetic acid (EDTA). Several 
small aliquots were removed for the triplicate determination of blood lactate and 
glucose concentration (YSI 2300 Stat, Yellow Springs Instruments, USA), blood 
haemoglobin concentration (Hemocue Ltd, UK), haematocrit (Micro haematocrit 
MK IV, Hawksley, England) and changes in plasma volume as previously described 
(Dill and Costill, 1974). The remaining blood was centrifuged at 3000 x g for 15 
min to obtain plasma, which was subsequently dispensed and frozen at -70°C. Two 
additional 7-mL blood sample were collected in serum separation tubes (Becton- 
Dickinson Ltd, UK), left to stand for 15 min, then centrifuged at 3000 x g for 15 min 
to obtain serum. The serum was transferred to appropriate containers and 
subsequently frozen at -70°C. Serum cortisol concentrations were determined using 
an automated time-resolved fluoroimmunoassay (AutoDELFIA™ Cortisol kit, 
Perkin Elmer, Life Sciences, UK).
Perceived Feeling States
Subjects were instructed to respond to the EFI (Appendix F) as described in detail 
by Gauvin and Rejeski (1993). Briefly, the subjects rated their feelings using the 12- 
item adjective scale on an analogue scale from 0 (do not feel) to 5 (feel very 
strongly). The appropriate adjectives were averaged to obtain four perceived feeling 
states (positive engagement, revitalisation, tranquillity and physical exhaustion) at
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each time point as previously described (Gauvin and Rejeski, 1993). The EFI was 
specifically developed to assess distinct feeling states that occur during stages of 
exercise and psychometric studies have indicated concurrent and discriminant 
validity (Gauvin and Rejeski, 1993). Moreover, the EFI has been demonstrated to be 
sensitive to interventions involving recreational active individuals (Lacaille et al., 
2004).
Statistical Analysis
Statistical analysis was carried out using SPSS software (version 12.0; SPSS Inc., 
IL). Group data were expressed as mean ± SEM and statistical significance was set 
at the P  < 0.05 level. Subject characteristics were compared under supplementation 
groups using independent samples /-tests (Table 5.1). The exercise times to 
exhaustion during familiarisation, T1 and T2 were assessed using mixed-model 
repeated measures ANOVA (within subject factors: trials; between subject factor: 
supplementation groups) followed by simple main effect analysis. The remaining 
data, which contained multiple time points during each trial, were analysed using 
mixed-model repeated measures ANOVA (within subject factors: trial x time of 
sample; between subject factor: supplementation groups). Mauchly’s test was 
consulted and Greenhouse-Geisser correction was applied if  the assumption of 
sphericity was violated. If a significant P  value was identified for the three-way 
interaction effect (supplementation group x trial x time of sample), supplementation 
was deemed to have a significant effect. If a significant P  value was identified for 
the main effect of time (time of sample), multiple pairwise comparisons were made
125
using Bonferonni confidence interval adjustment, with statistical significance set at 
P<  0.01.
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5.3 RESULTS
Exercise times to exhaustion at 85%V02max were similar between groups during 
familiarisation and T1 (PS, P: 8:02 ± 1:37, 7:46 ± 0:41; 7:51 ± 1:36, 8:09 ± 0:54 
min:s). A significant interaction effect (supplementation group x trial, F=7.27; 
P=0.007; partial eta =0.85) indicated that supplementation had a significant effect 
on time to exhaustion; post hoc analysis revealed no differences between trials for P 
(P=0.670) and significant differences between trials for PS (P=0.001). The 
magnitude of change in exercise times to exhaustion (individual T2 values minus T1 
values) in PS were 2:00 ± 0:28 min:s while P remained similar (0:07 ± 0:13 min:s) 
(Figure 5.3).
Heart Rates
Supplementation did not significantly affect last minute heart rates during the 
protocol (supplementation group x trial x time of sample, P=0.058). Mean last 
minute heart rates increased throughout the stages of the protocol (Table 5.2), being 
119 ± 2, 137 ± 3, 156 ± 3 and 183 ± 2 beats-min'1, respectively at 45, 55, 65 and 
85% V 02max-
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Figure 5.3 Exercise times to exhaustion at 85% V 02max completed at the end of 
each exercise trial. Individual data are presented as open shapes and mean data are 
presented as filled shapes. PS: phosphatidylserine group; P: placebo group, 
(supplementation group x trial interaction, P=0.007).
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Oxygen Uptake and Fuel Oxidation Rates
Last minute oxygen uptake data are presented in table 5.2. These data increased 
progressively with exercise intensity (47 ± 1, 58 ± 1, 70 ± 1 and 97 ± 2% Vo2max; 
time of sample effect, F=562.66; PO.OOl; partial eta2=0.98) and the supplement x 
trial x time of sample interaction was not significant (P=0.160). Steady state was 
confirmed in all stages at exercise intensities up to and including 65% V o2max- 
Mean carbohydrate oxidation, fat oxidation and total energy expenditure were: 1.40 
± 0.06, 1.95 ± 0.11, and 2.49 ± 0.14 g-min"1; 0.28 ± 0.02, 0.27 ± 0.02, and 0.27 ± 
0.02 g-min"1; 34.0 ± 0.8, 42.3 ± 1.0, and 51.1 ± 1.1 kj-min'1, respectively at each 
exercise stage (Figure 5.4). Supplementation had no effect on carbohydrate 
oxidation (supplementation group x trial x time of sample, P=0.596), fat oxidation 
(supplementation group x trial x time of sample, F=0.187) or calculated energy 
expenditure (supplementation group x trial x time of sample, P=0.595).
Oxygen Kinetic Analyses
The mean response times for the on-kinetic response (MRTon) were significantly 
higher at 85% V o2rnax than at 45-65% V o2max (time of sample effect, F=7.32; 
P=0.019; partial eta2=0.38); however, the three-way interaction was not significant 
(P=0.069) (Figure 5.5). Supplementation had no effect on MRT0ff (supplementation 
group x trial x time of sample, P=0.449), and exercise intensity had no significant 
effect (time of sample effect, F=4.53; P=0.055; partial eta2=0.21) (Figure 5.5).
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Figure 5.4 (a) Energy expenditure, (b) carbohydrate oxidation rates, and (c) fat 
oxidation rates during each main exercise trial. Values represent mean ± SEM 
(N=7). PS: phosphatidylserine group; P: placebo group. Trial 1: pre­
supplementation; Trial 2: post-supplementation.
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Figure 5.5 (a) On-kinetic mean response times and (b) off-kinetic mean response 
times during moderate and very heavy exercise stages. Values represent mean ± 
SEM (N=7). PS: phosphatidylserine group; P: placebo group. Trial 1: pre­
supplementation; Trial 2: post-supplementation.
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Estimated Plasma Volume Changes
Estimated plasma volume fell by 7-11% during the first two exercise, stages and 
remained below Pre-exercise values throughout exercise (Table 5.3); 
supplementation had no effect (supplementation group x trial x time of sample, 
P=0.392) and no statistical differences were identified between T1 and T2 (trial 
effect: P=0.491).
Blood Lactate and Glucose Concentrations
Blood lactate concentrations were significantly elevated from Pre-exercise values 
from Post-65% (Table 5.4), and peaked at Post-85% (mean value for all trials was 
7.70 ± 0.33 mmol-L'1). Blood glucose concentrations did not differ significantly 
from Pre-exercise values at any time point (Table 5.4), and no differences were 
identified between groups or as a result of supplementation.
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Serum Cortisol Concentrations
Serum cortisol concentrations were significantly elevated by exercise (time of 
sample effect, F=20.69; P<0.001; partial eta2=0.63) from Pre-exercise values of 378 
± 21 nmol-L'1 to Post-exercise values of 554 ± 32 nmol-L'1 (Figure 5.6). Serum 
cortisol concentrations were not significantly affected by supplementation 
(supplementation group x trial x time of sample, P=0.118).
Feeling States
Significant temporal changes were observed in all of the EFI subscales; subjects 
reported decreases in revitalisation, positive engagement, and tranquillity and 
increases in physical exhaustion through exercise (Table 5.5). The three-way 
interactions were not significant in any of the subscales (Table 5.5).
136
o
Ec
co
(0
+ - IcQ)Oco
o
o
CO
'€oo
E
3
L _
CD
</)
700 -I 
600  - 
500  - 
400  
300 H 
200 
100
P S  trial 1 
P S  trial 2 
P trial 1 
P trial 2
 1 1 1 1 1
P re -ex e rc ise  P ost-55%  Post-65%  P o st-ex e rc ise  Post-24  hr
Time of sample
Figure 5.6 Serum cortisol concentrations throughout each trial. Values represent 
mean ± SEM (N=8). Pre-P: trial prior to supplementation with placebo; P: trial 
supplemented with placebo; Pre-PS: trial prior to supplementation with 
phosphatidylserine; PS: trial supplemented with phosphatidylserine.
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5.4 DISCUSSION
The primary finding of this investigation was that oral supplementation with 750 
mg d'1 S-PtdSer for 10 d significantly affected exercise capacity in a group of 
recreationally active subjects during a staged intermittent cycling protocol. 
Furthermore, the enhancements in exercise capacity in PS ranged from 0:15 to 3:47 
min:s, while the exercise times to exhaustion remained unchanged in P. •
It was originally hypothesised that PtdSer would influence the primary oxygen 
uptake kinetic response and thereby increase exercise capacity. However, 
supplementation did not significantly affect MRTon. Furthermore, no differences 
were observed between trial or supplementation group in MRT0ff; therefore, the 
current data presents insufficient evidence to support any change in the primary 
oxygen uptake kinetic response following supplementation.
The causes of fatigue during cycling at 85% V o2max (within an intensity domain that 
has been previously classified as very heavy exercise (Ozyener et al., 2001)) have 
not been fully elucidated and might include central and peripheral components 
(Kent-Braun, 1999). Exercise during the final bout was associated with near 
maximal oxygen uptakes and heart rates in addition to relatively high blood lactate 
concentrations; therefore, it can be assumed that heavy demands were placed on 
both oxidative and non-oxidative phosphorylation. Metabolic acidosis has been 
implicated as a mechanism of peripheral fatigue either through direct effects on the 
contractile proteins or through inhibition of key regulatory enzymes such as 
phosphofructokinase (Cooke et a l , 1988); however, it might be more likely that
139
other ionic imbalances contribute to fatigue in this exercise model (Allen, 2004). In- 
vitro studies have demonstrated that low concentrations of PtdSer are effective in 
activating (Na+-K+)-dependent ATPase in mammalian kidney (Specht and Robinson, 
1973) and brain (Tsakiris and Deliconstantinos, 1984) preparations. Similarly, Ca2+- 
ATPase, an enzyme primarily responsible for Ca2+ re-uptake from the muscle 
cytosol into the sarcoplasmic reticulum, is known to require PtdSer (Morrot et al., 
1990; Sepulveda and Mata, 2004). Therefore, it is plausible that exogenous S-PtdSer 
delayed the onset of fatigue by maintaining ionic homeostasis for longer during 
exercise.
In addition, Tibbits et al. (1981) reported that extended exercise training increased 
the levels of phospholipids, especially PtdSer content, in rat cardiac sarcolemma. 
This adaptation to training suggests that additional PtdSer within the heart muscle 
has functional benefits during exercise. An increase in membrane bound PtdSer 
might have the potential to enhance myocardial excitation-contraction coupling, 
potentially through the activation of different protein kinase C isoforms (Sugden and 
Bogoyevitch, 1995) and/or enhanced calcium uptake (Pepeu et al., 1996). Thus, it is 
plausible that these mechanisms also might have contributed to delaying fatigue in 
the present study. However, without corroborating data from further studies that 
investigate the in-vivo pharmacological actions of S-PtdSer the proposed 
mechanisms remain speculative.
The significant rise in serum cortisol concentration that followed the final bout of 
exercise suggested that the protocol activated the HPA axis (Monteleone et al., 
1990). However, supplementation with PtdSer did not significantly influence serum
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cortisol concentrations (Figure 5.5). This finding does not concur with the results of 
Fahey and Pearl (1998) who found that S-PtdSer, using a similar supplementation 
regime, attenuated serum cortisol concentrations following resistance training. 
Furthermore, Monteleone et al. (1992) reported that 800 mg-d"1 BC-PtdSer resulted 
in significant reductions in plasma cortisol and adrenocorticotrophic hormone 
(ACTH) concentrations during submaximal cycle exercise in untrained subjects.
The elevation in blood cortisol is a generic response to stress from both 
psychological and physical origin; consequently, there is considerable inter­
individual variability in response to exercise. Although the choice of experimental 
design in the current study investigated individual changes in response (pre- to post­
supplementation) and, therefore, reduced the possible effect of subject selection 
related bias, the possibility exists that the current dose might have been insufficient 
to attenuate the cortisol response in these active individuals. Alternatively, the 
current exercise protocol required that all participants continued the final exercise 
bout until exhaustion in both trials; therefore, it remains plausible that any effect of 
PtdSer supplementation on cortisol concentrations were masked as the PS group 
completed significantly more work in T2 when compared with Tl.
Blood glucose concentrations remained unchanged throughout all trials. This finding 
was in agreement with previous studies using similar exercise protocols 
(Monteleone et al., 1990; Monteleone et al., 1992). The concomitant effects of 
reduced insulin and elevations in ACTH, cortisol and adrenaline are responsible for 
controlling blood glucose during exercise (Astrand and Rodahl, 1986). Therefore, 
any effects that S-PtdSer supplementation might have had on blood ACTH and
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cortisol did not appear to have over-challenged blood glucose homeostasis during 
exercise. Furthermore, the calculated rates of carbohydrate, fat and combined fuel 
oxidation during the steady state stages of exercise were similar in all trials, 
suggesting that any change in the HPA axis induced by S-PtdSer supplementation 
did not affect substrate oxidation during moderate exercise stages.
All subscales of the EFI were sensitive to change during the exercise. However, the 
three-way interaction did not reach significance in any subscale; therefore, there was 
no evidence to suggest that feeling states differed following supplementation in 
either supplementation group. The participants in the current study provided 
baseline responses that were similar to those of other recreationally active 
populations prior to exercise training (Lacaille et al., 2004), indicating that the 
testing procedures did not induce large changes in feeling states prior to exercise in 
these subjects. Benton et al. (2001) reported improvements in mood after mental 
stress within a sub-group of young healthy adults following short-term S-PtdSer 
supplementation. Nevertheless, these improvements were only identifiable in a sub­
group of subjects who scored higher than the median for neuroticism; people who 
score highly on this dimension are known to display strong emotional reactions to 
stress (Benton et al., 2001). Consequently, the baseline emotional state of an 
individual might influence the efficacy of S-PtdSer in altering feeling states during 
exercise.
This is the first study to identify the ergogenic properties of phosphatidylserine; 
therefore, we suggest that further studies are required to substantiate these findings 
and to investigate the potential uses of S-PtdSer in exercise and physical activity. In
142
addition, future studies are warranted to investigate the mechanism by which S- 
PtdSer might act physiologically.
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CHAPTER SIX
GENERAL DISCUSSION
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6 GENERAL DISCUSSION
The general aim of this research was to evaluate the effects of short-term oral 
supplementation with 750 mg d"1 soy derived phosphatidylserine (S-PtdSer) on 
exercise capacity, neuroendocrine function, inflammation, oxidative stress, muscle 
damage and perceived feeling states.
Results from the first experimental study (chapter 3) showed that S-PtdSer 
supplementation for 10 d prior to an exhaustive running protocol, consisting of 
intermittent running immediately followed by a progressive run, did not affect 
perceived muscle soreness or markers of muscle damage and lipid peroxidation. 
However, S-PtdSer tended to improve running performance. As the amount of 
exercise performed tended to be different between trials, it was difficult to evaluate 
the efficacy of S-PtdSer as an antioxidant under these exercise conditions. 
Consequently, the second experimental study (chapter 4) was designed to evaluate 
the effects of S-PtdSer supplementation on markers of muscle damage, 
inflammation and oxidative stress that follow downhill running. Additionally, the 
unexpected and potentially useful finding that S-PtdSer supplementation tended to 
improve performance led to the evolution of the third experimental study (chapter 5) 
which evaluated the potential ergogenic properties of S-PtdSer following 
intermittent cycling.
The second experimental study showed that moderate intensity downhill running led 
to elevations in markers of muscle damage (plasma myoglobin concentrations and 
creatine kinase activities), lipid peroxidation (serum hydroperoxide concentrations),
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inflammation (serum IL-6 concentrations) and DOMS (perceived soreness). 
However, the administration of 750 mg’d'1 S-PtdSer for 7 d prior to and continued 
until 2 d following exercise was not effective in attenuating any of the 
aforementioned markers in previously familiarised active males.
The main finding from experimental study 3 (chapter 5) was that 10 d of oral 
supplementation with S-PtdSer led to significant improvements in exercise capacity 
during a staged intermittent cycling protocol in recreationally active subjects. 
However, the mechanism(s) responsible for this finding were unclear as 
supplementation did not significantly affect oxygen kinetic mean response times, 
serum cortisol concentrations, substrate oxidation and feeling states during this 
study.
The findings from this series of experimental studies are collectively discussed in 
this chapter. Where appropriate, conclusions regarding current understanding are 
included and recommendations for future investigations aimed at evaluating the 
effects of phosphatidylserine supplementation on exercising humans are presented.
Effects o f Phosphatidylserine Supplementation on Neuroendocrine Function
Experimental studies 1 and 2 demonstrated that prior supplementation with 750 
mg d’1 S-PtdSer for 10 d was not effective in attenuating serum cortisol 
concentrations after exhaustive exercise. During experimental study 1, intermittent 
running caused elevations in circulatory cortisol concentrations in university soccer
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players that were similar regardless of supplementation. Likewise, circulatory 
cortisol concentrations in active male subjects were elevated following the last bout 
of intermittent cycling (study 3); although, these concentrations were unaffected by 
supplementation. The increases in serum cortisol concentrations confirmed that the 
exercise protocols used in both of these experimental studies induced changes in the 
hypothalamo-pituitary-adrenal (HPA) axis (Monteleone et al., 1990).
Monteleone et al. (1992) reported that 800 mg-d'1 of bovine cortex derived 
phosphatidylserine (BC-PtdSer) resulted in significant reductions in plasma cortisol 
and adrenocorticotrophic hormone (ACTH) concentrations during submaximal cycle 
exercise in untrained subjects. These equivocal findings might reflect the fact that 
the blood samples were taken following exhaustive exercise in experimental studies 
1 and 3, while S-PtdSer supplementation increased exercise capacity during cycling 
and tended to improve performance during running; therefore, any effect that S- 
PtdSer might have exerted on the HPA axis could have been masked. Alternatively, 
variations in these results might reflect the training status of the participants used in 
the respective studies, especially considering that trained subjects experience 
attenuated HPA alterations during exercise (Luger et a l, 1987).
During experimental study 2, downhill running did not significantly influence 
plasma cortisol and ACTH concentrations; additionally, in agreement with the 
results from experimental studies 1 and 3, supplementation did not significantly 
affect the concentrations of these hormones. Therefore, it is tempting to conclude 
that the source of PtdSer might influence the actions of this supplement on 
neuroendocrine function, and more specifically that S-PtdSer supplementation does
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not affect circulatory cortisol concentrations. However, Fahey and Pearl (1998) 
reported that 800 mg-d'1 S-PtdSer attenuated serum cortisol concentrations following 
intensive resistance training in weight-trained subjects.
There are several potential reasons for the discrepancy in findings between the 
current experimental data and those of Fahey and Pearl (1998). The study design 
used in experimental study 2 included pre-supplementation control trials that reduce 
the chance of type I error (incorrectly rejecting the null hypothesis), where as 
previous studies in this field (Monteleone et al., 1990; Monteleone et a l, 1992; 
Fahey and Pearl, 1998) have employed simple cross-over study designs. 
Additionally, although Fahey and Pearl (1998) reported significant decreases in 
circulatory cortisol concentrations following exercise after treatment with S-PtdSer, 
there were no significant differences in serum cortisol concentrations between 
treatments or any of the resting trials. The completion of post-hoc analyses after 
non-significant main effects have been determined elevates the probability of type I 
error; therefore, differences in statistical procedures could have contributed to these 
equivocal findings. Also, it remains plausible that differences in the mode and 
intensity of exercise, which influence the HPA axis, might have contributed to 
differences in findings; the intensive resistance training programme required 
subjects to train as hard as possible using as much weight as possible, while the 
exercise protocol used in experimental study 2 required the subjects to run downhill 
at a relatively low metabolic demand.
Supplementation did not influence blood glucose concentrations in any of the 
experimental studies (chapters 3 - 5). This finding was in agreement with previous
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studies using submaximal cycling exercise protocols (Monteleone et al., 1990; 
Monteleone et al., 1992). The concomitant effects of a number of hormones (e.g., 
insulin, ACTH, cortisol and adrenaline) are responsible for controlling blood 
glucose during exercise (Astrand and Rodahl, 1986). Therefore, even if S-PtdSer 
supplementation does influence neuroendocrine function, as suggested previously, 
there is no evidence to suggest that this level of supplementation influences blood 
glucose homeostasis during exercise. Furthermore, the calculated carbohydrate and 
fat oxidation rates using non-protein respiratory exchange ratios during the steady 
state stages of cycling were not influenced by supplementation in experimental 
study 3. Thus, any change in the HPA axis, induced by S-PtdSer supplementation, 
did not affect substrate oxidation during moderate exercise intensities. Although no 
data from these experimental studies, or other published research, are available at 
present, it remains possible that S-PtdSer supplementation might influence substrate 
utilisation at higher exercise intensities.
In conclusion, the effects of S-PtdSer supplementation on neuroendocrine function 
remain equivocal. The possibility exists that the dose employed during the current 
experimental studies might have been insufficient to attenuate the cortisol response 
in these active individuals. Consequently, the optimal dose of S-PtdSer might vary 
with the training status of the participants.
149
Effects o f Phosphatidylserine Supplementation on Muscle Damage
Data from experimental studies 1 and 2 showed that short-term supplementation 
with 750 mg'd"1 S-PtdSer did not effectively reduce muscle damage, as measured by 
creatine kinase activities and myoglobin concentrations in the circulation, in well 
accustomed active participants following intermittent running designed to simulate 
soccer match play (study 1) or downhill running (study 2). These findings are in 
agreement with Fahey and Pearl (1998) who reported that similar doses of S-PtdSer 
did not influence serum creatine kinase activities after heavy resistance training. 
Together, these data suggest that S-PtdSer supplementation does not directly 
influence the structural integrity of the muscle cell in well-accustomed participants.
The exercise protocols undertaken during these experimental studies caused 
increases in perceived muscle soreness; furthermore, the magnitude of reported 
soreness was similar during these trials and the temporal patterns were consistent 
with delayed onset of muscle soreness. However, supplementation did not affect 
perceived soreness during either experimental study. This finding could reflect the 
subjective nature of reporting perceived muscle soreness and the unknown variance 
in this measure is a limitation to the research.
In living cell membranes, PtdSer is mainly located within the cytosolic monolayer 
(Devaux, 1991). This membrane asymmetry is actively maintained and is believed 
to be vital for proper cell function (Voelker, 1989). The extemalisation of PtdSer is 
thought to signal apoptosis (programmed cell death) and initiate cell phagocytosis 
(Tyurina et al., 2000). It has been suggested that unfamiliar eccentric muscle activity
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causes mechanical damage to the most susceptible muscle fibres (Friden et a l, 
1983), which become subsequently removed through phagocytosis. Therefore, as the 
subjects used in experimental studies 1 and 3 completed familiarisation trials the 
level of structural muscle damage caused by the subsequent exercise trials was 
probably reduced. It is possible that S-PtdSer supplementation might be effective in 
reducing muscle damage in susceptible cells (i.e., when individuals have not 
completed prior familiarisation trials).
Effects o f Phosphatidylserine Supplementation on Exercise-Induced Oxidative Stress
Experimental study 1 investigated the effects of 10-d oral supplementation with 750 
mg d' 1 S-PtdSer on oxidative stress following exhaustive intermittent running in 
active young males. Although supplementation had no effect on lipid peroxidation 
(serum hydroperoxide concentrations) or resistance to oxidation (serum conjugated 
diene lag times), supplementation with S-PtdSer tended to improve performance. 
Consequently, it remained unclear if this supplementation regime was ineffective in 
enhancing the defences against exercise induced oxidative stress or if the completion 
of more work had led to the production of higher amounts of reactive oxygen 
species that had overwhelmed the combined defences.
With the findings from study 1 in mind, the subsequent experimental study (study 2) 
was designed to evaluate the effects of short-term oral supplementation on oxidative 
stress caused by repeatable amounts of downhill treadmill running in active young 
males. It was hypothesised that the eccentric components of downhill running would
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cause muscle damage and lead to the development of an acute inflammatory 
response (Childs et a l, 2001). The acute inflammatory response has been previously 
shown to elevate free radical production and activate cytokines (Macintyre et al., 
1995). Free radicals can lead to oxidative damage in a wide range of molecular 
structures where the antioxidant defences are overwhelmed. In addition, exercise 
induced erythrocyte haemolysis has the potential to elevate loosely bound iron in 
extracellular fluids and tissues (Jenkins et a l, 1993). Therefore, downhill treadmill 
running has the potential to induce oxidative stress.
As expected, the downhill running protocol used in experimental study 2 caused 
significant increases in lipid peroxidation (as measured by serum hydroperoxide 
concentrations), demonstrating that exercise led to elevations in free radical 
production that overwhelmed the antioxidant defences and increased oxidative 
stress. However, lipid peroxidation, susceptibility to LDL oxidation (as measured by 
changes in conjugated diene concentrations) and resistance to LDL oxidation (as 
measured by ti/2max LDL oxidation) were similar following supplementation with S- 
PtdSer and placebo. Therefore, no evidence was available to suggest that exogenous 
S-PtdSer was able to enhance antioxidant defences under these conditions.
The findings from experimental studies 1 and 2 showed that supplementation with 
S-PtdSer transiently increased plasma 7-tocopherol. Increases in plasma and tissue 7- 
tocopherol in rats have been demonstrated to attenuate protein and ascorbate 
oxidation following inflammation-mediated damage (Jiang et a l,  2002). Thus the 
increases in plasma 7-tocopherol concentrations and probable increases in tissue 7- 
tocopherol concentrations might have augmented the antioxidant defence, although
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supplementation had no effect on concentrations of the other plasma antioxidant 
vitamins (vitamin C, a-tocopherol, retinol and /3-carotene), lipid peroxidation or 
susceptibility of LDL to in-vitro oxidation during either experimental study.
Effects o f Phosphatidylserine Supplementation on Immune Function
Downhill running was confirmed to elevate interleukin-6 (IL-6) concentrations in 
plasma during experimental study 2. Increases in pro-inflammatory cytokines, such 
as IL-6, are characteristic of an acute inflammatory response (Childs et al., 2001). 
Although consistent with other downhill running studies (e.g., Thompson et a l, 
2004; Peake et a l, 2005), the magnitude of increase in IL-6 (2-3 times baseline 
values) was relatively modest when compared with the changes that have been 
reported to occur following exercise that is associated with higher metabolic 
demands, such as prolonged intermittent running (Thompson et a l, 2001b) and 
prolonged endurance running (Suzuki et a l, 2000).
Supplementation with S-PtdSer did not affect serum IL-6 concentrations after 
downhill running. It is possible that the magnitude of increase in EL-6 was 
insufficient to reveal any effect of supplementation. Alternatively, as the mode, 
intensity and duration of exercise appear to influence the immune response to 
exercise (Vassilakopoulos et a l, 2005), the lack of supplementation effect on 
circulatory IL-6 might be specific to eccentric exercise. The stimulus and/or 
mechanism of IL-6 induction during extended concentric exercise are probably 
different; therefore, it remains plausible, although speculative, that exogenous S-
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PtdSer could moderate IL-6 concentrations following other types of exercise. In 
support of this suggestion, vitamin C supplement (a recognised antioxidant) has 
been demonstrated to moderate IL-6 concentrations following prolonged shuttle 
running (Thompson et al., 2001b) but not downhill running (Thompson et a l, 2004).
Effects o f Phosphatidylserine Supplementation on Subjective Feelings During and 
Following Exercise
Short-term S-PtdSer supplementation has been previously reported to improve 
subjective well-being during two weeks of intense resistance training (Fahey and 
Pearl, 1998). Although the mechanism(s) behind this finding were not clear, these 
results might reflect an action of S-PtdSer to attenuate the exercise induced HPA 
axis. As cortisol has the potential to stimulate amino acid release from tissues (such 
as skeletal muscle), these authors hypothesised that S-PtdSer might have decreased 
protein degradation and consequently improved perceived well-being during this 
period of overtraining. In support of this hypothesis, they found that 
supplementation with S-PtdSer also reduced perceived muscular soreness when 
compared with placebo. However, markers of protein degradation were not 
quantified during this study to confirm that this was in fact the case. Also, 
supplementation did not affect serum creatine kinase activities. As increases in 
circulatory creatine kinase activity are accepted as an indirect marker of structural 
muscle damage, empirical data does not support this theory.
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An alternative explanation for the positive effect of supplementation on perceived 
muscle soreness and well-being could be that S-PtdSer positively influenced higher 
brain functions and moderated subjective feelings. As described in Chapter 1, PtdSer 
is an important cofactor that has the potential to influence higher brain functions. 
Exogenous PtdSer has been demonstrated to enhance cognitive function (Blokland 
et a l, 1999), improve learning/memory (Sakai et a l,  1996; Furushiro et a l, 1997; 
Alves et a l, 2000; Suzuki et a l, 2001) and attenuate the effects of stress (Drago et 
a l, 1991), in rodents. Additionally, PtdSer supplementation has been demonstrated 
to exert therapeutic actions on higher brain functions in human patients with 
cognitive decline (Amaducci and SMID group, 1988; Crook et a l, 1992; Cenacchi 
et a l, 1993). Furthermore, Benton et a l (2001) demonstrated that short-term S- 
PtdSer supplementation in a sub-group of healthy young males reduced feelings of 
stress and improved mood in the response to a stressful mathematical challenge.
Supplementation did not influence the ratings of perceived exertion during 
experimental study 1. However, this measure can only be employed during exercise. 
Also, this exercise protocol involved maximal sprinting during part A, and part B 
was continued until volitional fatigue; consequently, perceived exertion was unlikely 
to be affected by supplementation. Therefore, an exercise specific measure of 
exercise-induced feeling states (EFI) (Gauvin and Rejeski, 1993) was used in 
experimental studies 2 and 3 in order to assess the effects of S-PtdSer 
supplementation on feeling states (revitalisation, positive engagement, tranquillity, 
physical exhaustion) before and after exercise.
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Although feeling states were not significantly altered by downhill running during 
study 2, exhaustive intermittent cycling influenced all of the measured feeling states 
(study 3). Furthermore, supplementation did not significantly influence any of the 
measured feeling states in experimental study 2 or study 3. The small changes in 
feeling states recorded in study 2 probably reflected the low metabolic demand 
during the downhill exercise protocol and might have contributed to the lack of 
supplementation effect in this study. As the neuroendocrine responses to mental 
stress and physical stress are comparable and considering that S-PtdSer significantly 
enhanced exercise capacity during experimental study 3, it is possible that any effect 
of supplementation on feeling states might have been obscured. Additionally, as the 
variance in reporting the subjective feeling states was not quantified in this research, 
this limitation might have hidden any effect of supplementation.
Therefore, the effects of S-PtdSer on feeling states during exercise are unclear; 
consequently, future research could evaluate the effect of S-PtdSer supplementation 
on feeling states and decision-making during other types of exercise.
Ergogenic Effects o f Phosphatidylserine Supplementation
Unexpectedly, experimental study 1 demonstrated a tendency for S-PtdSer 
supplementation to improve sprint and exercise performances during intermittent 
running when compared with a placebo. These findings led to experimental study 3, 
which hypothesised that PtdSer supplementation could reduce accumulated oxygen 
deficit and improve exercise tolerance, as PtdSer has the potential to influence
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mitochondrial enzymatic activity and contribute to the maintenance of ionic 
homeostasis. Although these data did not support any change in the primary oxygen 
uptake kinetic response following supplementation, supplementation did affect 
exercise times to exhaustion at 85%V02max. Following supplementation, the PS 
group (750 m gd '1 of S-PtdSer for 10 d) increased times to exhaustion by 29 ± 8%, 
while the exercise times to exhaustion for the placebo group did not differ (-1 ±3% ) 
following supplementation with a glucose placebo.
The final bout of cycling elicited near maximal oxygen uptakes and heart rates in 
addition to relatively high blood lactate concentrations. The causes of fatigue during 
exercise that places high demands on aerobic and anaerobic phosphorylation have 
not been fully elucidated and might include central and peripheral components 
(Kent-Braun, 1999). Metabolic acidosis has been implicated as a mechanism of 
peripheral fatigue, either through direct effects on the contractile proteins or through 
inhibition of key regulatory enzymes such as phosphofructokinase (Cooke et al., 
1988); however, other ionic imbalances might be more likely contribute to fatigue in 
this exercise model (Allen, 2004). In-vitro studies have demonstrated that PtdSer is 
effective in activating (Na+-K+)-dependent ATPase in mammalian tissue 
preparations (Specht and Robinson, 1973; Tsakiris and Deliconstantinos, 1984).
I ^  j
Similarly, Ca -ATPase, an enzyme primarily responsible for Ca re-uptake from 
the muscle cytosol into the sarcoplasmic reticulum, is known to require PtdSer 
(Morrot et a l , 1990; Sepulveda and Mata, 2004). Therefore, it is plausible that 
exogenous S-PtdSer delayed the onset of fatigue by maintaining ionic homeostasis 
for longer during exercise. However, without corroborating data from further studies
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that investigate the in-vivo pharmacological actions of S-PtdSer, the preceding 
mechanism remains speculative.
The finding that S-PtdSer might possess ergogenic properties is of potential interest 
to the athletic population, especially those that undertake intermittent and/or high 
intensity exercise. However, these are the only published data to evaluate the 
ergogenic properties of PtdSer and the findings are based on relatively small 
numbers of moderately trained subjects; therefore, further research is warranted.
Directions fo r  Future Research
The placebo controlled experimental studies described within this thesis (chapters 3 
to 5) compared the effects of a PtdSer supplement (soybean lecithin enriched with S- 
PtdSer) with those of a glucose placebo. Therefore, it is important to point out that 
the findings presented here relate to the activity of this particular supplement. In 
order that future research can evaluate the effects of S-PtdSer supplementation, it is 
envisaged that further experiments could use a placebo containing soybean lecithin 
that is devoid of S-PtdSer rather than a glucose placebo.
Although it is likely that the dose of S-PtdSer provided in this series of experimental 
studies will have caused transient increases in the PtdSer content within systemic 
circulation and incorporation of PtdSer within cell membranes, the biokinetics of 
PtdSer following oral administration in humans are largely unknown. Future studies 
are required to quantify circulatory and tissue concentrations of PtdSer in animal and
human models following exogenous PS supplementation. Earlier in this chapter it 
was proposed that the dose employed in the current studies might have been 
insufficient to modify neuroendocrine function in these relatively active individuals; 
consequently, the optimal dose of S-PtdSer could vary between participants. It is 
envisaged that this research would help identify factors that might affect S-PtdSer 
availability and uptake (i.e., quality of supplement, interaction effects with other 
nutrients, training status, age, dietary habits, etc.).
The findings from experimental study 2 suggest that supplementation with PS does 
not influence muscle damage, muscle soreness, inflammation or oxidative stress 
following eccentric muscle activity in well accustomed young males. It remains 
possible that exogenous S-PtdSer supplementation might protect susceptible cells; 
therefore, the act of familiarisation might have negated any prophylactic effects of 
PtdSer supplementation in the present study. Consequently, future research could 
investigate the effects of S-PtdSer supplementation in naive subjects (subjects that 
have not completed familiarisation trials).
A variety of animal studies have confirmed anti-inflammatory functions of PtdSer; 
however, the findings from experimental study 2 did not show any effect of 
supplementation on plasma IL-6 concentrations following eccentric exercise that 
was associated with a low metabolic challenge. It would be of interest to evaluate 
the effects of S-PtdSer supplementation on immunological function following 
prolonged exercise, which has been demonstrated to cause a larger immunological 
challenge.
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The findings from experimental studies 1 and 3 suggest that S-PtdSer possess 
ergogenic properties. However, these findings are specific to the subject populations 
and the type of activities undertaken. Therefore, further research is warranted to 
identify whether these findings are transferable to other athletic and/or clinical 
populations. In addition, the specific mechanism(s) responsible for the ergogenic 
actions of S-PtdSer are currently speculative; consequently, there is potential to 
design and undertake experiments that specifically investigate both peripheral and 
central mechanism that might explain these findings.
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GENERAL CONCLUSIONS
With reference to the specific supplementation regimes, exercise protocols and 
measurement techniques used in this series of experiments, the following general 
conclusions can be made:
1. The results from experimental study 1 suggested that oral S-PtdSer 
supplementation tends to improve exercise performance. Although the 
findings from study 3 confirmed potential ergogenic properties of this 
supplement, supplementation did not significantly affect oxygen kinetics, 
neuroendocrine function or fuel oxidation rates. Therefore the mechanism(s) 
responsible for these findings remain unclear.
2. The results from all experimental studies suggested that oral S-PtdSer 
supplementation does not influence the effects of exercise on hypothalamo- 
pituitary-adrenal axis in active young males.
3. The results from experimental studies 1 and 2 suggested that oral S-PtdSer 
supplementation does not affect lipid peroxidation, muscle damage, and 
muscle soreness following prolonged exhaustive running and downhill 
running. However, oral S-PtdSer supplementation does cause a transient 
increase in the concentration of 7-tocopherol, an established plasma 
antioxidant vitamin.
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4. The results from experimental study 2 suggested that oral S-PtdSer 
supplementation does not influence inflammation caused by downhill 
running, as measured by circulatory concentrations of the pro-inflammatory 
cytokine interleukin-6.
5. The results from experimental study 2 and 3 suggested that oral S-PtdSer 
supplementation does not significantly change feeling states during, 
immediately after and on the day following exercise.
6. No adverse reactions to oral S-PtdSer supplementation were reported during 
this series of experimental studies. Furthermore, no data are presented to 
suggest negative effects of supplementation.
162
REFERENCES
Allen, D. G. (2004). Skeletal muscle function: role of ionic changes in fatigue, 
damage and disease. Clinical and Experimental Pharmacology and Physiology. 31 
485-493.
Alves, C. S., Andreatini, R., da Cunha, C., Tufik, S. and Vital, M. A. (2000). 
Phosphatidylserine reverses reserpine-induced amnesia. European Journal o f  
Pharmacology. 404 161-167.
Amaducci, L. and SMID group. (1988). Phosphatidylserine in the treatment of 
Alzheimer's Disease: results of a multicenter study. Psychopharmacology Bulletin. 
24 130-134.
Aoi, W., Naito, Y., Takanami, Y., Kawai, Y., Sakuma, K., Ichikawa, H., Yoshida, 
N. and Yoshikawa, T. (2004). Oxidative stress and delayed-onset muscle damage 
after exercise. Free Radical Biology and Medicine. 37 480-487.
Aramaki, Y., Matsuno, R., Nitta, F., Arima, H. and Tsuchiya, S. (1997). Negatively 
charged liposomes inhibit tyrosine phosphorylation of 41-kDa protein in murine 
macrophages stimulated with LPS. Biochemical and Biophysical Research 
Communications. 231 827-830.
Armstrong, R. B., Warren, G. L. and Warren, J. A. (1991). Mechanisms of exercise- 
induced muscle fibre injury. Sports Medicine. 12 184-207.
Astrand, P.-O. and Rodahl, K. (1986). Textbook o f Work Physiology, Physiological 
Bases o f Exercise, Third Edition. McGraw-Hill International Editions, pp 556-562.
Benton, D., Donohoe, R. T., Sillance, B. and Nabb, S. (2001). The influence of 
phosphatidylserine supplementation on mood and heart rate when faced with an 
acute stressor. Nutritional Neuroscience. 4 169-178.
163
Bick, R. J., Buja, L. M., Van Winkle, W. B. and Taffet, G. E. (1998). Membrane 
asymmetry in isolated canine cardiac sarcoplasmic reticulum: comparison with 
skeletal muscle sarcoplasmic reticulum. Journal o f Membrane Biology. 164 169-
175.
Bigon, E., Boarato, E., Bruni, A., Leon, A. and Toffano, G. (1979). Pharmacological 
effects of phosphatidylserine liposomes: regulation of gylcolysis and energy level in 
brain. British Journal o f Pharmacology. 66 167-174.
Blokland, A., Honig, W., Browns, F. and Jolles, J. (1999). Cognition-enhancing 
properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: 
comparison of bovine cortex PS with egg PS and soybean PS. Nutrition. 15 778-783.
Borg, G. (1998). Borg's Perceived Exertion and Pain Scales. Champaign, IL: 
Human Kinetics.
Bruni, A., Mietto, L., Secchi, F. E. and Chizzolini, C. (1994). Lipid mediators of 
immune reactions: effect of a linked phosphorylserine group. Immunology Letters.
42 87-90.
Bruni, A., Orlando, P., Mietto, L. and Viola, G. (1992). Phospholipid metabolism in 
rat intestinal mucosa after oral administration of lysophospholipids. In Neurobiology 
o f Essential Fatty Acids (edited by N. G. Bazan), pp. 243-249. New York: Plenum 
Press
Bruni, A., Toffano, G., Leon, A. and Boarato, E. (1976). Pharmacological effects of 
phosphatidylserine liposomes. Nature. 260 331-333.
Casamenti, F., Mantovani, P., Amaducci, L. and Pepeu, G. (1979). Effect of 
phosphatidylserine on acetylcholine output from the cerebral cortex of the rat. 
Journal o f  Neurochemistry. 32 529-533.
Casamenti, F., Scali, C. and Pepeu, G. (1991). Phosphatidylserine reverses the age- 
dependent decrease in cortical acetylcholine release: a microdialysis study.
European Journal o f  Pharmacology. 194 11-16.
164
Catignani, G. L. and Bieri, J. G. (1983). Simultaneous determination of retinol and 
alpha-tocopherol in serum or plasma by liquid chromatography. Clinical Chemistry. 
29 708-712.
Cenacchi, T., Baggio, C. and Palin, E. (1987). Human tolerability of oral 
phosphatidylserine assessed through laboratory examinations. Clinical Trials 
Journal. 21 125-130.
Cenacchi, T., Bertoldin, T., Farina, C., Fiori, M. G. and Crepaldi, G. (1993). 
Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter 
study on efficacy of phosphatidylserine administration. Aging. 5 123-133.
Childs, A., Jacobs, C., Kaminski, T., Halliwell, B. and Leeuwenburgh, C. (2001). 
Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in 
humans after an acute muscle injury induced by eccentric exercise. Free Radical 
Biology and Medicine. 31 745-753.
Clarkson, P. M., Nosaka, K. and Braun, B. (1992). Muscle function after exercise- 
induced muscle damage and rapid adaptation. Medicine and Science in Sports and 
Exercise. 24 512-520.
Cooke, R., Franks, K., Luciani, G. B. and Pate, E. (1988). The inhibition of rabbit 
skeletal muscle contraction by hydrogen ions and phosphate. Journal o f Physiology. 
395 77-97.
Cooney, R. V., Custer, L. J., Okinaka, L. and Franke, A. A. (2001). Effects of 
dietary sesame seeds on plasma tocopherol levels. Nutrition and Cancer. 39 66-71.
Crook, T., Petrie, W., Wells, C. and Massari, D. C. (1992). Effects of 
phosphatidylserine in Alzheimer's disease. Psychopharmacology Bulletin. 28 61-66.
Dacaranhe, C. D. and Terao, J. (2001). A unique antioxidant activity of 
phosphatidylserine on iron-induced lipid peroxidation of phospholipid bilayers. 
Lipids. 36 1105-1110.
165
Dekkers, J. C., Van Dooran, L. J. P. and Kemper, H. C. G. (1996). The role of 
antioxidant vitamins and enzymes in the prevention of exercise-induced muscle 
damage. Sports Medicine. 21 213-238.
Devaux, P. F. (1991). Static and dynamic lipid asymetry in cell membranes. 
Biochemistry. 30 1163-1173.
Diagne, A., Fauvel, J., Record, M., Chap, H. and Douste-Blazy, L. (1984). Studies 
on ether phospholipids. II. Comparative composition of various tissues from human, 
rat and guinea pig. Biochimica et Biophysica Acta. 793 221-231.
Dill, D. B. and Costill, D. L. (1974). Calculation of percentage changes in volumes 
of blood, plasma and red cells in dehydration. Journal o f Applied Physiology. 37 
247-248.
Drago, F., Spadaro, F., D'Agata, V., Valerio, C., Grassi, M., Mauceri, F., Pennisi, G. 
and Scapagnini, U. (1991). Protective action of phosphatidylserine on stress-induced 
behavioral and autonomic changes in aged rats. Neurobiology o f Aging. 12 437-440.
Facci, L., Cusinato, F., Negro, A., Monastra, G., Signorelli, A. and Bruni, A. (2000). 
The immunosuppressant steroid cholesterylphosphoserine inhibits tumour necrosis 
factor-alpha secretion in vitro and in vivo. Cytokine. 12 770-773.
Fahey, T. D. and Pearl, M. S. (1998). The hormonal and perceptive effects of 
phosphatidylserine administration during two weeks of resistive exercise-induced 
overtraining. Biology o f Sport. 15 135-144.
Feasson, L., Stockholm, D., Freyssenet, D. and add, t. (2002). Molecular adaptations 
of neuromuscular disease-associated proteins in response to eccentric exercise in 
human skeletal muscle. Journal o f Physiology. 543 297-306.
Folch, J. and Schneider, H. A. (1941). An amino acid constituent of ox brain 
cephalin. Journal o f Biological Chemistry. 137 51-62.
Friden, J., Sjostrom, M. and Ekblom, B. (1983). Myofibrillar damage following 
intense eccentric exercise in man. International Journal o f Sports Medicine. 4 170-
176.
166
Furushiro, M., Suzuki, S., Shishido, Y., Sakai, M., Yamatoya, H., Kudo, S., 
Hashimoto, S. and Yokokura, T. (1997). Effects of oral administration of soybean 
lecithin transphosphatidylated phosphatidylserine on impaired learning of passive 
avoidance in mice. Japanese Journal o f Pharmacology. 75 447-450.
Gauvin, L. and Rejeski, W. J. (1993). The Exercise-Induced Feeling Inventory: 
development and initial validation. Journal o f Sport and Exercise Psychology. 15 
403-423.
Ghosh, S., Xie, W. Q., Quest, A. F., Mabrouk, G. M., Strum, J. C. and Bell, R. M. 
(1994). The cysteine-rich region of raf-1 kinase contains zinc, translocates to 
liposomes, and is adjacent to a segment that binds GTP-ras. Journal o f Biological 
Chemistry. 269 10000-10007.
Giannesini, B., Cozzone, P. J. and Bendahan, D. (2003). Non-invasive investigations 
of muscular fatigue: metabolic and electromyographic components. Biochimie. 85 
873-883.
Gilbreath, M. J., Hoover, D. L., Alving, C. R., Swartz, G. M. and Meltzer, M. S. 
(1986). Inhibition of lymphokine-induced macrophage microbicidal activity against 
Leishmania major by liposomes: characterization of the physicochemical 
requirements for liposome inhibition. Journal o f Immunology. 137 1681-1687.
Gorski, J., Zendzian-Piotrowska, M., de Jong, Y. F., Niklinska, W. and Glatz, J. F.
C. (1999). Effect of endurance training on the phospholipid content of skeletal 
muscles in the rat. European Journal o f Applied Physiology. 79 421-425.
Goth, A., Adams, H. R. and Knoohuizen, M. (1971). Phosphatidylserine: selective 
enhancer of histamine release. Science. 173 1034-1035.
Grassi, B. (2000). Skeletal muscle V02 on-kinetics: set by 02  delivery or by 02 
utilization? New insights into an old issue. Medicine and Science in Sports and 
Exercise. 32 108-116.
167
Heikinheimo, L. and Somerhaiju, P. (2002). Translocation of pyrene-labeled 
phosphatidylserine from the plasma membrane to mitochondria diminishes 
systematically with molecular hydrophobicity: implications on the maintenance of 
high phosphatidylserine content in the inner leaflet of the plasma membrane. 
Biochimica et Biophysica Acta - Molecular Cell Research. 1591 75-85.
Hensley, K., Fedynyshyn, J., Ferrell, S., Floyd, R. A., Gordon, B., Grammas, P., 
Hamdheydari, L., Mhatre, M., Mou, S. and Pye et, al. (2003). Message and protein- 
level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha- 
modulating cytokines in spinal cords of the G93A-SOD1 mouse model for 
amyotrophic lateral sclerosis. Neurobiology o f Disease. 14 74-80.
Hoffmann, P. R., Kench, J. A., Vondracek, A., Kruk, E., Daleke, D. L., Jordan, M., 
Marrack, P., Henson, P. M. and Fadok, V. A. (2005). Interaction between 
phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in 
vivo. Journal o f Immunology. 174 1393-1404.
Hubley-Kozey, C. L. (1991). Testing flexibility. In Physiological testing o f the high- 
performance athlete (edited by J. A. MacDougall, H. A. Wenger and H. J. Green), 
pp. 309-359. Champaign, IL: Human Kinetics
Huynh, M. L., Fadok, V. A. and henson, P. M. (2002). Phosphatidylserine- 
dependent ingestion of apoptotic cells promotes TGF-fil secretion and the resolution 
of inflammation. Journal o f Clinical Investigation. 109 41-50.
International Society for the Advancement of Kinanthropometry (2001). 
International Standards for Anthropometric Assessment. Australia: The International 
Society for the Advancement of Kinanthropometry.
Jenkins, R. R., Krause, K. and Schofield, L. S. (1993). Influence of exercise on 
clearance of oxidant stress products and loosely bound iron. Medicine and Science 
in Sports and Exercise. 25 213-217.
168
Jiang, Q. and Ames, B. N. (2003). Gamma-tocopherol, but not alpha-tocopherol, 
decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB 
Journal: official publication o f the Federation o f American Societies for  
Experimental Biology. 17 816-822.
Jiang, Q., Lykkesfeldt, J., Shigenaga, M. K., Shigeno, E. T., Christen, S. and Ames, 
B. N. (2002). [gamma]-tocopherol supplementation inhibits protein nitration and 
ascorbate oxidation in rats with inflammation. Free Radical Biology and Medicine. 
33 1534-1542.
Jorissen, B. L., Brouns, F., Van Boxtel, M. P. and Riedel, W. J. (2002). Safety of 
soy-derived phosphatidylserine in elderly people. Nutritional Neuroscience. 5 337- 
343.
Kajikawa, N., Kaibuchi, K., Matsubara, T., Kikkawa, U., Takai, Y., Nishizuka, Y., 
Itoh, K. and Tomioka, C. (1983). A possible role of protein kinase C in signal- 
induced lysosomal enzyme release. Biochemical and Biophysical Research 
Communications. 116 743-750.
Kanter, M. M., lesmes, G. R., Kaminsky, L. A., Ham-Saeger, J. L. and Nequin, N.
D. (1988). Serum creatine kinase and lactate dehydrogenase changes following an 
eighty kilometre race. European Journal o f Applied Physiology. 57 60-63.
Kendall, B. and Eston, R. (2002). Exercise-Induced Muscle Damage and the 
Potential Protective Role of Estrogen. Sports Medicine. 32 103-123.
Kent-Braun, J. A. (1999). Central and peripheral contributions to muscle fatigue in 
humans during sustained maximal effort. European Journal o f  Applied Physiology. 
80 57-63.
Kim, H. Y., Akbar, M., Lau, A. and Edsall, L. (2000). Inhibition of neuronal 
apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in 
antiapoptotic effect. Journal o f Biological Chemistry. 275 35215-35223.
169
Koutoku, T., Takahashi, H., Tomonaga, S., Oikawa, D., Saito, S., Tachibana, T., 
Han, L., Hayamizu, K., Denbow, D. M. and Furuse et, a. (2005). Central 
administration of phosphatidylserine attenuates isolation stress-induced behavior in 
chicks. Neurochemistry International. 47 183-189.
Kuge, O., Nishijima, M. and Akamatsu, Y. (1986). Phosphatidylserine biosynthesis 
in cultured Chinese hamster ovary cells. II. Isolation and characterization of 
phosphatidylserine auxotrophs. Journal o f Biological Chemistry. 261 5790-5794.
LaCaille, R. A., Masters, K. S. and Heath, E. M. (2004). Effects of cognitive 
strategy and exercise setting on running performance, perceived exertion, affect, and 
satisfaction. Psychology o f  Sport and Exercise. 5 461-476.
Latorraca, S., Piersanti, P., Tesco, G., Piacentini, S., Amaducci, L. and Sorbi, S. 
(1993). Effect of phosphatidylserine on free radical susceptibility in human diploid 
fibroblasts. Journal o f Neural Transmission. Parkinson's Disease and Dementia 
Section. 6 73-77.
Liang, M. T., Meneses, P., Glonek, T., Kopp, S. J., Paulson, D. J., Schwartz, F. N. 
and Gierke, L. W. (1993). Effects of exercise training and anabolic steroids on 
plantaris and soleus phospholipids: a 3 IP nuclear magnetic resonance study. 
International Journal o f Biochemistry. 25 337-347.
Lou, P., Gutman, R. L., Mao, F. W. and Greenspan, P. (1994). Effects of 
phosphatidylserine on the oxidation of low density lipoprotein. International 
Journal o f  Biochemistry. 26 539-545.
Luger, A., Deuster, P. A., Kyle, S. B., Gallucci, W. T., Montgomery, L. C., Gold, P. 
W., Loriaux, D. L. and Chrousos, G. P. (1987). Acute hypothalamic-pituitary- 
adrenal responses to the stress of treadmill exercise. Physiologic adaptations to 
physical training. New England Journal o f Medicine. 316 1309-1315.
MacIntyre, D. L., Reid, D. W. and McKenzie, D. C. (1995). Delayed muscle 
soreness: the inflamation response to muscle injury and its clinical implications. 
Sports Medicine. 20 24-40.
170
McDowell, I. F., McEneny, J. and Trimble, E. R. (1995). A rapid method for 
measurement of the susceptibility to oxidation of low-density lipoprotein. Annals o f  
Clinical Biochemistry. 32 (2) 167-174.
McEneny, J., Trimble, E. R. and Young, I. S. (1998). A simple method for assessing 
copper-mediated oxidation of very-low-density lipoprotein isolated by rapid 
ultracentrifugation. Annals o f Clinical Biochemistry. 35 (4) 504-514.
Miller, P. C., Bailey, S. P., Barnes, M. E., Derr, S. J. and Hall, E. E. (2004). The 
effects of protease supplementation on skeletal muscle function and DOMS 
following downhill running. Journal o f Sports Sciences. 22 365-372.
Monastra, G. and Bruni, A. (1992). Decreased serum level of tumor necrosis factor 
in animals treated with lipopolysaccharide and liposomes containing 
phosphatidylserine. Lymphokine Cytokine Research. 11 39-43.
Monastra, G., Pege, G., Zanoni, R., Toffano, G. and Bruni, A. (1991). 
Lysophosphatidylserine-induced activation of mast cells in mice. Journal o f Lipid 
Mediators. 3 39-50.
Mongar, J. L. and Svec, P. (1972). The effect of phospholipids on anaphylactic 
histamine release. British Journal o f Pharmacology. 46 741-752.
Monteleone, P., Beinat, L., Tanzillo, C., Maj, M. and Kemali, D. (1990). Effects of 
phosphatidylserine on the neuroendocrine response to physical stress in humans. 
Neuroendocrinology. 52 243-248.
Monteleone, P., Maj, M., Beinat, L., Natale, M. and Kemali, D. (1992). Blunting by 
chronic phosphatidylserine administration of the stress-induced activation of the 
hypothalamo-pituitary-adrenal axis in healthy men. European Journal o f Clinical 
Pharmacology. 42 385-388.
Moodley, I. and Mongar, J. L. (1981). IgG receptors on the mast cells. Agents and 
Actions. 11 77-83.
171
Morrot, G., Zachowski, A. and Devaux, P. F. (1990). Partial purification and 
characterisation of the human erythrocyte. American Journal o f Physiology. 216 82- 
86 .
Nagai, Y., Aoki, J., Sato, T., Amano, K., Matsuda, Y., Arai, H. and Inoue, K. 
(1999). An alternative splicing form of phosphatidylserine-specific phospholipase 
Al that exhibits lysophosphatidylserine-specific lysophospholipase activity in 
humans. Journal o f Biological Chemistry. 274 11053-11059.
Nicholas, C. W., Nuttall, F. E. and Williams, C. (2000). The Loughborough 
Intermittent Shuttle Test: a field test that simulates the activity pattern of soccer. 
Journal o f Sports Sciences. 18 97-104.
Nishijima, M., Kuge, O. and Akamatsu, Y. (1986). Phosphatidylserine biosynthesis 
in cultured Chinese hamster ovary cells. I. Inhibition of de novo phosphatidylserine 
biosynthesis by exogenous phosphatidylserine and its efficient incorporation. 
Journal o f Biological Chemistry. 261 5784-5789.
Ozyener, F., Rossiter, H. B., Ward, S. A. and Whipp, B. J. (2001). Influence of 
exercise intensity on the on- and off-transient kinetics of pulmonary oxygen uptake 
in humans. Journal o f Physiology. 533 891-902.
Palatini, P., Viola, G., Bigon, E., Menegus, A. M. and Bruni, A. (1991). 
Pharmacokinetic characterization of phosphatidylserine liposomes in the rat. British 
Journal o f Pharmacology. 102 345-350.
Peake, J. M., Suzuki, K., Wilson, G., Hordern, M., Nosaka, K., Mackinnon, L. and 
Coombes, J. S. (2005). Exercise-induced muscle damage, plasma cytokines, and 
markers of neutrophil activation. Medicine and Science in Sports and Exercise. 37 
737-745.
Pepeu, G., Giovannelli, L., Giovannini, M. G. and Pedata, F. (1986). Effect of 
phosphatidylserine on cortical acetylcholine release and calcium uptake in adult and 
aging rats. In Phospholipid research and the nervous system. Biochemical and 
molecular pharmacology (edited by L. A. Horrocks, L. Freysz and G. Toffano), pp. 
265-271. Padova: Liviana Press
172
Pepeu, G., Pepeu, I. M. and Amaducci, L. (1996). A review of phosphatidylserine 
pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing 
brain? Pharmacological Research. 33 73-80.
Peronnet, F. and Massicotte, D. (1991). Table of nonprotein respiratory quotient: an 
update. Canadian Journal o f Sport Sciences. 16 23-29.
Ponzin, D., Mancini, C., Toffano, G., Bruni, A. and Doria, G. (1989). 
Phosphatidylserine-induced modulation of the immune response in mice: effect of 
intravenous administration. Immunopharmacology. 18 167-176.
Ramsbottom, R., Brewer, J. and Williams, C. (1988). A progressive shuttle run test 
to estimate maximal oxygen uptake. British Journal o f Sports Medicine. 22 141-144.
Rossiter, H. B., Howe, F. A., Ward, S. A., Kowalchuk, J. M., Griffiths, J. R. and 
Whipp, B. J. (2000). Intersample fluctuations in phosphocreatine concentration 
determined by 3 IP-magnetic resonance spectroscopy and parameter estimation of 
metabolic responses to exercise in humans. Journal o f Physiology. 528 359-369.
Sakai, M., Yamatoya, H. and Kudo, S. (1996). Pharmacological effects of 
phosphatidylserine enzymatically synthesized from soybean lecithin on brain 
functions in rodents. Journal o f Nutritional Science and Vitaminology. 42 47-54.
Schneider, D. A., Wing, A. N. and Morris, N. R. (2002). Oxygen uptake and heart 
rate kinetics during heavy exercise: a comparison between arm cranking and leg 
cycling. European Journal o f Applied Physiology. 88 100-106.
Sepulveda, M. R. and Mata, A. M. (2004). The interaction of ethanol with 
reconstituted synaptosomal plasma membrane Ca2+-ATPase. Biochimica et 
Biophysica Acta (BBA) - Biomembranes. 1665 75-80.
Shores, A. J. and Mongar, J. L. (1980). Modulation of histamine secretion from 
Concanavalin A-activated rat mast cells by phosphatidyl serine, calcium, cAMP, pH 
and metabolic inhibitors. Agents and Actions. 10 131-137.
Singer, S. J. and Nicolson, G. L. (1972). The fluid mosaic model of the structure of 
cell membranes. Science. 175 720-731.
173
Smith, L. L., McCammon, M., Smith, S., Chamness, M., Israel, R. G. and O'Brien, 
K. F. (1989). White blood cell response to uphill walking and downhill jogging at 
similar metabolic loads. European Journal o f Applied Physiology and Occupational 
Physiology. 58 833-837.
Soares, J. C. and Gershon, S. (1994). Advances in the pharmacotherapy of 
Alzheimer's disease. European Archives o f Psychiatry and Clinical Neuroscience. 
244 261-271.
Specht, S. C. and Robinson, J. D. (1973). Stimulation of the (Na++K+)-dependent 
adenosine triphosphatase by amino acids and phosphatidylserine: chelation of trace 
metal inhibitors. Archives o f Biochemistry and Biophysics. 154 314-323.
Sugden, P. H. and Bogoyevitch, M. A. (1995). Intracellular signalling through 
protein kinases in the heart. Cardiovascular Research. 30 478-492.
Sumikawa, K., Mu, Z., Inoue, T., Okochi, T. and Yoshida, T. (1993). Changes in 
erythrocyte membrane phospholipid composition induced by physical training and 
exercise. European Journal o f Applied Physiology. 67 132-137.
Suzuki, K., Totsuka, M., Nakaji, S., Yamada, M., Kudoh, S., Liu, Q., Sugawara, K., 
Yamaya, K. and Sato, K. (1999). Endurance exercise causes interaction among 
stress hormones, cytokines, neutrophil dynamics, and muscle damage. Journal o f  
Applied Physiology. 87 1360-1367.
Suzuki, K., Yamada, M., Kurakake, S., Okamura, N., Yamaya, K., Liu, Q., Kudoh, 
S., Kowatari, K., Nakaji, S. and Sugawara, e. a. (2000). Circulating cytokines and 
hormones with immunosuppressive but neutrophil-priming potentials rise after 
endurance exercise in humans. European Journal o f Applied Physiology. 81 281- 
287.
Suzuki, S., Yamatoya, H., Sakai, M., Kataoka, A., Furushiro, M. and Kudo, S. 
(2001). Oral administration of soybean lecithin transphosphatidylated 
phosphatidylserine improves memory impairment in aged rats. Journal o f Nutrition. 
131 2951-2956.
174
Suzuki, T. T. and Kanfer, J. N. (1985). Purification and properties of an 
ethanolamine-serine base exchange enzyme of rat brain microsomes. Journal o f 
Biological Chemistry. 260 1394-1399.
Takai, Y., Kishimoto, A., Iwasa, Y., Kawahara, Y., Mori, T. and Nishizuka, Y. 
(1979). Calcium-dependent activation of a multifunctional protein kinase by 
membrane phospholipids. Journal o f Biological Chemistry. 254 3692-3695.
Tanaka, Y. and Schroit, A. J. (1983). Insertion of fluorescent phosphatidylserine into 
the plasma membrane of red blood cells. Journal o f Biological Chemistry. 258 
11335-11343.
Thompson, D., Bailey, D. M., Hill, J., Hurst, T., Powell, J. R. and Williams, C. 
(2004). Prolonged vitamin C supplementation and recovery from eccentric exercise. 
European Journal o f  Applied Physiology. 92 133-138.
Thompson, D., Williams, C., Kingsley, M., Nicholas, C. W., Lakomy, H. K., 
McArdle, F. and Jackson, M. J. (2001a). Muscle soreness and damage parameters 
after prolonged intermittent shuttle-running following acute vitamin C 
supplementation. International Journal o f Sports Medicine. 22 68-75.
Thompson, D., Williams, C., McGregor, S. J., Nicholas, C. W., McArdle, F., 
Jackson, M. J. and Powell, J. R. (2001b). Prolonged vitamin C supplementation and 
recovery from demanding exercise. International Journal o f Sport Nutrition and 
Exercise Metabolism. 11 466-481.
Thumham, D. I., Smith, E. and Flora, P. S. (1988). Concurrent liquid- 
chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, 
lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal 
standard. Clinical Chemistry. 34 377-381.
Tibbits, G. F., Nagatomo, T., Sasaki, M. and Barnard, R. J. (1981). Cardiac 
sarcolemma: compositional adaptation to exercise. Science. 213 1271-1273.
Tidball, J. G. (2005). Inflammatory processes in muscle injury and repair. American 
Journal o f Physiology. Regularory, Integrative and Comparative Physiology. 288 
345-353.
175
Toffano, G. and Bruni, A. (1980). Pharmacological properties of phospholipid 
liposomes. Pharmacological Research Communications. 12 829-845.
Toffano, G., Leon, A., Benvegnu, D., Boarato, E. and Azzone, G. F. (1976). Effect 
of brain cortex phospholipids on catechol-amine content of mouse brain. 
Pharmacological Research Communications. 8 581-590.
Tsakiris, S. and Deliconstantinos, G. (1984). Influence of phosphatidylserine on 
(Na++K+)-stimulated ATPase and acetylcholinesterase activities in dog brain 
synaptosomal plasma membranes. Biochemical Journal. 220 301-307.
Tyurina, Y. Y., Shvedova, A. A., Kawai, K., Tyurin, V. A., Komminineni, C., 
Quinn, P. J., Schor, N. F., Fabisiak, J. P. and Kagan, V. E. (2000). Phospholipid 
signaling in apoptosis: peroxidation and extemalization of phophatidylserine. 
Toxicology. 148 93-101.
Van Loon, L. J., Greenhaff, P. L., Constantin-Teodosiu, D., Saris, W. H. and 
Wagenmakers, A. J. (2001). The effects of increasing exercise intensity on muscle 
fuel utilisation in humans. Journal o f Physiology. 536 295-304.
Vance, J. E. and Steenbergen, R. (2005). Metabolism and functions of 
phosphatidylserine. Progress in Lipid Research. 44 207-234.
Vassilakopoulos, T., Roussos, C. and Spyros, Z. (2005). When are antioxidants 
effective in blunting the cytokine response to exercise? Medicine and Science in 
Sports and Exercise. 37 342-343.
Vincent, P., Sargueil, F., Sturbois-Balcerzak, B., Cassagne, C. and Moreau, P. 
(2001). Phosphatidylserine increase in rat liver endomembranes during the acute 
phase response. Biochimie. 83 957-960.
Voelker, D. R. (1989). Phosphatidylserine translocation to the mitochondrion is an 
ATP-dependent process in permeabilized animal cells. Proceedings o f the National 
Academy o f  Sciences o f the United States o f America. 86 9921-9925.
176
Voelker, D. R. and Frazier, J. L. (1986). Isolation and characterization of a Chinese 
hamster ovary cell line requiring ethanolamine or phosphatidylserine for growth and 
exhibiting defective phosphatidylserine synthase activity. Journal o f Biological 
Chemistry. 261 1002-1008.
Vuilleumier, J. P. K. (1993). Fluorimetric assay of vitamin C in biological materials 
using a centrifugal analyser with fluorescence attachment. Journal o f Micronutrient 
Analysis. 5 25-34.
Whipp, B. J., Ward, S. A., Lamarra, N., Davis, J. A. and Wasserman, K. (1982). 
Parameters of ventilatory and gas exchange dynamics during exercise. Journal o f  
Applied Physiology. 52 1506-1513.
Yamatoya, H., Sakai, M. and Kudo, S. (2000). The effects of soybean 
transphosphatidylated phosphatidylserine on cholinergic synaptic functions of mice. 
Japanese Journal o f Pharmacology. 84 93-96.
177
Appendix A1: Ethical Application (Study 1)
Application for Ethical Approval 
Department of Psychology, University of Wales Swansea
Research Project in Collaboration with the 
Department of Sports Science, University of Wales Swansea
All Project students should complete this form in consultation with their project supervisor. 
If your supervisor feels that the project involves any potentially controversial procedures 
(i.e. they feel that the ethical issues raised need to be considered by the Department Ethics 
Committee) then the form should be placed in the tray in the Resources Centre for 
consideration by the Departmental Ethics Committee. Further advice will then be given to 
you by the Ethics Committee via your supervisor. The completed form should be bound 
along with your project report.
Project Title: The effects of chronic phosphatidylserine (PS) supplementation on recovery 
following intermittent exercise.
Principal investigator/Supervisor: Mike Kingsley; MSc (Lough), BPhEd (Otago), PGCE 
Students Name: Daniel Wadsworth; BSc, (Wales)
Collaborator: Professor David Benton; PhD
Brief description of the purpose and methods of the project:
Purpose: Phosphatidylserine (PS) has been shown to reduce blood levels of cortisol in 
response to resistance training (Fahey and Pearl, 1998) and physical exercise (Monteleone et 
al., 1992). The elevation of cortisol levels in response to exercise stress leads to the 
accelerated catabolism of amino acids. As such, elevated cortisol levels can be viewed as a 
possible precursor to muscle damage. Subsequently, suppression of cortisol levels could 
theoretically prevent muscle damage. Supplementation with PS may therefore enhance 
recovery following exercise. Burke (2000) supports the possible benefits on recovery of PS
178
supplementation, suggesting that it may minimize muscle fibre damage caused by muscular 
stress.
Aims: To investigate the effects of chronic phosphatidylserine (PS) supplementation, on 
heart rate and cortisol levels, during and immediately following intermittent exercise. To 
investigate the effects of chronic phosphatidylserine supplementation (PS) supplementation 
on muscle soreness/damage following intermittent exercise.
No. o f participants'. 16-20.
How and where are the participants to be recruited: Undergraduate and postgraduate male 
student volunteers will be recruited.
Experimental procedure (brief details only): Preliminary testing of subjects will include an 
estimation of maximal oxygen uptake, by multi-stage fitness test. Subjects will then 
complete a familiarization trial of a prolonged intermittent exercise protocol, designed to 
replicate the physiological demands of soccer match play. Subsequently, subjects will 
complete two further exercise trials, once with no supplement (control) (Tl) and once with 
either a PS supplement or a glucose placebo (T2). Chronic supplementation of 900 mg/day 
of PS or a weight matched glucose placebo (T2) will take place for 10 days prior to T2. 
Subjects will be randomly allocated to supplementation group using a double blind 
procedure. A minimum of 1 week will separate the familiarization and Tl trials, with T2 
occuring approximately 2-4 weeks later.
During Tl and T2, physiological measurement procedures will consist of heart rate 
monitoring, 2 venous blood samples (<30 ml per sample), and sprint/endurance performance 
assessment. Subjects will be required to return for tests 1 and 2 days after exercise to assess 
recovery, when further blood samples (<30 ml per sample) will be collected in order to 
assess their recovery (one sample per day), and muscle soreness assessed. Blood samples 
will then be analysed for markers of muscle damage, oxidative stress and cortisol 
concentrations.
Details of any payment given: None
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Consent and Debriefing
Have you prepared a consent form for participants? YES (attached)
Have you prepared an information sheet to debrief participants? YES (attached)
You must attach the consent form and information sheet before handing this form to your 
supervisor. You must also attach a copy of any questionnaire(s) that you intend using. 
Environmental validity questionnaire 
Perceived muscle soreness questionnaire 
Ethical Considerations
Please read the following declarations carefully and detail below any ways in which your 
project deviates from them. Then sign where indicated.
1. I have ensured that there will be no active deception of participants.
2. I have ensured that no data will be personally identifiable.
3. I have ensured that no participant should suffer any undue physical or psychological
discomfort
4. I certify that there will be no administration of potentially harmful drugs, medicines
or foodstuffs. *
5. I will obtain written permission from an appropriate authority before recruiting
members of any outside institution as participants.
6. I certify that the participants will not experience any potentially unpleasant
stimulation or deprivation?
7. I certify that any ethical considerations raised by this proposal have been discussed
in detail with my supervisor.
8. I certify that the above statements are true with the following exception(s):
* Phosphatidylserine is a naturally occurring phospholipid predominantly found in the brain 
cell membranes but also found in other structures (RCC, 1996). It is considered a safe food 
supplement with no known side effects. The dosage given for this study will be 300mg/day 
in three lOOmg tablets. This dose will be taken for 30 days.
Registration and consulting company. (1996) Expert report on the safety of 
Phophatidylserine PS 50 as produced from soya lecithin by enzymatic transesterification. 
RCC project 629910.
Signature: Date:
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In the supervisor’s opinion, this project (tick one only):
Does not raise any significant issues.
Raises some ethical issues, but I consider that appropriate steps and precautions have been 
tak-en-and I have approved the proposal and accept the responsibility for-having-done-so. 
Raises ethical issues that need to be considered by the Departmental Ethics Committee. 
Raises ethical issues such that it should not be allowed to proceed in its current form.
Supervisor’s signature: Date:
(For Ethics Committee use only)
The ethical issues raised by this project have been considered by members of the 
Departmental Ethics Committee who made the following comments:
Please ensure that you take account of these comments and prepare a revised submission 
that should be shown to your supervisor/ resubmitted to the Department Ethics Committee 
(delete as appropriate).
Signed: Date:
(Chair, Departmental Ethics Committee)
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Singleton Park, Swansea, SA2 8PP
Mike Kingsley 
Sports Science
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The effects of phosphatidylserine supplementation on recovery following 
prolonged intermittent exercise.
Dear Mike,
The departmental ethics committee has reviewed the above study and have agreed that 
it raises no substantive ethical issues, provided that die information obtained is kept 
confidential and that no personally identifiable information is entered onto computer. 
With these provisions we are happy for you to proceed with your study.
Yours sincerely,
9
Kate Bullen, PhJD.
On behalf o f the ethics committee
Pennaeth yr Adran • Professor Philip J.J. Coir • Head of Department 
Tel 01792 295081 Fax 01792 295679 Email psychology@swansea.ac.uk
Pennaeth vr Ysgol • Professor Phil Reed • Head of School 
Tel 01792 602047 Fax 01792 295679 Emailp.reed@swansea.ac.uk
P R I F Y S G O L  C Y M R U  A B E R T A W E  _rot
Yr Adran Seicoleg 
Ysgol Gwyddorau Dynol 
Parc Singleton, Abertawe, SA2 8PP
182
Appendix A2: Ethical Application (Study 2)
UNIVERSITY OF WALES SWANSEA 
DEPARTMENT OF SPORTS SCIENCE 
DEPARTMENTAL ETHICS ADVISORY COMMITTEE
APPLICATION FOR ETHICAL COMMITTEE APPROVAL OF A RESEARCH PROJECT
In accordance with Departmental Safety Policy, all research undertaken in the department must be 
approved by the Departmental Ethics Advisory Committee prior to data collection. Applications for 
approval should be typewritten on this form using the template available in the Public Folders. 
The researcher(s) should complete the form in consultation with the project supervisor. Where 
appropriate, the application must include the following appendices:
(A) subject information sheet;
(B) subject consent form;
(C) subject health questionnaire.
After completing sections 1-12 of the form, seven copies of the form should be handed into the 
Department Administrator who will submit the application for consideration by the 
Departmental Ethics Advisory Committee. The applicant(s) will be informed of the decision of 
the Committee in due course.
1. DRAFT TITLE OF PROJECT
Effects o f Phosphatidylserine Supplementation on Muscle Damage, mental tasks and stress following 
Downhill Running
2. NAMES AND STATUS OF RESEARCH TEAM
Mr Mike Kingsley - Supervisor 
Richard Elms - BSc Sports Science 3rd year student 
David Maycock - BSc Sports Science 3rd year student 
Gareth Matthews - BSc Sports Science 3rd year student 
Nick Hodgson - BSc Sports Science 3rd year student
3. RATIONALE
Byrnes et al. (1985) suggested that downhill running is considered to induce delayed-onset muscle 
soreness (DOMS) due to bias towards eccentric contractions, with soreness peaking between 48 to 72 
hours post exercise. Fahey et al. (1998) suggests that soreness is due to two different causes of 
damage to the muscle fibres: muscular damage, which is instant, caused by excessive force, and 
secondary cellular damage caused by elevation of proteases and phosopholipids due to physical stress 
on the body. An elevation in Cortisol is also achieved, which Fahey et al. (1998) suggested increased 
protein breakdown, and decreases protein synthesis, which may lead to the deterioration of muscle 
tissue. Studies based on the effects o f PS supplementation, have mainly focused on the hypothalamo- 
pituitary-adrenal axis, and not the possible effects on DOMS. The studies by Monteleone et al. (1990) 
and Monteleone et al. (1992) concluded that PS supplementation did "blunt" the elevation o f Cortisol 
and its controlling hormone adrenocorticotrophic hormone (ACTH). In theory, PS supplementation 
may decrease serum creatine kinase (CK) levels due to a reduction in fibre trauma, which may lead to 
a reduction symptoms o f DOMS by decreasing muscle damage caused by the secondary cellular 
breakdown o f protein by elevated levels o f cortisol after exercise.
According to Gullick and Kimura (1996), muscle soreness can either be 'acute' or have a 'delayed 
onset' dependant on when muscle soreness occurs. Acute muscle soreness tends to transpire during 
the latter stages o f exercise whereby, delayed onset muscle soreness (DOMS) is seen to peak 24-48 
hours after exercise (Gullick and Kimura, 1996; Maughan et al., 1989). DOMS has been seen to have 
a negative effect on athletic performance, including tenderness to palpation and a decreased 
flexibility. The effect o f repeated exercise and familiarisation bouts during experiments has been 
thought to diminish the muscle fibre injury resulting from eccentric exercise, which is the source of 
DOMS (Armstrong, 1986). The symptoms o f DOMS have been seen to be markedly lower following
183
general or task specific training (Byrnes et al., 1985). There has not been an experiment that looks 
directly at the effect o f a familiarisation eccentric exercise bout on the symptoms o f DOMS when 
compared to a non- familiarised bout. Previous studies have supported the hypothesis that a 
familiarisation bout o f specific exercise causes a marked decrease in DOMS symptoms for up to three 
weeks (Byrnes et al., 1985).
The effects o f physical exercise on mental function has been widely studied by psychologists; 
however, results have produced contradictory findings leading researchers identifying several 
methodological factors to control in studies including the nature o f the psychological task, intensity 
and duration o f physical exercise (Brisswalter, et al., 2002). Researchers have produced consistent 
results showing physical exercise enhances cognitive performance mainly through the use of 
decisional tasks. However, this is subject to the type, intensity and duration o f the exercise. 
Brisswalter et al. (2001) found that an improvement in cognitive performance was observed with 
long-term aerobic exercise. Anaerobic exercise has also been found to increase cognitive 
performance with Davey (1973) finding that anaerobic exercise demonstrated facilitation in the 
subject's cognitive performance. Phosphatidylserine has been widely used as a memory aid through 
the treatment o f patients with cognitive dysfunctions such as Alzheimers with some success (Crooks 
et al., 1992) and therefore the link has been made to use the supplement for reducing stress. Benton et 
al. (2001) found PS supplementation decreased feelings o f being stressed after performing a 
demanding mental arithmetic task. However, nothing has been done on the effects that PS has on 
exercise stress o f cognitive performance. Task complexity must also be taken into account when 
looking into the effects o f cognitive performance during physical exercise, with the nature of the task 
interpret ting the allocation o f attention capacity to the physical or mental task (Abemethy, 1988).
Physical exercise significantly increases blood lactate concentration. It is thought that PS may 
influence the response o f the body to stress. This is thought to be due to exogenous PS affects the 
number and affinity o f membrane receptor site (Stockert et al., 1989; De Robertis et al., 1989). This 
influences cell membrane transduction mechanisms such as specific protein kinase activation 
(Canonico and Scapagnini, 1989). Information transduction systems are important in cell to cell 
communication and therefore crucial in homeostatic adaptation to changing stimuli, such as stress. 
Thus PS may alter the bodies response to stress (Monteleone et al. 1991) by altering functional events 
in the cell Appendices XI membrane. During physical exercise the hypothalamo-pituitary-adrenal 
(HP A) axis is stimulated. PS partly counteracts the activation o f HPA. This suggests that 
Phosphatidylserine has an acute effect on the stress-induced release of the adrenocorticotrophic 
(ACTH) hormone and cortisol (Monteleone et al.., 1990), and therefore may alternate the 
physiological response to exercise.
4. REFERENCES
1. Abemethy, B. (1988). Dual task methodology and motor skills research: some applications
and methodological constraints. J o u r n a l  o f  H u m a n  M o v e m e n t  S tu d ie s , 14, 101-32
2. Armstrong, R.B. (1986). Muscle Damage and Endurance Events. J o u r n a l  o f  S p o r ts  
M e d ic in e .  3, 370-381
3. Benton, D., Donohoe, R.T., Sillance, B., Nabb, S. (2001). The influence of
phosphatidylserine supplementation on mood and heart rate when faced with an acute 
stressor. N u tr i t io n a l  N e u r o s c ie n c e ,  4, 169-178.
3. Byrnes, W.C., Clarkson, P;M., White, J.S., Hsieh, S.S., Frykman, P.N., & Maughan, RJ.
(1985). Delayed onset muscle soreness following repeated bouts o f downhill running. 
J o u r n a l  o f  A p p l i e d  P h y s i o l io l g y  59, 710-715
4. Brisswalter, J., Collardeau, M., and Rene, A. (2002). Effects o f acute physical exercise
characteristics on cognitive performance. S p o r ts  M e d ic in e ,  32, 555-66.
5. Collardeau, M., Brisswalter, J., and Audiffren, M. (2001). Effects o f a prolonged mn on
simple reaction time o f well trained runners. P e r c e p t u a l  a n d  M o to r  S k i l l s ,  93, 679-689.
6. Davey, C.P. (1973). Physical exertion and mental performance, E r g o n o m ic s ,  16, 595-599.
6. Fahey, T.D. and Pearl, M.S. (1998). The Hormonal and Perceptive Effects of
Phosphatidylserine Administration During two Weeks o f Resistive Exercise-Induced 
Overtraining. B i o l o g y  o f  S p o r t . 15, 135-144.
7. Gulick, D.T. and Kimura, I.F. (1996) Delayed Onset Muscle Soreness: What is it and how
do we treat it? J o u r n a l  o f  S p o r ts  R e h a b i l i ta t io n .  5, 234-236.
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8. Maughan, R.J., Donnelly, A.E., Gleeson, M., Whiting, P.H., Walker,K.A. and Clough, P.J. 
(1989). Delayed-onset muscle damage and lipid peroxidation in man after a downhill run. 
M u s c le  a n d  N e r v e .  12, 332-336.
9. Monteleone, P., Beinat, L., Tanzillo, C., Maj, M. and Kemali, D. (1990). Effects of
Phosphatidylserine on the Neuroendocrine Response to Physical Stress in Humans. 
N e u r o e n d o c r in o lo g y .  52 ,243-248.
10. Monteleone, P., Beinat, L., Maj, M., Natale, M., and Kemali, D. (1992). Blunting by
Chronic Phosphatidylserine Administration o f the stress-induced activation o f the 
Hypothalamo-Pituitary-Adrenal axis in healthy men. E u r o p e a n  J o u r n a l  o f  C l in ic a l  
P h a r m a c o lo g y .  41, 385-388.
11. Tomporowski P.D., and Ellis, N.R. (1986). Effects on Cognitive Processes: A Review.
P s y c h o l o g i c a l  B u l l e t in , 99, 338-336.
5. AIMS and OBJECTIVES
The aim o f the study is to determine the effect o f chronic PS supplementation on Physiological stress, 
oxidative stress and the development o f DOMS on 8, 19-24 year old male subjects.
The specific objectives are:
1. To determine the effect o f a familiarisation bout development o f DOMS.
2. To investigate the effect o f PS on markers o f oxidative stress and inflammation that follow 
downhill running.
3. Assess the effects o f PS supplementation on muscle damage and self reported DOMS after 
downhill running. 4. Assess the effects o f PS supplementation on the performance o f mental tasks 
following downhill running.
6. METHODOLOGY
6.1 Study Design
8 male physically fit subjects aged from 19-24 will be asked to complete the study. All prior to 
participation subjects will be required to complete an AHA ACSM pre-participation screening 
questionnaire. Subjects will be required to take part in a progressive maximal exercise test, and five 
thirty minute downhill runs each followed by a cognitive task, and 24 and 48 hours after each run 
flexibility and blood samples will be taken. Subjects will complete a preliminary testing session; a 
familiarization session and four main trials over duration o f 10 weeks. 10 days prior to the second 
main trial the subjects will receive either a PS supplement or Placebo.
6.2 Experimental Procedures
Preliminary Testing: Subjects will complete a progressive maximal exercise test in order to determine 
the exercise intensity for the downhill exercise trials.
Familiarisation and main trials: Subjects will complete a 5 minute warm up jog on the treadmill at 
there own selected pace. This will be followed by a 30 minute downhill run at a gradient of -10 
percent and a work rate equivalent to approximately 70% o f their maximum heart rate. Measurements 
of DOMS (perceived muscle soreness), range of motion and venous blood samples (<30 ml per 
sample) will be taken at the following time points during each trial (before exercise, after exercise, 24 
hours after exercise and 48 hours after exercise).
Supplementation: The subjects will be required to take an oral supplement containing either 
approximately 800 mg/day for 10 days prior to and for 2 days after main trials 2 and 4. Subjects will 
receive either PS or glucose supplements in a balanced cross-over design.
6.3 Data Analysis Techniques
Statistical analysis o f the data will be completed using statistical packages such as Excel and SPSS.
6.4 Storage and Disposal of Data and Samples
Data will be stored electronically; however, access to the data will be restricted to the research team. 
Any published information will not include any information that would potentially reveal the 
identification o f subjects. Blood samples will be stored prior to analysis and then disposed of using 
standard biological procedures.
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7. LOCATION OF THE PREMISES WHERE THE RESEARCH WILL BE CONDUCTED.
Exercise Physiology Labs, Vivian Tower, University o f Wales Swansea
8. SUBJECT RISKS AND DISCOMFORTS
Subjects will be completing 5 downhill runs at approximately 70% of their maximum heart rate and 
as a result they are expected to exhibit some degree o f muscle soreness; however, all subjects will be 
familiar with DOMS. All the subjects will be monitored immediately post exercise and any risk due 
to blood testing will be minimized through strict adherence to standard procedures as specified in the 
department safety policy. In addition, prior to testing health screening will be fulfilled using the 
AHA/ACSM pre-participation screening questionnaire (Appendix C). Subjects will be required to 
take an oral supplement containing PS; PS is a naturally occurring phospholipid that is predominantly 
found in the cell membranes and is considered safe to use and is currently marketed as a memory aid.
9. INFORMATION SHEET AND INFORMED CONSENT
T h e  s u b m is s io n  s h o u l d  b e  s p e c i f ic  a b o u t  th e  ty p e  o f  c o n s e n t  th a t  w i l l  b e  s o u g h t:
Have you included a Subject Information Sheet for the participants of the study ? YES (Appendix A) 
Have you included a Subject Consent Form for the participants o f the study? YES (Appendix B) 
If written consent will not be obtained, explain why
10. COMPUTERS
Are computers to be used to store data? YES
If so, is the data registered under the Data Protection Act? YES
NB : For UWS students, the answer to this question is YES, but the question has been included in 
order to stress the importance of adherence to the Data Protection Act in research activity
11. STUDENT DECLARATION
Please read the following declarations carefully and provide details below of any ways in which your 
project deviates from them. Having done this, each student listed in section 2 is required to sign 
where indicated.
1. I have ensured that there will be no active deception of participants.
2. I have ensured that no data will be personally identifiable.
3. I have ensured that no participant should suffer any undue physical or psychological discomfort
4. I certify that there will be no administration of potentially harmful drugs, medicines or foodstuffs.
5. I will obtain written permission from an appropriate authority before recruiting members of any 
outsideinstitution as participants.
6. I certify that the participants will not experience any potentially unpleasant stimulation or 
deprivation.
7. I certify that any ethical considerations raised by this proposal have been discussed in detail with 
my supervisor.
8. I certify that the above statements are true with the following exception(s):
Student signature: Date:
Student signature: Date:
Student signature: Date:
Student signature: Date:
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12. SU PER V ISO R ’S DECLARATION
In the supervisor’s opinion, this project (delete those that do not apply):
 •--------- Does not raise any significant-issues.
•  Raises some ethical issues, but I consider that appropriate steps and precautions have been
taken and I have approved the proposal.
 •--------- Raises ethical issues that need to be considered by the Departmental Ethics Committee.
 •--------- Raises ethical issues such that it should not be allowed to proceed in its current form.
Supervisor’s signature: Date:
13. ETHICS COMMITTEE DECISION (COMMITTEE USE ONLY)
ETHICAL APPROVAL: GRANTED REJECTED (delete as
appropriate)
The ethical issues raised by this project have been considered by members o f the Departmental 
Ethical Approval Committee who made the following comments:
Please ensure that you take account o f these comments and prepare a revised submission that should 
be shown to your supervisor/ resubmitted to the Department Ethical Approval Committee (delete as 
appropriate).
Signed: Date:
(Chair, Departmental Ethics Advisory Committee)
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P R I F Y S G O L  C Y M R U  A B E R T A W E  
U N I V E R S I T Y  OF WAL E S  S W A N S E A
Department of Sports Sclenee 
Departmental Ethical Advisory Committee
From : Dr M J Lewis, Chairman, DEAC
To : Mr M Kingsley, Mr R Elms, Mr G Matthews and Mr N Hodgson
Subject: Application for Ethics Committee Approval
Date: 25/11/03
Your application (submitted 29/10/03) for ethical approval for:
Effects of phosphotidylserine supplementation on muscle damage, mental tasks and 
stress following downhill running.
was considered by the Departmental Ethics Advisory Committee members on 
5/11/03. DEAC Committee approval subject to conditions and resubmission was 
given.
Following resubmission of the application, members of the DEAC agree that the 
study raises no substantive ethical issues. Therefore, Chair’s approval granted 
20/11/03.
Mrc.
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Appendix A3: Ethical Application (Study 3)
Application for Ethical Approval 
Department of Psychology, University of Wales Swansea 
Research Project in Collaboration with the 
Department of Sports Science, University of Wales Swansea
All Project students should complete this form in consultation with their project supervisor. 
If your supervisor feels that the project involves any potentially controversial procedures 
(i.e. they feel that the ethical issues raised need to be considered by the Department Ethics 
Committee) then the form should be placed in the tray in the Resources Centre for 
consideration by the Departmental Ethics Committee. Further advice will then be given to 
you by the Ethics Committee via your supervisor. The completed form should be bound 
along with your project report.
Project Title: Chronic phosphatidylserine (PS) supplementation and its effects on recovery 
following exercise stress.
Principal investigator/Supervisor: Mike Kingsley; MSc (Lough), BPhEd (Otago), PGCE 
Students Name: Mark Miller; BSc, (Wales)
Collaborator: Professor David Benton; PhD
Brief description of the purpose and methods of the project:
Aims & purpose: To investigate the effects of chronic PS supplementation and on recovery 
following intermittent running.
No. of participants'. Approximately twenty-four.
How and where are the participants to be recruited: Undergraduate and postgraduate 
student volunteers will be recruited.
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Experimental procedure (brief details onlyf. Chronic supplementation of PS (800mg/day 
for 10 days) will be allocated using a placebo controlled double blind procedure. 
Preliminary testing will include anthropometric measurement and a progressive maximal 
exercise test on a cycle ergometer. Subjects will then undergo a familiarisation trail 
followed by 2 trials (pre and post supplementation). The exercise administration will be in 
the form of a staged intermittent cycling exercise with passive recovery periods. 
Measurement procedures will consist of heart rate monitoring, venous blood samples, 
respiratory gas analysis and other non-invasive procedures. A full description of the study 
design is attached.
Details o f any payment given: None 
Consent and Debriefing
Have you prepared a consent form for participants? YES (attached)
Have you prepared an information sheet to debrief participants? YES (attached)
You must attach the consent form and information sheet before handing this form to your 
supervisor. You must also attach a copy of any questionnaire(s) that you intend using.
Ethical Considerations
Please read the following declarations carefully and detail below any ways in which your 
project deviates from them. Then sign where indicated.
1. I have ensured that there will be no active deception of participants.
2. I have ensured that no data will be personally identifiable.
3. I have ensured that no participant should suffer any undue physical or psychological
discomfort
4. I certify that there will be no administration of potentially harmful drugs, medicines or 
foodstuffs. *
5. I will obtain written permission from an appropriate authority before recruiting 
members of any outside institution as participants.
6. I certify that the participants will not experience any potentially unpleasant 
stimulation or deprivation?
7. I certify that any ethical considerations raised by this proposal have been discussed in 
detail with my supervisor.
8. I certify that the above statements are true with the following exception(s):
190
* Phosphatidylserine is a naturally occurring phospholipid predominantly found in the brain 
cell membranes but also found in other structures (RCC, 1996). It is considered a safe food 
supplement with no known side effects. The dosage given for this study will be 300mg/day 
in three lOOmg tablets. This dose will be taken for 30 days.
Registration and consulting company. (1996) Expert report on the safety of 
Phophatidylserine PS 50 as produced from soya lecithin by enzymatic transesterification. 
RCC project 629910.
Signature: Date:
In the supervisor’s opinion, this project (tick one only):
Does not raise any significant issues.
Raises some ethical-issues, but-I consider-that appropriate steps and precautions have been 
taken and-I have-approved-the-proposal-and accept the responsibility for having done so. 
Raises ethical issues that need to be considered by the Departmental Ethics Committee. 
Raises ethical issues-such-that it should-not be-allowed to proceed in its current form.
Supervisor’s signature: Date:
(For Ethics Committee use only)
The ethical issues raised by this project have been considered by members of the 
Departmental Ethics Committee who made the following comments:
Please ensure that you take account of these comments and prepare a revised submission 
that should be shown to your supervisor/ resubmitted to the Department Ethics Committee 
(delete as appropriate).
Signed: Date: 21/03/2002
(Chair, Departmental Ethics Committee)
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PSYCHOLOGY 
DEPARTMENT 
ETHICS COMMITTEE 
emc
*
lb: Professor David Becton
Front Professor David ( 3 ^  O ar ofDcptftmental Edict ConiTTtffnc 
Date: 19*\farch,2003
Ra ImjMrt.of jAotidMtid]fiKriBe(PS)m»rac<^^
Members of the departmental Ethics Committee have now reviewed the above stucjy and 
agree tiatitraaca no aubrtamivo ethical atuesi provided the tafoma lioo obtained from fee 
<}uestk)nnairesiakeptabsokjtdycofvfideaia]aodtl^nopeaora3^identifiabteipfbnrrtfioo b 
entered on computer. You nay therefore proceed with your study.
•  Pegt2
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Appendix B1: Subject Information Sheet (Study 1)
i'YHl U Alt a I.AWt TK%n UMYI1?*1T? 4JI ft Alt* A
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Contact Details:
Mr Mike Kingsley 
Lecturer in Sports Science 
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
1. Study title
The effects o f chronic phosphatidylserine (PS) supplementation on recovery following prolonged 
intermittent exercise.
2. Invitation paragraph
You are being asked to volunteer for this research study, which is being conducted for research. It is 
important that before you decide to take part you know what it will involve. If you do not understand 
anything please feel free to ask. Consumers for ethics in research (CERES) publish a leaflet entitled 
“medical research and you”. This leaflet gives more information about medical research and looks at 
some questions you may wish to ask. A copy may be obtained from CERES, PO box 1365 London 
N 16 OBW. Thank you for reading this.
3. What is the purpose of this study?
This study aims to investigate the effect o f chronic supplementation o f PS on recovery. The short­
term effects (immediately after exercise) o f supplementation on heart rate, oxidative stress and 
cortisol levels will be investigated, as will long-term (up to 48 hours post exercise) effects on muscle 
soreness, damage and oxidative stress.
4. Why have I been chosen?
You have been chosen as a subject for this study as you are an active male, aged 18-25 years old. 
Your participation in this study is entirely voluntary, and you should be aware that you have the right 
to withdraw at any time without providing a reason.
5. What will happen to me if I take part?
Preliminary testing will consist o f a multi-stage fitness test (the “beep test”) in order to assess your 
fitness. After this, you will complete an exercise protocol designed to simulate the activity levels and 
demands o f a soccer match. The protocol consists o f 90 minutes o f walking, jogging, cruising and 
sprinting, and also includes frequent rest periods (1 minute breaks) and a 15 minute “half-time”.
You will need to complete this protocol on 3 separate occasions, the first trial will familiarize you 
with the protocol. You will then complete two further trials, once with no supplement (control) (T l) 
and once with either a PS supplement or a glucose placebo (T2). You will be supplemented with 
either 900 mg day'1 o f PS or a glucose placebo for 10 days prior to T2.
During T l and T2, physiological measurement procedures will consist o f heart rate monitoring and 
sprint/endurance performance assessment before and after T l and T2.
Blood will be taken intravenously, (<30 ml per sample). You will be required to return for tests 1 and 
2 days after exercise to assess your recovery, when further blood samples will be collected (one each 
day), and your soreness will be assessed by questionnaire.
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6. What are the possible disadvantages of taking part?
As the study aims to assess the effects o f PS supplementation with regards to muscle soreness, 
subjects are expected to feel some degree o f discomfort on the days following exercise.
Blood samples are to be taken intravenously by a trained individual, and whilst this is not a painful 
process, subjects must be comfortable with such collection methods. Even though the volume of 
blood taken is small (<30 ml per sample) there exists the possibility that during or immediately 
following this procedure subjects may feel light headed and faint. There is an extremely small risk 
that this procedure could result in an air or plastic embolism, but good practice minimises this risk. 
In addition, every effort will be made to minimise the risks o f contaminating the wound by using 
sterile disposable equipment and standardised procedures for the collection and disposal o f biohazard 
wastes.
7. What are the possible benefits of taking part?
Taking part in this study will allow you to assess your fitness at the time o f the study, and also follow 
your progress throughout the duration o f the study. It has been suggested that PS may improve 
confidence and composure during exercise, which is clearly of benefit. In addition, PS may enhance 
perceived soreness following exercise. As such, PS may enhance recovery and therefore may have 
possible benefits on future exercise bouts.
8. Will my taking part in the study be kept confidential?
Whilst the study will be available to all within the University o f Wales Swansea, all results from this 
study will remain anonymous.
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Appendix B2: Subject Information Sheet (Study 2)
r * i n s < u c u  C I M K C  A M K f A W *  l ' M V * K » m  Ol  I M l t *
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Version 1.0
Date: 15th October 2003
Mr Mike Kingsley 
Lecturer in Sports Science 
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
1. Study title
Effects o f Phosphatidylserine supplementation on muscle damage, mental tasks and stress from 
downhill running.
2. Invitation paragraph
You are invited to take part in this study to help with research. You are more than welcome to ask 
questions at any time and you are able to withdraw from any part o f the study at any time, without 
being asked to give a reason.
3. What is the purpose of this study?
The purpose o f this study is to investigate the effects of phosphatidylserine (PS) supplementation on 
muscle damage, mental tasks and stress levels during and after five bouts o f downhill running. In 
particular, the effects on markers o f muscle damage, oxidative stress, inflammation and severity of 
delayed onset o f muscle soreness (DOMS). This study will provide an idea into the possible benefits 
o f PS (if any) being supplemented to athletes for use with eccentric muscle activities. The study also 
aims to investigate the effect o f familiarisation bout of exercise on flexibility and DOMS.
4. Why have I been chosen?
All subjects are volunteers from the University of Wales Swansea (UWS) and consists of 
undergraduates males aged between 19-24 years old. Approximately 16 subjects will take part.
5. What will happen to me if I take part?
If you choose to participate in this study then you will be required to carry out physical tests used to 
assess your fitness. You will be required to visit the exercise physiology laboratory during five 
further exercise trials, each visit will last approximately 1 hour. During these trials you will be asked 
to complete 30 min o f downhill treadmill running, which is used to promote DOMS in the legs. 
Flexibility tests, mental task testing and venous blood samples (<30 ml per sample) will be taken pre­
exercise, post-exercise at 24 hours and 48 hours after exercise. Prior to the third and fifth treadmill 
run you will be required to undertake a ten-day oral supplementation period, during which time you 
will consume either 800 mg-day'1 o f phosphatidylserine (PS) or a placebo, in a cross-over design.
6. What are the possible disadvantages of taking part?
The risks associated with exercise are very small. However, this will be further minimised by the 
health screening you will complete prior to undertaking exercise. There is an extremely small risk 
that venepuncture could result in an air or plastic embolism, but good practice minimises this risk. 
The samples will be taken by trained staff members.
7. What are the possible benefits of taking part?
Possible benefits for receiving the PS supplement include a reduction in DOMS and improved 
recovery following exercise.
8. Will my taking part in the study be kept confidential?
All information collected about you will be kept strictly confidential. Any information that is 
distributed by the Department o f Sports Science will only be identifiable by number and not name.
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Appendix B3: Subject Information Sheet (Study 3)
risi* * * c r u u v  A*i*f.AWt u M v iK * m  m  * al e^  *.wanma
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Contact Details:
Mr Mike Kingsley 
Lecturer in Sports Science 
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
1. Study title
Chronic phosphatidylserine (PS) supplementation and its effects on recovery following exercise 
stress.
2. Invitation paragraph
You are being asked to volunteer for this research study. It is important that before you decide to 
take part you know what it will involve. Take time to read this information sheet and discuss, if  you 
feel you need to with friends, relatives or even you’re G.P. If you do not understand anything please 
feel free to ask. Consumers for ethics in research (CERES) publish a leaflet entitled “medical 
research and you”. This leaflet gives more information about medical research and looks at some 
questions you may wish to ask. A copy may be obtained from CERES, PO box 1365 London N16 
OBW. Thank you for reading this.
3. What is the purpose of this study?
The study aims to investigate the effect o f chronic supplementation o f PS on recovery following 
exercise. It has been suggested that supplementation may increase the rate o f recovery following 
exercise.
4. Why have I been chosen?
All subjects are volunteers from the University o f Wales Swansea (UWS). They will consist of 
undergraduates and graduates. Approximately 24 subjects will take part.
5. Do I have to take part?
Taking part is entirely voluntary. If you do decide to take part you will be given this information 
sheet to keep and will be asked to sign a consent form. Even if  you decide to take part you are free to 
withdraw at any time without a reason. This will not affect the treatment you receive.
6. What will happen to me if I take part?
If you decide to take part in this study you will be required to visit the exercise physiology laboratory 
four times, each visit will last approximately 1 hour. Your first three visits will take place over the 
space o f one to two weeks. During these visits you will complete preliminary tests, a familiarisation 
trial and the pre-supplement main trial. You will then be required to undertake a ten-day oral 
supplementation period, during which time you will consume either 800 mg day'1 of 
phosphatidylserine (PS) or a placebo. A placebo is a dummy treatment, which looks like the real 
thing but contains no active ingredients. You will be randomly assigned to either the PS or placebo 
group in such a way that neither yourself o f the researcher will know which group you are in until the 
end of the study. Following the supplementation period you will complete the post-supplement main 
trial.
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You will be required to complete the following:
1) Preliminary testing: Following the completion o f a health screening questionnaire your weight, 
height and body composition will be measured. Following this you will complete an exercise test 
at progressively increasing intensity until you are unable to continue exercising. Heart rate, 
perceived exertion and respiratory data will be monitored throughout. This assessment will be 
used to identify your maximal exercise capacity and calculate the intensities you will complete 
each main trial.
2) Familiarisation: You will undergo an intermittent exercise test on an exercise ergometer. The 
test will require you to complete five 6-min bouts o f exercise separated by approximately 10-min 
of recovery. The work rate for the first exercise bout will start at a relatively low intensity and 
progress to a moderately hard intensity for the last exercise bout.
3) Main trials: During both main trials you will complete the same intermittent exercise test as 
completed during the familiarisation. Your heart rate and expired respiratory gas will be 
monitored throughout the trials. In addition, 10 ml venous blood samples will be obtained by the 
means o f an indwelling cannula (a thin, flexible plastic tube) or venepuncture (a small hollow 
needle) inserted in a forearm vein. Blood samples will be taken prior to exercise and after each 
recovery period.
4) Additional requirements: You will be required to consume oral supplementation (PS; 300 
mg day'1 or placebo) over a 30-day period and complete 3-day exercise and dietary records 
during the week prior to each main trial. You will be asked fast overnight before reporting to the 
laboratory.
8. W hat is the supplement that is being tested?
Phosphatidylserine are naturally occurring phospholipids predominantly found in cell membranes and 
other structures. It is considered safe to use and is currently on the market as a memory aid.
9. W hat are the effects of taking part?
There are no known side effects o f the supplement, however, if  you experience any adverse effects 
please contact us straight away.
10. What are the possible disadvantages of taking part?
The acute risks associated with exercise are very small. However, this will be further minimised by 
the health screening you will complete prior to undertaking exercise. There is an extremely small 
risk that cannulation could result in an air or plastic embolism, but good practice minimises this risk. 
The samples will be taken by trained staff members.
11. What are the possible benefits o f taking part?
If you receive the PS supplement it could benefit your recovery from exercise. Preliminary studies 
have shown this might be the case.
12. Will new information become available?
New information can always come to light about research areas. If this happens while the study is 
taking place you will be informed and a course of action will be decided.
13. What happens when the research study stops?
The supplement is available on the open market if  you wish to carry on taking it.
14. Will my taking part in the study be kept confidential?
All information collected about you will be kept strictly confidential. Any information that is 
distributed by the Department o f Sports Science will only be identifiable by number and not name.
15. What will happen to the results of the research study?
The results o f the study will be disseminated to the wider Sports Science and Psychology community. 
It is intended that this will be available late 2002 early 2003.
16. Who is organising the research?
The Department o f Sports Science UWS is carrying out the research in collaboration with the 
Department o f Psychology UWS.
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Appendix C: Health Questionnaire
PRirt*t«PL CTfWKU ASERIAWl I
Yr Adran Gwyddor Chwaraeon Department of Sports Science
AHA/ACSM Health/Fitness Facility Preparticipation Screening Questionnaire.
Name __________
Address __________
Phone number 
Emergency contact name 
Date of birth
home work
phone
History
You have had:
□ a heart attack
□ heart surgery
□ cardiac catheterization
□ coronary angioplasty (PTCA)
□ pacemaker/implantable cardiac 
defibrillator/rhythm disturbance
□ heart valve disease
□ heart failure
□ heart transplantation
□ congenital heart disease
Assess your health needs by marking all true statements.
I f  you marked any o f  the statements 
in this section, consult you a health 
provider before engaging in exercise. 
You may need to use a facility with a 
medically qualified staff.
Symptoms and other health issues:
□You experience chest discomfort with exertion.
□ You experience unreasonable breathlessness.
□ You experience dizziness, fainting, blackouts.
□ You take heart medications.
□ You take prescription medication(s).
□ You have musculoskeletal problems.
□You have concerns about the safety of exercise.
□You are pregnant.
Cardiovascular risk factors
□ You are a man older than 45 years.
□ You are a woman older than 55 years or you have had a 
hysterectomy or you are postmenopausal.
□ You smoke.
□ Your blood pressure is greater than 140/90.
□ You don't know your blood pressure.
□ You take blood pressure medication.
□ Your blood cholesterol level is >240 mg/dL.
□ You don't know your cholesterol level.
□ You have a blood relative who had a heart attack
before age 55 (father or brother) or age 65 (mother or sister).
□ You are diabetic or take medicine to control your blood sugar
□ You are physically inactive (i.e., you get less than 30 minutes 
of physical activity on at least 3 days per week).
□ You are more than 20 pounds overweight.
I f  you marked two or more 
o f  the statements in this 
section, you should consult 
your healthcare provider 
before engaging in exercise. 
You might benefit by using a 
faciltiy with professionally 
qualified exercise staff to 
guide your exercise program.
□None of the above is true.
You should be able to exercise safely without consulting your healthcare provider in 
almost any facility that meets your exercise programme needs.___________________
Declaration:
Please sign below to confirm that you have answered questions honestly and to the best o f  your ability.
Signature Date
AHA/ACSM indicates American Heart Association/American College of Sports Medicine.
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Appendix D1: Subject Consent Form (Study 1)
C Y M i U  A U K f . ^ l  I M V I I M I Y  P I  W A L t *  f c - WA S * * *
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Contact Details:
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
The effects of chronic phosphatidylserine (P S) supplem entation on recovery  
following prolonged intermittent exercise.
1. I confirm that I hav e  read  and  understood  th e  information sh e e t d a ted
 / ......../  (version n u m b e r ................................... ) for the  ab o v e
study  and  h av e  had  the opportunity to a sk  questions.
Please initial box
□
I un d erstan d  that m y participation is voluntary and  th a t I am  free  to 
w ithdraw  a t any  tim e, without giving any  reaso n , w ithout m y m edical 
c a re  or legal rights being affected.
N am e of S ub jec t D ate S ignatu re
N am e of P e rso n  taking co n sen t D ate S ignatu re
Researcher Date Signature
□
3. I u n d erstan d  that sec tio n s of any  of d a ta  obtained  m ay b e  looked
a t by responsib le  individuals from the  University of W ales S w a n se a  or 
from regulatory authorities w here  it is relevant to my taking part in I I
re sea rch . I give perm ission for th e se  individuals to h av e  a c c e s s  to '— I
th e se  records.
4. I a g re e  to tak e  part in the  ab o v e  study.
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Appendix D2: Subject Consent Form (Study 2)
F X I M I C O I  C T M I U  A f t t i f A W t  U M V I K S i n  m  v a i e *  s-s a
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Contact Details:
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
Effects of phosphatidylserine (P S) supplem entation on m uscle dam age, 
mental tasks and stress  following downhill running
Please initial box
1. I confirm that I hav e  read  and  understood  the  information sh e e t da ted
 / ......../  (version n u m b e r ................................... ) for the  ab o v e
study  and  h av e  had  the  opportunity to a sk  questions.
2. I u n d erstan d  that m y participation is voluntary and  tha t I am  free  to 
w ithdraw  a t any  tim e, without giving any  reaso n , w ithout m y m edical 
ca re  or legal rights being affected.
□
□
3. I u n d erstan d  that sec tio n s of any  of d a ta  obtained m ay b e  looked
a t by resp o n sib le  individuals from the University of W ales S w a n se a  or 
from regulatory  authorities w here  it is relevant to my taking part in I I
re sea rch . I give perm ission for th e se  individuals to h av e  a c c e s s  to '— '
th e se  records.
4. I a g re e  to tak e  part in th e  ab o v e  study.
N am e of Sub jec t D ate S ignatu re
N am e of P e rso n  taking co n sen t D ate S ignatu re
Researcher Date Signature
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Appendix D3: Subject Consent Form (Study 3)
r g i r t s t ' t n  o w * u  A t e k i  A w t  u m v k k s i t t  o i  s-w a n *. *a
Yr Adran Gwyddor Chwaraeon Department of Sports Science
Contact Details:
Department of Sports Science 
Vivian Tower
University of Wales Swansea, SA28PP 
Tel: 01792 295086
Chronic phosphatidylserine (P S) supplem entation and its effects on recovery  
following ex erc ise  s tress
Please initial box
1. I confirm th a t I h av e  read  and  understood  the  information s h e e t d a ted  -----
 / ......../ ........(version n u m b e r .................................... ) for the a b o v e_______________ ___
study and  have  had  the  opportunity to a sk  questions.
2. I u n d erstand  th a t my participation is voluntary and  th a t I am  free  to -----
withdraw a t any  tim e, without giving any  reaso n , without my m edical ___
ca re  or legal rights being affected .
3. I understand  th a t sec tio n s of any  of da ta  obtained m ay be  looked
at by responsib le  individuals from the  University of W ales S w a n se a  or 
from regulatory authorities w here  it is relevant to m y taking part in
research . I give perm ission for th e se  individuals to h av e  a c c e s s  to -----
th e se  records.
4. I ag ree  to tak e  part in th e  ab o v e  study.
N am e of S ubject D ate S ignatu re
N am e of P erson  taking co n se n t D ate S ignatu re
Researcher Date Signature
Appendix E: Perceived Muscle Soreness Scale
Instructions: Please use the following scale to indicate the extent to which each 
word below describes how sore your muscles feel at this moment in time.
0 Not Sore
1
2 Light soreness
3
4 Somewhat sore
5
6 Sore
7
8 Very sore
9
10 Very, very sore
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Appendix F: Exercise-Induced Feeling Scale
Instructions: Please use the following scale to indicate the extent to which each 
word below describes how you feel at this moment in time. Record your responses 
by placing an X in the appropriate box.
0 = Do Not Feel [DNF]
1 = Feel Slightly
2 = Feel Moderately
3 = Feel Strongly
4 = Feel Very Strongly [FVS]
DNF FVS
0 1 2 3 4
1. Refreshed
2. Calm
3. Fatigued
4. Enthusiastic
5. Relaxed
6. Energetic
7. Happy
8. Tired
9. Revived
10. Peaceful
11. Worn-out
12. Upbeat
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